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1. Introduction 
The Centers for Disease Control and Prevention (CDC) recommends routine vaccination 
to prevent 17 vaccine-preventable diseases that occur in infants, children, adolescents, 
or adults. This report provides information for clinicians and other health care providers 
about concerns that commonly arise when vaccinating persons of various ages. 
Providers and patients must navigate numerous issues, such as the timing of each dose, 
screening for contraindications and precautions, the number of vaccines to be 
administered, the educational needs of patients and parents, and interpreting and 
responding to adverse events. Vaccination providers help patients understand the 
substantial body of (occasionally conflicting) information about vaccination.  
This vaccination best practice guidance is intended for clinicians and other health care 
providers who vaccinate patients in varied settings, including hospitals, provider offices, 
pharmacies, schools, community health centers, and public health clinics. The updated 
guidelines include 1) new information on simultaneous vaccination and febrile seizures; 
2) enhancement of the definition of a “precaution” to include any condition that might 
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confuse diagnostic accuracy; 3) confirmation that if a patient is not acutely moderately 
or severely ill, vaccination during hospitalization is a best practice; 4) more descriptive 
characterization of anaphylactic allergy; 5) incorporation of protocols for management 
of anaphylactic allergy; 6) allowances for alternate route (subcutaneous instead of 
intramuscular) for hepatitis A vaccination; 7) an age cutoff of 12 years through 17 years 
of age for validating a dose of intradermal influenza vaccine; 8) deletion of much of the 
content from storage and handling, including storage units, temperature monitoring, 
and expiration dates (because this content is now codified and continually updated in 
the CDC’s Vaccine Storage and Handling Toolkit, available at 
www.cdc.gov/vaccines/recs/storage/toolkit/default.htm.); 9) incorporation of 
Infectious Diseases Society of America guidance on vaccination of persons with altered 
immunocompetence; 10) timing of intramuscular administration in patients with 
bleeding disorders; 11) updated data on vaccination record policy; 12) additional 
impacts of the Affordable Care Act (1,2) on adult vaccination; and 13) updated 
programmatic contact information on source material for vaccine information. 
The guidance is organized in the following 10 documents: 1) Timing and Spacing of 
Immunobiologics; 2) Contraindications and Precautions; 3) Preventing and Managing 
Adverse Reactions; 4) Vaccine Administration; 5) Storage and Handling of 
Immunobiologics; 6) Altered Immunocompetence; 7) Special Situations; 8) Vaccination 
Records; 9) Vaccination Programs; and 10) Vaccine Information Sources. A glossary 
follows (see Appendix 1: Glossary).  
This report will help vaccination providers to assess vaccine benefits and risks, use 
recommended administration practices, understand the most effective strategies for 
ensuring that vaccination coverage in the population remains high, and communicate 
the importance of vaccination to reduce the effects of vaccine-preventable disease. These 
best practice guidelines are intended for use in the United States; vaccine availability, 
use, and epidemiologic circumstances might differ in other countries and might warrant 
different guidance. 
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2. Methods 
The Advisory Committee on Immunization Practices (ACIP) General Recommendations 
Work Group (GRWG) reviews the evidence for best practices regarding immunization 
and releases updated guidance every 3 to 5 years (see Appendix 2: Membership). Work 
group members are required to report conflicts of interests. Conflict of interest 
information for those individuals who must report is available upon request to the 
corresponding author. Relevant topics are those identified by ACIP as topics related to 
all vaccines, including timing and spacing of doses, vaccine administration, and vaccine 
storage and handling. New topics are added when ACIP decides previous ACIP good 
practice statements on general issues (such as combination vaccines, adolescent 
vaccination, or adult vaccination) should be revised and incorporated into the General 
Best Practice Guidelines for Immunization. 
The best practice guidelines in this report update the previous ACIP General 
Recommendations on Immunization (1) and are based both on review and analysis of 
available scientific evidence and on expert opinion of the diverse group of health-care 
providers and public health officials who are members of GRWG. This group includes 
professionals from academic medicine (pediatrics, family practice, and pharmacy); 
international (Canada), federal, and state public health professionals; and a member 
from the nongovernmental Immunization Action Coalition (see Appendix 2: 
Membership). This revision involved consensus-building based on new evidence from 
the published literature and opinion from subgroups of subject matter experts consulted 
on specific topics.  
The process by which the guidelines were drafted varied for each document; each 
document is therefore discussed individually below. ACIP voted to accept the proposed 
guidance in October 2014; for additional information, see 
http://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.  
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Timing and Spacing of Immunobiologics 
GRWG met monthly beginning in January 2011, and formed a subgroup to focus on 
review of guidelines around administration of simultaneous vaccination and febrile 
seizures. Meetings were held in April, May, and June 2011 to discuss the evidence. Other 
issues related to timing and spacing of vaccinations were discussed between February 
2012 and September 2014 over 7 meetings (in February 2012, June 2012, August 2012, 
November 2012, January 2013, January 2014, May 2014, and September 2014). The 
evidence supporting this document is based on expert opinion and arrived at by 
consensus. Presentations of the evidence were made to ACIP in June 2011, October 
2011, and February 2013. Major changes include 1) guidance for simultaneous 
vaccination in the context of a risk for febrile seizures and 2) clarification of the use of 
the grace period between doses of the measles, mumps, rubella, and varicella vaccine 
(MMRV).  
Contraindications and Precautions 
GRWG met monthly and focused on revisions to the Contraindications and Precautions 
section beginning in January 2012, over 6 meetings (January 2012, February 2012, June 
2012, August 2012, November, 2012, December 2012, and January 2013; see 
http://www.cdc.gov/vaccines/acip/meetings/meetings-info.html). The evidence 
supporting this document is based on a review of the published literature. Publications 
about vaccination during surgery, hospitalization, and anesthesia were obtained from 
the databases PubMed and MDConsult, searched from 1973 to 2014 using the MeSH 
(medical subject headings) terms “anesthesia” and “immunization”. The search and 
selection of studies was limited to English-language and human studies. The search and 
selection process yielded 20 publications, including review articles, observational 
studies, and letters to the editor. Presentations of proposed best practices were made to 
ACIP in February 2013 and a vote from ACIP affirming the language below was made in 
October 2014. Major changes include 1) enhancement of the definition of a “precaution” 
to include any condition that might confuse diagnostic accuracy and 2) guidance to 
vaccinate during a hospitalization if a patient is not acutely moderately or severely ill.  
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Preventing and Managing Adverse Reactions 
GRWG met monthly and focused on revisions to the Preventing and Managing Adverse 
Reactions section beginning in April 2013, following revision to the document by the 
Allergy Subgroup. Selected members from this subgroup participated in the April 2013 
main work group call. GRWG then met again in May 2013. The evidence supporting this 
document is based on expert opinion and arrived at by consensus. Presentations of 
proposed guidance were made to ACIP in June 2013, and a vote from ACIP affirming the 
language below was made in October 2014. Major changes included 1) more descriptive 
characterization of anaphylactic allergy and 2) incorporation of protocols for managing 
adverse reactions. ACIP voted to accept the proposed statement in October 2014. 
Vaccine Administration  
GRWG met monthly beginning in May 2013 to discuss Vaccine Administration and met 
for 4 additional meetings (July 2013, August 2013, December 2013 and September 
2014). The evidence supporting this document is based on expert opinion and arrived at 
by consensus. Presentations of the proposed guidance were made to ACIP in October 
2013, and a vote from ACIP affirming the language below was made in October 2014. 
Major changes from 2011 include 1) allowances for alternate administration route 
(subcutaneous instead of intramuscular) for hepatitis A vaccine and 2) an age cutoff of 
12 years through 17 years of age for validating a dose of intradermal influenza vaccine if 
given in error. ACIP voted to accept the proposed statement in October 2014. 
Storage and Handling of Immunobiologics 
GRWG met in December 2013 to discuss Storage and Handling of Immunobiologics and 
met one additional time in January 2014. The evidence supporting this document is 
based on expert opinion and arrived at by consensus. A presentation of proposed 
language was made to ACIP in February 2014, and a vote from ACIP approving the 
language below was made in October 2014. Most of the 2011 language was removed 
because this content is now codified and continually updated in the CDC’s Vaccine 
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Storage and Handling Toolkit, available at 
www.cdc.gov/vaccines/recs/storage/toolkit/default.htm. This content included Storage 
Units, Monitoring Storage Temperature, Vaccine Inventory, and Vaccine Transport.  
Altered Immunocompetence 
GRWG met twice in March and April 2014 to discuss best practices guidance for Altered 
Immunocompetence. This section incorporates general content from the Infectious 
Diseases Society of America (IDSA) policy statement 2013 IDSA Clinical Practice 
Guideline for Vaccination of the Immunocompromised Host (2), to which CDC 
provided input in November 2011. The evidence supporting this document is based on 
expert opinion and arrived at by consensus. ACIP voted to accept this proposed 
statement in June 2015.  
Special Situations 
GRWG met in April 2012 and then in 4 follow-up meetings in May, August, and 
November 2012, and January 2013. A focal point of discussion involved best practices 
guidance for intramuscular administration of persons with increased bleeding risk. 
Subject matter experts from the National Center for Birth Defects and Developmental 
Disabilities (NCBDDD) were invited to a work group meeting, and revisions to the 
guidance involving the timing of intramuscular administration were made in 
collaboration with these subject matter experts, primarily to ensure that ACIP’s best 
practices guidance does not conflict with NCBDDD recommendations regarding the 
timing of clotting factor deficiency replacement. The evidence supporting this document 
is based on expert opinion and arrived at by consensus.  
GRWG presented the Special Situations section to ACIP in February 2013. ACIP voted to 
accept the proposed statement in June 2015.  
Vaccination Records 
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GRWG met in August and September 2013, and presented the vaccination records 
language to ACIP in October 2013. The evidence supporting this document is based on 
expert opinion and arrived at by consensus. ACIP voted to accept this proposed best 
practices guidance in June 2015. 
Vaccination Programs 
GRWG met in April 2014. The major revision to this section is the addition of language 
related to Affordable Care Act (3,4) coverage of adult vaccination. The evidence 
supporting this document is based on expert opinion and arrived at by consensus. 
GRWG presented this section to ACIP in June 2014. ACIP voted to accept this proposed 
statement in June 2015. 
Vaccination Information Sources 
GRWG met in September 2014 and presented this section to ACIP. The evidence 
supporting this document is based on expert opinion and arrived at by consensus. ACIP 
voted to accept this proposed statement in June 2015.  
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3. Timing and Spacing of Immunobiologics 
Updates 
Major changes to the best practice guidance for timing and spacing of immunobiologics 
include 1) guidance for simultaneous vaccination in the context of a risk for febrile 
seizures and 2) clarification of the use of the grace period between doses of MMRV. 
General Principles for Vaccine Scheduling 
Optimal response to a vaccine depends on multiple factors, including the type of 
vaccine, age of the recipient, and immune status of the recipient. Recommendations for 
the age at which vaccines are administered are influenced by age-specific risks for 
disease, age-specific risks for complications, age-specific responses to vaccination, and 
potential interference with the immune response by passively transferred maternal 
antibodies. Vaccines are generally recommended for members of the youngest age group 
at risk for experiencing the disease for which vaccine efficacy and safety have been 
demonstrated. 
Tetanus and diphtheria toxoids require booster doses to maintain protective antibody 
concentrations (1). Unconjugated polysaccharide vaccines do not induce T-cell memory, 
and additional doses (although they elicit the same or a lower antibody concentration) 
might increase the duration of protection. Conjugation with a protein carrier improves 
the effectiveness of polysaccharide vaccines by inducing T-lymphocyte–dependent 
immunologic function (2). Many vaccines that stimulate both cell-mediated immunity 
and neutralizing antibodies (e.g., live, attenuated virus vaccines) can usually induce 
prolonged immunity, even if antibody titers decline over time (3). Subsequent exposure 
to such viruses usually results in a rapid anamnestic antibody response without viremia. 
Approximately 90%-95% of recipients of a single dose of certain live vaccines 
administered by injection at the recommended age (i.e., measles, rubella, and yellow 
fever vaccines) develop protective antibodies, generally within 14 days of the dose. For 
varicella and mumps vaccines, 80%-85% of vaccinees are protected after a single dose. 
However, because a limited proportion (5%-20%) of measles, mumps, and rubella 
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(MMR) or varicella vaccinees fail to respond to 1 dose, a second dose is recommended to 
provide another opportunity to develop immunity (4). Of those who do not respond to 
the first dose of the measles component of MMR or varicella vaccine, 97%-99% respond 
to a second dose (5,6). 
The Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and 
the Recommended Adult Immunization Schedule are revised annually. Physicians and 
other health-care providers should ensure that they are following the most up-to-date 
schedules, which are available from CDC at  
http://www.cdc.gov/vaccines/schedules/hcp/index.html . 
Spacing of Multiple Doses of the Same Antigen 
Vaccination providers should adhere to recommended vaccination schedules (Table 3-
1). Administration at recommended ages and in accordance with recommended 
intervals between doses of multidose antigens provides optimal protection. 
Administration of doses of a multidose vaccine using intervals that are shorter than 
recommended might be necessary in certain circumstances, such as impending 
international travel or when a person is behind schedule on vaccinations but needs 
rapid protection. In these situations, an accelerated schedule can be implemented using 
intervals between doses that are shorter than intervals recommended for routine 
vaccination (7). The accelerated or minimum intervals and ages for scheduling catch-up 
vaccinations are available at http://www.cdc.gov/vaccines/schedules/hcp/index.html . 
Vaccine doses should not be administered at intervals less than these minimum 
intervals or at an age that is younger than the minimum age.*(a) 
Before administering a vaccine dose, providers might need to verify that all previous 
doses were administered after the minimum age and in accordance with minimum 
intervals (Table 3-1). In clinical practice, vaccine doses occasionally are administered at 
intervals less than the minimum interval or at ages younger than the minimum age. 
Doses administered too close together or at too young an age can lead to a suboptimal 
immune response. However, administering a dose a few days earlier than the minimum 
interval or age is unlikely to have a substantially negative effect on the immune response 
General Best Practice Guidelines for Immunization: Timing and Spacing of Immunobiologics 14 
to that dose. Known as the “grace period”, vaccine doses administered ≤4 days before 
the minimum interval or age are considered valid; however, local or state mandates 
might supersede this 4-day guideline (7).(b) (Day 1 is the day before the day that marks 
the minimum age or minimum interval for a vaccine.) The scenario most applicable to 
the grace period is a visit to a provider several days prior to the date indicated by the 
minimum interval, such as for a mild illness. Follow-up is unlikely soon after or even for 
a longer period of time following this mild illness visit; this therefore raises the question 
of whether vaccines be administered during the mild illness visit to avoid missed 
opportunities to vaccinate. Because of the unique schedule for rabies vaccine, the 4-day 
guideline does not apply to this vaccine (8). Doses of any vaccine administered ≥5 days 
earlier than the minimum interval or age should not be counted as valid doses and 
should be repeated as age appropriate. The repeat dose should be spaced after the 
invalid dose by the recommended minimum interval (Table 3-1). For example, if the 
first and second doses of Haemophilus influenzae type b (Hib) were administered only 
14 days apart, the second dose would be invalid and need to be repeated because the 
minimum interval from dose 1 to dose 2 is 4 weeks. The repeat dose should be 
administered ≥4 weeks after the invalid dose (in this case, the second) (7). The repeat 
dose is counted as the valid second dose. If the first and second doses of hepatitis A 
vaccine were administered less than 6 months apart, the second dose is invalid and 
should be repeated 6 months after the invalid second dose (7). However, if this repeat 
dose (the third dose) is administered anytime 6 months or more after the first dose, the 
series can be considered complete.  
If the first dose in a series is given ≥5 days before the recommended minimum age, the 
dose should be repeated on or after the date when the child reaches at least the 
minimum age (7). If the vaccine is a live vaccine, ensuring that a minimum interval of 28 
days has elapsed from the invalid dose is recommended (7). For example, if the first 
dose of varicella vaccine were inadvertently administered at age 10 months, the repeat 
dose would be administered no earlier than the child’s first birthday (the minimum age 
for the first dose). If the first dose of varicella vaccine were administered at age 11 
months and 2 weeks, the repeat dose should be administered no earlier than 4 weeks 
thereafter, which would occur after the first birthday. 
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Certain vaccines (e.g., adult tetanus and diphtheria toxoids [Td], pediatric diphtheria 
and tetanus toxoids [DT], tetanus toxoid) produce increased rates of local or systemic 
reactions in certain recipients when administered more frequently than recommended 
(9,10). Careful record keeping, maintenance of patient histories, use of immunization 
information systems (IISs), and adherence to recommended schedules can decrease the 
incidence of such reactions without adversely affecting immunity. 
Simultaneous Administration 
Simultaneous administration of vaccines is defined as administering more than one 
vaccine on the same clinic day, at different anatomic sites, and not combined in the 
same syringe. Experimental evidence and extensive clinical experience provide the 
scientific basis for administering vaccines simultaneously (11). Simultaneously 
administering all vaccines for which a person is eligible at the time of a visit increases 
the probability that a child, adolescent, or adult will be vaccinated fully by the 
appropriate age (12). A study conducted during a measles outbreak demonstrated that 
approximately one-third of measles cases among unvaccinated but vaccine-eligible 
preschool children might have been prevented if MMR had been administered at the 
same visit when another vaccine was administered (13). Simultaneous administration 
also is critical when preparing for foreign travel in the near future and when a health-
care provider is uncertain that a patient will return for additional doses of vaccine. 
With some exceptions, simultaneously administering the most widely used live and 
inactivated vaccines has produced seroconversion rates and rates for adverse reactions 
similar to those observed when the vaccines are administered separately (11, 14-16). 
Routine administration of all age-appropriate doses of vaccines simultaneously is 
recommended for children for whom no specific contraindications exist at the time of 
the visit (7). MMR and varicella vaccine can be administered simultaneously (7). Live, 
attenuated influenza vaccine (LAIV) does not interfere with the immune response to 
MMR or varicella vaccines administered at the same visit (17). No data exist about the 
immunogenicity of oral Ty21a typhoid vaccine when administered concurrently or 
within 30 days of live-virus vaccines. In the absence of such data, if typhoid vaccination 
is warranted, administration should not be delayed because of recent administration of 
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live, attenuated virus vaccines (18). Simultaneous administration of pneumococcal 
polysaccharide vaccine (PPSV) and inactivated influenza vaccine elicits a satisfactory 
antibody response without increasing the incidence or severity of adverse reactions (19). 
Simultaneous administration of PPSV23 and inactivated influenza vaccine is 
recommended for all persons for whom both vaccines are indicated. Tetanus toxoid, 
reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) and inactivated 
influenza vaccine (IIV) can be administered simultaneously (20). Hepatitis B vaccine 
administered with yellow fever vaccine is as safe and immunogenic as when these 
vaccines are administered separately (21). Measles and yellow fever vaccines have been 
administered safely at the same visit and without reduction of immunogenicity of either 
component (22,23). 
During the 2010-2011 influenza season, surveillance systems detected safety signals for 
febrile seizures in young children following IIV and PCV13 vaccines (24). CDC studied 
the health-care visit records of more than 200,000 vaccinated children ages 6 months 
through 59 months through the Vaccine Safety Datalink Project during the 2010-2011 
influenza season. The analyses found that febrile seizures following IIV and PCV13 
vaccines given to this age group were rare, but did occur at higher than expected rates. 
The risk for febrile seizures peaked in children age 16 months and were more common 
when the 2 vaccines were given during the same health-care visit. In this group, about 
one additional febrile seizure occurred among every 2,200 children vaccinated. After 
assessing benefits and risks, ACIP continues to recommend IIV and PCV13 be given 
concomitantly if both are recommended (24,25).  
There are 2 exceptions to the recommendation that vaccines should be administered 
simultaneously. In persons with anatomic or functional asplenia, quadrivalent 
meningococcal conjugate vaccine (MCV4)-D (MenACWY-D, Menactra) and 
pneumococcal conjugate vaccine (PCV)13 (PCV13, Prevnar 13) should not be 
administered simultaneously (26). This is based on immunogenicity studies that showed 
reduced antibody concentrations for 3 serotypes of pneumococcus (subtypes 4, 6B, and 
18C) when PCV7 was administered simultaneously with MenACWY-D. For persons with 
anatomic or functional asplenia, PCV13 should be administered first and MenACWY-D 
4 weeks later.  
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 In patients recommended to receive both PCV13 and PPSV23, the 2 vaccines should not 
be administered simultaneously (27). PCV13 should be administered first. If PPSV23 
has been administered first, PCV13 should be administered no earlier than 8 weeks later 
in children 6-18 years, and one year later in adults 19 years and older. Immunogenicity 
studies evaluating responses to PCV13 and PPSV23 administered in series showed a 
better immune response when PCV13 was administered first. An evaluation of immune 
response after a second pneumococcal vaccination administered 1 year after the initial 
study doses showed that subjects who received PPSV23 as the initial study dose had 
lower antibody responses after subsequent administration of PCV13 than those who had 
received PCV13 as the initial dose followed by a dose of PPSV23, regardless of the level 
of the initial response to PPSV23 (28,29). 
Depending on which vaccines are administered during the first year of life, a child might 
receive up to 9 injections at the 12- through 15-month visit (MMR, varicella, Hib, PCV13, 
pediatric diphtheria and tetanus toxoids and acellular pertussis [DTaP], inactivated 
poliovirus [IPV], hepatitis A, hepatitis B [HepB], and influenza vaccines). Although 
there is no exact limit on the number of injections, with a little flexibility, a provider can 
ensure that the primary series doses are given without administering too many 
injections at each visit. To reduce the number of injections at the 12- through 15-month 
visit, the hepatitis B series and 3 doses of IPV (30) can be administered before the 
child’s first birthday. 
There are many other examples of ways the vaccination schedule provides flexibility. 
The majority of children aged 1 year who have received 2 Hib vaccine doses 
(polyribosylribitol phosphate-meningococcal outer membrane protein [PRP-OMP]) or 3 
Hib vaccine doses (PRP-tetanus [PRP-T]) and 3 previous doses of DTaP and PCV13 have 
protection against Hib, diphtheria, pertussis, tetanus, and pneumococcus, which lasts 
throughout infancy (2,31). The third (PRP-OMP) or fourth (PRP-T) dose of the Hib 
series and the fourth doses of DTaP and PCV13 are critical in boosting antibody titer and 
ensuring continued protection (2,32-34). The fourth dose of DTaP is recommended at 
age 15-18 months but may be administered as early as age 12 months if 6 months have 
elapsed since the third dose and if there is concern that the child might not return by age 
18 months (32). For infants at low risk for infection with hepatitis B virus (i.e., mother 
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tested negative for hepatitis B surface antigen [HBsAg] at the time of delivery and is not 
in a high risk group), the hepatitis B series can be completed at any time for children 
aged 6-18 months (35). The minimum age for administration of combination vaccines is 
the oldest minimum age for any of the individual components; the minimum interval 
between doses is equal to the greatest minimum interval of any of the individual 
components. With use of the combination Hib-hepatitis B vaccine, the minimum age of 
administration of the final dose is 12 months because of the minimum age requirement 
for the last dose of the Hib series (35). Recommended spacing of doses should be 
maintained (Table 3-1). 
Combination Vaccines 
Combination vaccines merge equivalent component vaccines into single products to 
prevent more than one disease or to protect against multiple strains of infectious agents 
causing the same disease. Licensed combination vaccines can be used whenever any 
components of the combination are indicated and its other components are not 
contraindicated and if licensed by the Food and Drug Administration (FDA) for that 
dose in the series. Use of combination vaccines can reduce the number of injections 
patients receive and alleviate concern associated with the number of injections 
(30,36,37). Studies have demonstrated that parents and providers might be 
uncomfortable with multiple injections during single visits (38-40). Potential 
advantages of combination vaccines include 1) improved vaccine coverage rates (41), 2) 
timely vaccination coverage for children who are behind the schedule (42-43), 3) 
reduced shipping and stocking costs, 4) reduced costs for extra health-care visits 
necessitated by deferral of vaccination, and 5) facilitation of additional new vaccines 
into vaccination programs. 
Potential disadvantages of combination vaccines include the following: 1) adverse events 
that might occur more frequently after administration of a combination vaccine 
compared with administration of separate antigens at the same visit, such as fever that 
occurs with the combination MMRV vaccine and combination DTaP-HepB-IPV vaccine 
(44,45); 2) confusion and uncertainty about selection of vaccine combinations and 
schedules for subsequent doses, especially when vaccinations are given by multiple 
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providers who might be using different products; 3) reduced pathogen coverage if the 
combination product covers fewer types of one particular vaccine-preventable disease-
causing agent (46); 4) extra doses of certain antigens in the combination product (e.g., a 
provider who administers 4 doses of DTaP-HepB-IPV vaccine will give an extra dose of 
hepatitis B component); and 5) a shorter shelf-life than the individual component 
vaccines. The economic impact of the use of combination vaccines is unclear because 
combination products have the potential for either increased or decreased costs 
compared with single-antigen component vaccines. The price of a combination vaccine 
might exceed the total price of separate vaccines containing the same antigens. 
However, combination vaccines might represent a better overall economic value if the 
direct and indirect costs of extra injections, delayed or missed vaccinations, and 
additional handling and storage are taken into consideration (47). 
Licensed Combination Vaccines 
In this report, a combination vaccine is defined as a product containing components 
that can be divided equally into independently available routine vaccines. A dash ( - ) 
between vaccine products indicates that products are supplied in their final form by the 
manufacturer and do not require mixing or reconstitution by the user. A slash ( / ) 
indicates that the products must be mixed or reconstituted by the user. Seven 
combination vaccines for which separate antigens or antigen combinations exist have 
been licensed by FDA since 1996 in the United States (Table 3-2) (48-54). In the future, 
combination vaccines might include increasing numbers of components in different 
arrays to protect against these and other diseases. (The status of licensure and 
recommendations for new vaccines is available at 
http://aapredbook.aappublications.org/news/vaccstatus.shtml.) The use of a 
combination vaccine generally is preferred over separate injections of the equivalent 
component vaccines (55). Considerations should include provider assessment,(c) patient 
preference, and the potential for adverse events. An exception is the first dose of MMRV. 
Unless the parent or caregiver expresses a preference for MMRV vaccine, MMR and 
varicella vaccine should be administered for the first dose for children aged 12-47 
months (see Contraindications and Precautions) (44). 
General Best Practice Guidelines for Immunization: Timing and Spacing of Immunobiologics 20 
Situations might arise in which one component of a combination vaccine is specifically 
preferred to another component in that same vaccine. Future research considerations 
for newly licensed combination vaccines should focus on safety of doses that are not 
needed because a patient is already vaccinated against the agents, whether the 
combination vaccine will improve the timeliness of vaccination, and potential reduced 
costs from disease prevention resulting from timely vaccination. 
Combination Vaccines and FDA Licensure 
Only combination vaccines licensed by FDA should be used (55). Vaccination providers 
should not combine separate vaccines into the same syringe to administer together 
unless mixing is indicated for the patient’s age and is explicitly specified on the FDA-
approved product label inserts. Only 2 combination vaccines, (DTaP-IPV/Hib vaccine, 
marketed as Pentacel, and Hib-MenCY, marketed as MenHibrix) contain separate 
antigen components for which FDA approves mixing by the user. The safety, 
immunogenicity, and effectiveness of unlicensed combinations are unknown. 
Interchangeability of Formulations 
FDA generally licenses a combination vaccine based on studies demonstrating that the 
product’s immunogenicity (or efficacy) and safety are comparable or equivalent to 
monovalent or combination products licensed previously (37). FDA licensure also 
generally indicates that a combination vaccine may be used interchangeably with 
monovalent formulations and other combination products with similar component 
antigens produced by the same manufacturer to continue the vaccination series. For 
example, DTaP, DTaP-IPV/Hib, DTaP-HepB-IPV, and future DTaP vaccines that 
contain similar acellular pertussis antigens from the same manufacturer may be used 
interchangeably if licensed and indicated for the patient’s age (34). 
Interchangeability of Combination Vaccines from Different 
Manufacturers 
Licensure of a vaccine by FDA does not necessarily indicate that the vaccine is 
interchangeable with products from other manufacturers. Such data are ascertained and 
interpreted more readily for diseases with known correlates of protective immunity 
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(e.g., specific serologic markers). For diseases without such surrogate laboratory 
markers, prelicensure field vaccine efficacy (phase III) trials or postlicensure 
surveillance generally are required to determine protection (56). ACIP prefers that doses 
of vaccine in a series come from the same manufacturer; however, if this is not possible 
or if the manufacturer of doses given previously is unknown, providers should 
administer the vaccine that they have available. 
Vaccine Supply 
Although vaccination providers should stock sufficient quantities of combination and 
monovalent vaccines needed to vaccinate children, adolescents, and adults against all 
diseases for which vaccines are recommended (30,37), all available types or brand-name 
products need not be stocked. Potential advantages of stocking a limited number of 
vaccines include 1) reducing confusion and potential errors when staff members must 
handle redundant products and formulations, 2) minimizing waste when less commonly 
used products expire, 3) decreasing cold storage capacity requirements, and 4) 
minimizing administrative costs related to accounting, purchasing, and handling. The 
National Pediatric Vaccine Stockpile exists to offset supply challenges (57). 
Extra Doses of Vaccine Antigens 
Administering extra antigens contained in a combination vaccine should be avoided in 
most situations (55). Using combination vaccines containing certain antigens not 
indicated at the time of administration to a patient might be justified when 1) the extra 
antigen is not contraindicated, 2) products that contain only the needed antigens are not 
readily available, and 3) potential benefits to the patient outweigh the potential risk for 
adverse events associated with the extra antigens. An extra dose of many live-virus 
vaccines and Hib or hepatitis B vaccine has not been found to be harmful (58,59). 
However, the risk for an adverse event might increase when extra doses are 
administered at an earlier time than the recommended interval for certain vaccines 
(e.g., tetanus toxoid vaccines and PPSV) (19,32,60). 
A vaccination provider might not have vaccines available that contain only the antigens 
needed as indicated by a child’s vaccination history. Alternatively, although the 
indicated vaccines might be available, the provider might prefer to use a combination 
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vaccine to reduce the required number of injections. In such cases, the benefits and risks 
of administering the combination vaccine with an unneeded antigen should be carefully 
considered and discussed with the patient or parent. 
When inactivated (i.e., killed) or subunit vaccines (which are often adsorbed to 
aluminum-salt adjuvants) are administered, the reactogenicity of the vaccine must be 
considered in balancing the benefits and risks of extra doses (55). Because clinical 
experience suggests low reactogenicity, an extra dose of Hib or hepatitis B vaccine may 
be administered as part of a combination vaccine to complete a vaccination series for 
another component of the combination. Administration of extra doses of tetanus toxoid 
vaccines earlier than the recommended intervals can increase the risk for severe local 
reactions (20,33). Examples of such vaccines include DTaP, DT (for children), and Td 
(for adolescents and adults). Extra doses of tetanus-toxoid–containing vaccines might 
be appropriate for certain patients, including for children who previously received DT or 
Td vaccine and need protection from pertussis (in DTaP or Tdap) or for immigrants with 
uncertain vaccination histories. 
Conjugate Vaccine Carrier Proteins 
Protein conjugates used in Hib conjugate vaccines produced in the United States include 
tetanus toxoid (in PRP-T) which is also used as a component of DTaP and Tdap vaccines 
(61). Simultaneous or sequential vaccination with Hib and these tetanus-toxoid 
containing vaccines is recommended when both are indicated (55). MCV4 and PCV13 
both contain diphtheria-toxoid conjugates. There has been concern about simultaneous 
administration of vaccines containing like conjugates. One brand of MCV4, MenACWY-
D (Menactra), demonstrates reduced immunogenicity of the antibody response to 
Streptococcal pneumonia strains when administered simultaneously with PCV13 
compared with separate administration. It is recommended to space these vaccines by 
28 days in a person with anatomic asplenia (46). Simultaneous or sequential vaccination 
of MCV4-CRM (Menveo), PCV13, and Tdap (33,61), all of which contain diphtheria 
toxoid, is not associated with reduced immunogenicity or increase in local adverse 
events.  
Nonsimultaneous Administration 
General Best Practice Guidelines for Immunization: Timing and Spacing of Immunobiologics 23 
There is no evidence that inactivated vaccines interfere with the immune response to 
other inactivated vaccines or to live vaccines. Any inactivated vaccine can be 
administered either simultaneously or at any time before or after a different inactivated 
vaccine or live vaccine (Table 3-3). The 2 exceptions, as mentioned above, are a 4-week 
interval between PCV13 and MenACWY-D in a person with anatomic asplenia and the 
separation of doses between PCV13 and PPSV23 (6-12 months recommended for non-
high risk, 8 week minimum) if PCV13 is given first, 8 weeks in children 6-18 years, and 1 
year minimum in adults 19 years and older if PPSV23 is given first (26). 
Limited data are available regarding interference between live vaccines used in the 
United States. The immune response to one live-virus vaccine might be impaired if 
administered within 28 days (i.e., 4 weeks) of another live-virus vaccine (62,63). In a 
study conducted in 2 U.S. health maintenance organizations, the risk for varicella 
vaccine failure (i.e., varicella disease in a vaccinated person) among persons who 
received varicella vaccine within 28 days of MMR vaccination was threefold higher than 
among persons who received varicella vaccine >28 days after MMR vaccination (64). 
Another study determined that the response to yellow fever vaccine is not affected by 
monovalent measles vaccine administered 1-27 days earlier (22). The effect of 
nonsimultaneous administration of rubella, mumps, varicella, and yellow fever vaccines 
is unknown. 
Two or more injectable or nasally administered live vaccines not administered on the 
same day should be separated by at least 4 weeks (Table 3-3), to minimize the potential 
risk for interference. If 2 such vaccines are separated by <4 weeks, the second vaccine 
administered should not be counted and the dose should be repeated at least 4 weeks 
later. On the day a live injectable or intranasal vaccine will be administered, providers 
should ensure that no live injectable or intranasal vaccine was given in the previous 28 
days. 
The 4-day grace period discussed earlier, which may be used to shorten the minimum 
interval between doses of the same vaccine, should not be applied to this 4-week interval 
between 2 different live vaccines (55). Confusion about this prohibition may arise when 
2 live vaccines whose intervals are identical are administered simultaneously. For 
example, if MMR and varicella vaccines are administered on the same day, the second 
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dose of each vaccine could come due 4 weeks later (depending on the patient’s age). If 
either vaccine had been given alone at both time points, the 4-day grace period could be 
applied to the second dose. But in this situation the live vaccine rule prevents the grace 
period from being applied to the second dose of either vaccine, because Varicella-2, if 
administered earlier than 4 weeks, could potentially be affected by MMR1, and likewise 
MMR2 could be affected by Varicella-1. Note that this prohibition also applies if the 
combination MMRV is used rather than individual MMR and varicella vaccines.  
The oral vaccines Ty21a typhoid vaccine and rotavirus can be administered 
simultaneously with or at any interval before or after other live vaccines (injectable or 
intranasal) if indicated (65). 
Spacing of Vaccines and Antibody-Containing Products 
Live Vaccines 
Ty21a typhoid, yellow fever, LAIV, zoster, and rotavirus vaccines may be administered at 
any time before, concurrent with, or after administration of any antibody-containing 
preparation such as immune globulin, hyperimmune globulin, or intravenous immune 
globulin (IGIV) (66). Blood (e.g., whole blood, packed red blood cells, and plasma) and 
other antibody-containing blood products (e.g., immune globulin, hyperimmune 
globulin, and IGIV) can inhibit the immune response to measles and rubella vaccines for 
≥3 months. The effect of blood and immune globulin preparations on the response to 
mumps and varicella vaccines is unknown; however, commercial immune globulin 
preparations contain antibodies to these viruses. Blood products available in the United 
States are unlikely to contain a substantial amount of antibody to yellow fever virus. The 
length of time that interference with injectable live-virus vaccine (other than yellow 
fever) can persist after the antibody-containing product is a function of the amount of 
antigen-specific antibody contained in the product (67-69). Therefore, after an 
antibody-containing product is received, live vaccines (other than Ty21a typhoid, yellow 
fever, LAIV, zoster, and rotavirus vaccines) should be delayed until the passive antibody 
has degraded (Table 3-4). If a dose of injectable live-virus vaccine (other than yellow 
fever and zoster) is administered after an antibody-containing product but at an interval 
shorter than recommended in this report, the vaccine dose should be repeated unless 
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serologic testing is feasible and indicates a response to the vaccine. The repeat dose or 
serologic testing should be performed after the interval indicated for the antibody-
containing product (Table 3-5). 
Although passively acquired antibodies can interfere with the response to rubella 
vaccine, the low dose of anti-Rho(D) globulin or any other blood product administered 
to postpartum women have not been demonstrated to reduce the response to the 
RA27/3 strain rubella vaccine (70). Congenital rubella syndrome and congenital 
varicella are conditions with considerable morbidity and represent a true risk in future 
pregnancies. Because of the importance of rubella and varicella immunity among 
women of child-bearing age (4,71), the postpartum vaccination of women without 
evidence of immunity to rubella or varicella with MMR, varicella, or MMRV vaccines 
should not be delayed because of receipt of anti-Rho(D) globulin or any other blood 
product during the last trimester of pregnancy or at delivery. Any reduction in immunity 
caused by anti-Rho(D) globulin or other blood products is outweighed by the 
opportunity to generate immunity. These women should be vaccinated immediately 
after giving birth and, if possible, tested ≥3 months later to ensure immunity to rubella 
and, if appropriate, to measles (2). Measles and rubella serologies have a low false-
positive rate and are therefore acceptable for use in this limited postpartum context.  
Interference might occur if administration of an antibody-containing product becomes 
necessary after administration of MMR or varicella vaccines. Usually, vaccine virus 
replication and stimulation of immunity occurs 1-2 weeks after vaccination. If the 
interval between administration of any of these vaccines and subsequent administration 
of an antibody-containing product is <14 days, vaccination should be repeated after the 
recommended interval (Tables 3-4 and 3-5) unless serologic testing indicates a 
protective antibody response (7). 
A humanized mouse monoclonal antibody product (palivizumab) is available as 
prophylaxis for serious lower respiratory tract disease from respiratory syncytial virus 
among infants and young children. This product contains only antibody to respiratory 
syncytial virus and does not interfere with the immune response to licensed live or 
inactivated vaccines. 
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Inactivated Vaccines 
Antibody-containing products interact less with inactivated, recombinant subunit, and 
polysaccharide vaccines and toxoids than with live vaccines (72). Therefore, 
administering inactivated vaccines and toxoids either simultaneously with or at any 
interval before or after receipt of an antibody-containing product should not 
substantially impair development of a protective antibody response (Table 3-4). The 
vaccine or toxoid and antibody preparation should be administered at different sites 
using the standard recommended dose. 
Interchangeability of Single-Component Vaccines from 
Different Manufacturers 
Certain vaccines that provide protection from the same diseases are available from 
different manufacturers, and these vaccines usually are not identical in antigen content 
or in amount or method of formulation. Manufacturers use different production 
processes, and their products might contain different concentrations of antigen per dose 
or a different stabilizer or preservative. 
Available data indicate that infants who receive sequential doses of different Hib 
conjugate, hepatitis B, and hepatitis A vaccines produce a satisfactory antibody response 
after a complete primary series (73-76). All brands of Hib conjugate, hepatitis B,(d) 
hepatitis A, rotavirus,(e) and quadrivalent meningococcal conjugate vaccines are 
interchangeable within their respective series. If different brands of a particular vaccine 
require a different number of doses for series completion (e.g., Hib and rotavirus 
vaccines) and a provider mixes brands in the primary series, the higher number of doses 
is recommended for series completion (e.g., doses of either rotavirus or Hib vaccine). 
For Hib vaccines, any monovalent or combination conjugate vaccine is acceptable for 
the booster dose of the series, if only one product was used for the primary series (55). 
Limited data are available about the safety, immunogenicity, and efficacy of using 
acellular pertussis (i.e., DTaP) vaccines from different manufacturers for successive 
doses of the pertussis series. Data from one study indicate that for the first 3 doses of the 
DTaP series, 1-2 doses of Tripedia (Sanofi Pasteur) followed by Infanrix 
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(GlaxoSmithKline) for the remaining dose (or doses) is comparable to 3 doses of 
Tripedia with regard to immunogenicity, as measured by antibodies to diphtheria, 
tetanus, and pertussis toxoids, and filamentous hemagglutinin (77). However, in the 
absence of a clear serologic correlate of protection for pertussis, the relevance of these 
immunogenicity data for protection against pertussis is unknown. When feasible, the 
same brand of DTaP vaccine should be used for all doses of the vaccination series (55). If 
vaccination providers do not know or have available the type of DTaP vaccine previously 
administered to a child, any DTaP vaccine may be used to continue or complete the 
series (55). For a child who needs 2 doses of influenza vaccine (IIV or LAIV), it is 
preferable to use the same type of vaccine for both doses. However, if the child is eligible 
for either IIV or LAIV, and the type of vaccine used for the first dose is not available, 
either vaccine can be used for the second dose (55). In a postlicensure study, 
meningococcal conjugate vaccines from different manufacturers were evaluated for 
successive doses of meningococcal conjugate vaccine. Persistence of antibodies were 
studied in recipients of MCV4-CRM after previous receipt of either MCV4-CRM or 
MenACWY-D. The percentage of persons with protective titers were the same for all 
serogroups. No data exist on the use of MenACWY-D after MCV4-CRM. Health-care 
providers should use every opportunity to provide a dose when indicated, regardless of 
the vaccine brand used for the previous dose or doses. For vaccines in general, 
vaccination should not be deferred because the brand used for previous doses is not 
available or is unknown (30,78). 
Lapsed Vaccination Schedule 
Vaccination providers should administer vaccines as close to the recommended intervals 
as possible. However, intervals between doses that are longer than recommended 
typically do not reduce final antibody concentrations, although protection might not be 
attained until the recommended number of doses has been administered. With some 
exceptions (e.g. oral typhoid vaccine) an interruption in the vaccination schedule does 
not require restarting the entire series of a vaccine or toxoid or addition of extra doses 
(7). 
Unknown or Uncertain Vaccination Status 
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Vaccination providers frequently encounter persons who do not have adequate 
documentation of vaccinations. With the exception of influenza vaccine and PPSV23, 
providers should only accept written, dated records as evidence of vaccination; self-
reported doses of influenza vaccine and PPSV23 are acceptable (60,79). The rationale 
for acceptance for influenza vaccine is that the time period of recall is one year or less, 
making it very likely that correct recall will occur. The rationale for acceptance for 
PPSV23 is high frequency of vaccination leads to an increased rate of local reactions due 
to the reactogenicity of this vaccine. Although vaccinations should not be postponed if 
records cannot be found, an attempt to locate missing records should be made by 
contacting previous health care providers, reviewing state or local IISs, and searching 
for a personally held record. If records cannot be located within a reasonable time, these 
persons should be considered susceptible and started on the age-appropriate 
vaccination schedule. Serologic testing for immunity is an alternative to vaccination for 
certain antigens (e.g., measles, rubella, hepatitis A, and tetanus). However, commercial 
serologic testing might not always be sufficiently sensitive or standardized for detection 
of vaccine-induced immunity (with the exception of hepatitis B vaccination at 1-2 
months after the final dose), and research laboratory testing might not be readily 
available. 
(a) During measles outbreaks, if cases are occurring among infants aged <12 months, measles vaccination of infants as young as 6 
months can be used as an outbreak control measure. However, doses administered at ages <12 months should not be counted as part 
of the series (80).  
(b) In certain situations, local or state requirements might mandate that doses of selected vaccines be administered on or after 
specific ages. For example, a school entry requirement might not accept a dose of MMR or varicella vaccine administered before the 
child’s first birthday. ACIP recommends that physicians and other health-care providers comply with local or state vaccination 
requirements when scheduling and administering vaccines. 
(c) Provider assessment should include number of injections, vaccine availability, likelihood of improved coverage, likelihood of 
patient return, and storage and cost considerations. 
(d) The exception is the 2-dose hepatitis B vaccination series for adolescents aged 11-15 years. Only Recombivax HB (Merck Vaccine 
Division) should be used in the schedule. Engerix-B (GlaxoSmithKline) is not approved by FDA for this schedule.  
(e)Based on expert opinion. 
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TABLE 3-1. Recommended and minimum ages and intervals between 





age for this dose 
Minimum 
age for this 
dose 
Recommended 





DTaP-1(e) 2 months 6 weeks 8 weeks 4 weeks 
DTaP-2 4 months 10 weeks 8 weeks 4 weeks 
DTaP-3 6 months 14 weeks 6-12 months(f) 6 months(f) 
DTaP-4 15-18 months 15 months(f) 3 years 6 months 
DTaP-5 4-6 years 4 years — — 
HepA-1(e) 12-23 months 12 months 6-18 months 6 months 
HepA-2 ≥18 months 18 months — — 
HepB-1 Birth Birth 4 weeks-4 months 4 weeks 
HepB-2 1-2 months 4 weeks 8 weeks-17 months 8 weeks 
HepB-3(g) 6-18 months 24 weeks — — 
Hib-1(e),(h) 2 months 6 weeks 8 weeks  4 weeks 
Hib-2 4 months 10 weeks 8 weeks 4 weeks 
Hib-3(i) 6 months 14 weeks 6-9 months 8 weeks 
Hib-4 12-15 months 12 months — — 
HPV-1(j) 11-12 years 9 years  8 weeks  4 weeks 
HPV-2 11-12 years (+2 
months) 
9 years (+4 
weeks) 
4 months 12 weeks(j) 
HPV-3(j), (k) 11-12 years (+6 
months) 
9 years (+5 
months) 
— — 
HZV(l) ≥60 years 60 years — — 
Influenza, 
inactivated(m) 
≥6 months 6 months(n) 4 weeks  4 weeks 
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IPV-1(e) 2 months 6 weeks 8 weeks 4 weeks 
IPV-2 4 months 10 weeks 8 weeks-14 months 4 weeks 
IPV-3 6-18 months 14 weeks 3-5 years 6 months 
IPV-4(o) 4-6 years 4 years  — — 
LAIV 
(intranasal)(m) 
2-49 years  2 years 4 weeks 4 weeks 
MenACWY-1(p) 11-12 years 6 weeks(q) 4-5 years 8 weeks 
MenACWY-2 16 years 11 years (+8 
weeks)(r) 
— — 
MMR-1(s) 12-15 months 12 months 3-5 years 4 weeks 
MMR-2(s) 4-6 years 13 months — — 
MPSV4-1(p) — 2 years 5 years 5 years 
MPSV4-2 — 7 years — — 
PCV13-1(h) 2 months 6 weeks 8 weeks  4 weeks 
PCV13-2 4 months 10 weeks 8 weeks  4 weeks 
PCV13-3 6 months 14 weeks 6 months 8 weeks 
PCV13-4 12-15 months 12 months — — 
PPSV-1 — 2 years 5 years 3 years 
PPSV-2(t) — 7 years — — 
Rotavirus-1(u) 2 months 6 weeks 8 weeks  4 weeks 
Rotavirus-2 4 months 10 weeks 8 weeks  4 weeks 
Rotavirus-3(u) 6 months 14 weeks — — 
Td 11-12 years  7 years 10 years 5 years 
Tdap(v) ≥11 years 7 years — — 
Varicella-1 12-15 months 12 months 3-5 years 12 weeks(w) 
Varicella-2 4-6 years 15 months(x) — — 
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Abbreviations: DTaP = diphtheria and tetanus toxoids and acellular pertussis; HepA = hepatitis A; HepB = 
hepatitis B; Hib = Haemophilus influenzae type b; HPV = human papillomavirus; HZV = herpes zoster vaccine; IPV 
= inactivated poliovirus; LAIV = live, attenuated influenza vaccine; MenACWY = quadrivalent meningococcal 
conjugate vaccine; MMR = measles, mumps, and rubella; MMRV = measles, mumps, rubella, and varicella; MPSV4 
= quadrivalent meningococcal polysaccharide vaccine; PCV13 = pneumococcal conjugate vaccine; PPSV23= 
pneumococcal polysaccharide vaccine; PRP-OMP = polyribosylribitol phosphate-meningococcal outer membrane 
protein conjugate; Td = tetanus and diphtheria toxoids; Tdap = tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis. 
(a) Combination vaccines are available. Use of licensed combination vaccines is generally preferred to separate 
injections of their equivalent component vaccines. When administering combination vaccines, the minimum age for 
administration is the oldest age for any of the individual components (exception: the minimum age for the first dose 
of MenHibrix is 6 weeks). The minimum interval between doses is equal to the greatest interval of any of the 
individual components.  
(b) Information on travel vaccines, including typhoid, Japanese encephalitis, and yellow fever, is available at 
http://www.cdc.gov/travel. Information on other vaccines that are licensed in the United States but not distributed, 
including anthrax and smallpox, is available at http://emergency.cdc.gov/bioterrorism/ . 
(c) “Months” refers to calendar months. 
(d) Within a number range, a hyphen (-) should be read as “through.” 
(e) Combination vaccines containing the hepatitis B component are available (see Table 3-2). These vaccines should 
not be administered to infants aged <6 weeks because of the other vaccine components (i.e., Hib, DTaP, HepA, and 
IPV). 
(f) The minimum recommended interval between DTaP-3 and DTaP-4 is 6 months. However, DTaP-4 need not be 
repeated if administered at least 4 months after DTaP-3. This is a special grace period of 2 months which can be 
used if evaluating records retrospectively. An additional 4 days should not be added to this grace period.  
(g) HepB-3 should be administered at least 8 weeks after HepB-2 and at least 16 weeks after HepB-1 and should not 
be administered before age 24 weeks. 
(h) For Hib and PCV13, children receiving the first dose of vaccine at age ≥7 months require fewer doses to complete 
the series. 
(i) If PRP-OMP (Pedvax-Hib, Merck Vaccine Division) was administered at ages 2 and 4 months, a dose at age 6 
months is not necessary. The final dose has a minimum age of 12 months. 
(j) Quadrivalent and nine-valent HPV vaccines are approved for males and females aged 9-26 years. The minimum 
age for HPV-3 is based on the baseline minimum age for the first dose (i.e., 9 years) and the minimum interval of 5 
months between the first and third dose. Dose 3 need not be repeated if it is administered at least 5 months after 
the first dose and the intervals between dose 1 and dose 2, and dose 2 and dose 3, are maintained at 4 weeks and 12 
weeks, respectively.  
(k) A two-dose schedule of HPV vaccine is recommended for most persons beginning the series between 9 through 
14 years of age. See HPV vaccine-specific recommendations for details.  
www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6549a5.pdf / 
(l) Herpes zoster vaccine is recommended as a single dose for persons aged ≥60 years. 
(m) One dose of influenza vaccine per season is recommended for most persons. To determine which children 
younger than 9 years should receive 2 doses in a single season, please see influenza vaccine-specific 
recommendations (81).  
(n) The minimum age for inactivated influenza vaccine varies by vaccine manufacturer. See package insert for 
vaccine-specific minimum ages. 
(o) A fourth dose is not needed if the third dose was administered at ≥4 years and at least 6 months after the 
previous dose. 
(p) Revaccination with meningococcal vaccine is recommended for previously vaccinated persons who remain at 
high risk for meningococcal disease (46). 
(q) MenACWY-D (Menactra) can be given as young as 9 months for high-risk persons. MenACWY=CRM (Menveo) 
can be given as young as 2 months for high-risk persons. Hib-MenCY can be given as young as 6 weeks for high-risk 
persons. Hib-MenCY is given as a 4-dose series at 2 months, 4 months, 6 months and 12-18 months. 
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(r) For routine non-high risk adolescent vaccination, the minimum age for the booster dose is 16 years. 
(s) Combination MMRV vaccine can be used for children aged 12 months-12 years. See text for details. 
(t) A second dose of PPSV235 years after the first dose is recommended for persons aged ≤65 years at highest risk for 
serious pneumococcal infection and those who are likely to have a rapid decline in pneumococcal antibody 
concentration (60). 
(u) The first dose of rotavirus must be administered at age 6 weeks through 14 weeks and 6 days. The vaccine series 
should not be started for infants aged ≥15 weeks, 0 days. Rotavirus should not be administered to children older 
than 8 months, 0 days of age regardless of the number of doses received between 6 weeks and 8 months, 0 days of 
age. If 2 doses of Rotarix (GlaxoSmithKline) are administered as age appropriate, a third dose is not necessary. 
(v) Only 1 dose of Tdap is recommended. Subsequent doses should be given as Td. For management of a tetanus-
prone wound in persons who have received a primary series of tetanus-toxoid–containing vaccine, the minimum 
interval after a previous dose of any tetanus-containing vaccine is 5 years. 
(w) A special grace period of 2 months, based on expert opinion, can be applied to the minimum interval of 3 
months, when evaluating records retrospectively, which results in an acceptable minimum interval of 4 weeks. An 
additional 4 days should not be added on to this grace period.  
(x) A special grace period of 2 months, based on expert opinion, can be applied to the minimum age of 15 months 
when evaluating records retrospectively, which results in an acceptable minimum age of 13 months. An additional 4 
days should not be added on to this grace period.  
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TABLE 3-2. FDA-licensed combination vaccines(a) 
Vaccine(b) Trade name 
(year licensed) 
Age range Routinely 
recommended ages 
HepA-HepB Twinrix (2001) ≥18 years  Three doses on a schedule 
of 0, 1, and 6 months  
DTaP-HepB-IPV Pediarix (2002) 6 weeks-6 
years 
Three-dose series at 2, 4, 
and 6 months of age 
MMRV ProQuad (2005) 12 months-12 
years 
Two doses, the first at 12-15 
months, the second at 4-6 
years 
DTaP-IPV Kinrix (2008) 4-6 years  Fifth dose of DTaP and 
fourth dose of IPV 
DTaP-IPV/Hib Pentacel (2008) 6 weeks-4 
years 
Four-dose schedule at 2, 4, 
6, and 15-18 months of age 
Hib-MenCY MenHibrix (2012) 6 weeks-18 
months 
Four-dose schedule at 2, 4, 
6, and 12-15 months of 
age(c) 
DTaP-IPV Quadracel (2015) 4-6 years Fifth dose of DTaP and 
fourth or fifth dose of IPV 
Abbreviations: DT = diphtheria and tetanus toxoids; DTaP = diphtheria and tetanus toxoids and acellular 
pertussis; FDA = Food and Drug Administration; HepA = hepatitis A; HepB = hepatitis B; Hib = Haemophilus 
influenzae type b; IPV = inactivated poliovirus; MMR = measles, mumps, and rubella; MMRV = measles, mumps, 
rubella, and varicella; Td = tetanus and diphtheria toxoids; Tdap = tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis.    
Source: (82). 
(a) Although MMR, DTaP, DT, Td, and Tdap are combination vaccines, they are not included on this list because 
they are not available in the United States as single-antigen products.   
(b) In descriptions of combination vaccines, dash (-) indicates products in which the active components are 
supplied in their final (combined) form by the manufacturer; slash ( / ) indicates products in which active 
components must be mixed by the user.  
(c) Hib-MenCY can be used for routine dosing of Hib vaccine but is recommended only for meningococcal 
vaccination in persons at high-risk of meningococcal disease. 
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TABLE 3-3. Guidelines for spacing of live and inactivated antigens 
Antigen combination Recommended minimum interval between 
doses 
Two or more inactivated(a),(b) May be administered simultaneously or at any interval 
between doses 
Inactivated and live(c)  May be administered simultaneously or at any interval 
between doses 
Two or more live injectable(c) 28 days minimum interval, if not administered 
simultaneously 
Source: (82). 
(a) Certain experts suggest a 28-day interval between tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis (Tdap) vaccine and tetravalent meningococcal conjugate vaccine if they are not administered 
simultaneously. 
(b) In persons with functional or anatomic asplenia, MCV-D and PCV13 should not be administered simultaneously 
and should be spaced by 4 weeks. Likewise for persons with immunosuppressive high-risk conditions indicated for 
PCV13 and PPSV23, PCV13 should be administered first, and PPSV23 should be administered no earlier than 8 
weeks later. For persons 65 years old or older indicated for PCV13 and PPSV23, PCV13 should be administered first 
and PPSV23 should be administered 6-12 months later. 
(c) The live oral vaccines Ty21a typhoid vaccine and rotavirus vaccine may be administered simultaneously with or at 
any interval before or after inactivated or live injectable vaccines. 
  
General Best Practice Guidelines for Immunization: Timing and Spacing of Immunobiologics 35 




Products administered Recommended minimum 
interval between doses 
Simultaneous 
(during the same 
clinic day) 
Antibody-containing products and 
inactivated antigen 
Can be administered 
simultaneously at different 
anatomic sites or at any time 
interval between doses 
Antibody-containing products and 
live antigen 
Should not be administered 
simultaneously.(b) If 
simultaneous administration 
of measles-containing vaccine 
or varicella vaccine is 
unavoidable, administer at 
different sites and revaccinate 
or test for seroconversion after 
the recommended interval (see 
Table 3-5) 












































(a) Blood products containing substantial amounts of immune globulin include intramuscular, subcutaneous, and 
intravenous immune globulin, specific hyperimmune globulin (e.g., hepatitis B immune globulin, tetanus immune 
globulin, varicella zoster immune globulin, and rabies immune globulin), whole blood, packed red blood cells, 
plasma, and platelet products. 
(b) Yellow fever vaccine; rotavirus vaccine; oral Ty21a typhoid vaccine; live, attenuated influenza vaccine; and zoster 
vaccine are exceptions to these recommendations. These live, attenuated vaccines can be administered at any time 
before or after or simultaneously with an antibody-containing product. 
(c) The duration of interference of antibody-containing products with the immune response to the measles 
component of measles-containing vaccine, and possibly varicella vaccine, is dose related (see Table 3-5). 
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TABLE 3-5. Recommended intervals between administration of antibody-
containing products and measles- or varicella-containing vaccine, by 
product and indication for vaccination  
Product/Indication Dose (mg IgG/kg) 
and route(a) 
Recommended interval 





Blood transfusion   
RBCs, washed 10 mL/kg, negligible 
IgG/kg IV 
None 
RBCs, adenine-saline added 10 mL/kg (10 mg 
IgG/kg) IV 
3 
Packed RBCs (hematocrit 65%)(c) 10 mL/kg (60 mg 
IgG/kg) IV 
6 
Whole blood (hematocrit 35%-
50%)(c) 
10 mL/kg (80-100 
mg IgG/kg) IV 
6 
Plasma/platelet products 10 mL/kg (160 mg 
IgG/kg) IV 
7 
Botulinum Immune Globulin 
Intravenous (Human) 
1.5 mL/kg (75 mg 
IgG/kg) IV 
6 
Cytomegalovirus IGIV 150 mg/kg 
maximum 
6 
Hepatitis A IG   
Contact prophylaxis 0.02 mL/kg (3.3 mg 
IgG/kg) IM 
3 
International travel, <3 month 
stay 
0.02 mL/kg (3.3 mg 
IgG/kg) IM 
3 
International travel, ≥3 month 
stay 
0.06 mL/kg (10 mg 
IgG/kg) IM 
3 
Hepatitis B IG 0.06 mL/kg (10 mg 
IgG/kg) IM 
3 
IGIV    
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Replacement therapy for immune 
deficiencies(d) 
300-400 mg/kg IV(d) 8 
Immune thrombocytopenic 
purpura treatment 
400 mg/kg IV 8 
Postexposure varicella 
prophylaxis(e) 
400 mg/kg IV 8 
Postexposure measles prophylaxis 
for immunocompromised contacts 
400 mg/kg IV 8 
Immune thrombocytopenic 
purpura treatment 
1000 mg/kg IV 10 
Kawasaki disease 2 g/kg IV 11 
Measles prophylaxis IG   
Standard (i.e., 
nonimmunocompromised) contact 
0.50 mL/kg (80 mg 
IgG/kg) IM 
6 
Monoclonal antibody to 
respiratory syncytial virus F 
protein (e.g., Synagis 
[MedImmune])(f) 
15 mg/kg IM None 
Rabies IG 20 IU/kg (22 mg 
IgG/kg) IM 
4 
Tetanus IG 250 units (10 mg 
IgG/kg) IM 
3 
Varicella IG 125 units/10 kg (60-
200 mg IgG/kg) IM, 
maximum 625 units 
5 
Abbreviations: HIV = human immunodeficiency virus; IG = immune globulin; IgG = immune globulin G; IGIV = 
intravenous immune globulin; mg IgG/kg = milligrams of immune globulin G per kilogram of body weight; IM = 
intramuscular; IV = intravenous; RBCs = red blood cells. 
(a) This table is not intended for determining the correct indications and dosages for using antibody-containing 
products. Unvaccinated persons might not be protected fully against measles during the entire recommended 
interval, and additional doses of IG or measles vaccine might be indicated after measles exposure. Concentrations 
of measles antibody in an IG preparation can vary by manufacturer’s lot. Rates of antibody clearance after receipt of 
an IG preparation also might vary. Recommended intervals are extrapolated from an estimated half-life of 30 days 
for passively acquired antibody and an observed interference with the immune response to measles vaccine for 5 
months after a dose of 80 mg IgG/kg. 
(b) Does not include zoster vaccine. Zoster vaccine may be given with antibody-containing blood products. 
(c) Assumes a serum IgG concentration of 16 mg/mL. 
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(d) Measles vaccination is recommended for children with mild or moderate immunosuppression from HIV 
infection, and varicella vaccination may be considered for children with mild or moderate immunosuppression, but 
both are contraindicated for persons with severe immunosuppression from HIV or any other immunosuppressive 
disorder. 
(e) Licensed VariZIG, similar to licensed varicella-zoster IG (VZIG), is a purified human IG preparation made from 
plasma containing high levels of antivaricella antibodies (IgG).  
(f) Contains antibody only to respiratory syncytial virus. 
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4. Contraindications and Precautions 
Updates 
Major changes to the best practice guidance in this section include 1) enhancement of 
the definition of a “precaution” to include any condition that might confuse diagnostic 
accuracy and 2) recommendation to vaccinate during a hospitalization if a patient is not 
acutely moderately or severely ill. 
General Principles  
Contraindications (conditions in a recipient that increases the risk for a serious adverse 
reaction) and precautions to vaccination are conditions under which vaccines should not 
be administered. Because the majority of contraindications and precautions are 
temporary, vaccinations often can be administered later when the condition leading to a 
contraindication or precaution no longer exists. A vaccine should not be administered 
when a contraindication is present; for example, MMR vaccine should not be 
administered to severely immunocompromised persons (1). However, certain conditions 
are commonly misperceived as contraindications (i.e., are not valid reasons to defer 
vaccination). 
National standards for pediatric vaccination practices have been established and include 
descriptions of valid contraindications and precautions to vaccination (2). Persons who 
administer vaccines should screen patients for contraindications and precautions to the 
vaccine before each dose of vaccine is administered (Table 4-1). Screening is facilitated 
by consistent use of screening questionnaires, which are available from certain state 
vaccination programs and other sources (e.g., the Immunization Action Coalition, 
http://www.immunize.org). 
Severely immunocompromised persons generally should not receive live vaccines (3). 
Because of the theoretical risk to the fetus, women known to be pregnant generally 
should not receive live, attenuated virus vaccines (4). Persons who experienced 
General Best Practice Guidelines for Immunization: Contraindications and Precautions  51 
encephalopathy within 7 days after administration of a previous dose of pertussis-
containing vaccine not attributable to another identifiable cause should not receive 
additional doses of a vaccine that contains pertussis (4,5). Severe Combined 
Immunodeficiency (SCID) disease and a history of intussusception are both 
contraindications to the receipt of rotavirus vaccines (6).  
A precaution is a condition in a recipient that might increase the risk for a serious 
adverse reaction, might cause diagnostic confusion, or might compromise the ability of 
the vaccine to produce immunity (e.g., administering measles vaccine to a person with 
passive immunity to measles from a blood transfusion administered up to 7 months 
prior) (7). A person might experience a more severe reaction to the vaccine than would 
have otherwise been expected; however, the risk for this happening is less than the risk 
expected with a contraindication. In general, vaccinations should be deferred when a 
precaution is present. However, a vaccination might be indicated in the presence of a 
precaution if the benefit of protection from the vaccine outweighs the risk for an adverse 
reaction.  
The presence of a moderate or severe acute illness with or without a fever is a precaution 
to administration of all vaccines (Table 4-1). The decision to administer or delay 
vaccination because of a current or recent acute illness depends on the severity of 
symptoms and etiology of the condition. The safety and efficacy of vaccinating persons 
who have mild illnesses have been documented (8-11). Vaccination should be deferred 
for persons with a moderate or severe acute illness. This precaution avoids causing 
diagnostic confusion between manifestations of the underlying illness and possible 
adverse effects of vaccination or superimposing adverse effects of the vaccine on the 
underlying illness. After they are screened for contraindications, persons with moderate 
or severe acute illness should be vaccinated as soon as the acute illness has improved. 
Studies indicate that failure to vaccinate children with minor illnesses can impede 
vaccination efforts (12–14). Among persons whose compliance with medical care cannot 
be ensured, use of every opportunity to administer appropriate vaccines is critical. 
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Hospitalization should be used as an opportunity to provide recommended vaccinations. 
Health-care facilities are held to standards of offering influenza vaccine for hospitalized 
patients, so providers are incentivized to vaccinate these patients at some point during 
hospitalization (15). Likewise, patients admitted for elective procedures will not be 
acutely ill during all times during their hospitalization. Most studies that have explored 
the effect of surgery or anesthesia on the immune system were observational, included 
only infants and children, and were small and indirect, in that they did not look at the 
immune effect on the response to vaccination specifically (16-35). They do not provide 
convincing evidence that recent anesthesia or surgery significantly affect response to 
vaccines. Current, recent, or upcoming anesthesia/surgery/hospitalization is not a 
contraindication to vaccination (16-35). Efforts should be made to ensure vaccine 
administration during the hospitalization or at discharge. For patients who are deemed 
moderately or severely ill throughout the hospitalization, vaccination should occur at 
the earliest opportunity (i.e., during immediate post-hospitalization follow-up care, 
including home or office visits) when patients’ clinical symptoms have improved.  
A personal or family history of seizures is a precaution for MMRV vaccination; this is 
because a recent study found an increased risk for febrile seizures in children 12-23 
months who receive MMRV compared with MMR and varicella vaccine (36). 
Clinicians or other health-care providers might misperceive certain conditions or 
circumstances as valid contraindications or precautions to vaccination when they 
actually do not preclude vaccination (2) (Table 4-2). These misperceptions result in 
missed opportunities to administer recommended vaccines (37).  
Routine physical examinations and procedures (e.g., measuring temperatures) are not 
prerequisites for vaccinating persons who appear to be healthy. The provider should ask 
the parent or guardian if the child is ill. If the child has a moderate or severe illness, the 
vaccination should be postponed.  
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TABLE 4-1. Contraindications and precautions(a) to commonly used vaccines 
Vaccine Citation Contraindications  Precautions 
DT, Td (4) Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
GBS <6 weeks after previous dose of 
tetanus-toxoid–containing vaccine 
History of Arthus-type 
hypersensitivity reactions after a 
previous dose of diphtheria-toxoid—
containing or tetanus-toxoid–
containing vaccine; defer vaccination 
until at least 10 years have elapsed 
since the last tetanus-toxoid-
containing vaccine 
Moderate or severe acute illness with 
or without fever 
DTaP (38) Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
Encephalopathy (e.g., 
coma, decreased level of 
consciousness,  
prolonged seizures), not 
attributable to another 
identifiable cause, 
within 7 days of 
administration of 
previous dose of DTP or 
DTaP 
Progressive neurologic disorder, 
including infantile spasms, 
uncontrolled epilepsy, progressive 
encephalopathy; defer DTaP until 
neurologic status clarified and 
stabilized 
Temperature of ≥105°F (≥40.5°C) 
within 48 hours after vaccination with 
a previous dose of DTP or DTaP 
Collapse or shock-like state (i.e., 
hypotonic hyporesponsive episode) 
within 48 hours after receiving a 
previous dose of DTP/DTaP 
Seizure ≤3 days after receiving a 
previous dose of DTP/DTaP 
Persistent, inconsolable crying lasting 
≥3 hours within 48 hours after 
receiving a previous dose of 
DTP/DTaP 
GBS <6 weeks after previous dose of 
tetanus-toxoid–containing vaccine 
History of Arthus-type 
hypersensitivity reactions after a 
previous dose of diphtheria-toxoid–
containing or tetanus-toxoid–
containing vaccine; defer vaccination 
until at least 10 years have elapsed 
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since the last tetanus-toxoid–
containing vaccine 
Moderate or severe acute illness with 
or without fever 
Hepatitis A (39) Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
Moderate or severe acute illness with 
or without fever 
Hepatitis B (40) Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
Hypersensitivity to yeast 
Moderate or severe acute illness with 
or without fever 
Hib (41) Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
Age <6 weeks 
Moderate or severe acute illness with 
or without fever 
HPV (42)  Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
Pregnancy  
Moderate or severe acute illness with 
or without fever 
IIV  (43) Severe allergic reaction 
(e.g., anaphylaxis) after 
previous dose of 
influenza vaccine or to 
vaccine component. 
GBS <6 weeks after a previous dose of 
influenza vaccine 
Moderate or severe acute illness with 
or without fever 
Egg allergy other than hives, e.g., 
angioedema, respiratory distress, 
lightheadedness, recurrent emesis; or 
required epinephrine or another 
emergency medical intervention (IIV 
may be administered in an inpatient 
or outpatient medical setting and 
under the supervision of a health care 
provider who is able to recognize and 
manage severe allergic conditions).  
 
 
IPV (44) Severe allergic reaction 
(e.g., anaphylaxis) after 
Pregnancy 
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a previous dose or to a 
vaccine component 
Moderate or severe acute illness with 
or without fever 
LAIV(b) (43) Severe allergic reaction 
(e.g., anaphylaxis) after 
a vaccine component, 
including egg protein  
Concomitant use of 
aspiring or aspirin-
containing medication 
in children and 
adolescents 
 
GBS <6 weeks after a previous dose of 
influenza vaccine 
Asthma in persons aged 5 years old or 
older 
Medical conditions which might 
predispose to higher risk of 
complications attributable to 
influenza(c) 
Moderate of severe acute illness with 
or without fever 
 
MenACWY (45) Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
Moderate or severe acute illness with 
or without fever 
MMR(d),(e) (1) Severe allergic reaction 
(e.g., anaphylaxis) after 





from hematologic and 






therapy(f) or patients 
with HIV infection who 
are severely 
immunocompromised) 
Recent (≤11 months) receipt of 
antibody-containing blood product 
(specific interval depends on product) 
History of thrombocytopenia or 
thrombocytopenic purpura 
Need for tuberculin skin testing or 
interferon-gamma release assay 
(IGRA) testing(g) 
Moderate or severe acute illness with 
or without fever 
MPSV4 (46) Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
Moderate or severe acute illness with 
or without fever 
PCV13 (47) Severe allergic reaction 
(e.g., anaphylaxis) after 
Moderate or severe acute illness with 
or without fever 
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a previous dose of 
PCV13 or any 
diphtheria-toxoid–
containing vaccine or to 
a component of a 
vaccine (PCV13 or any 
diphtheria-toxoid–
containing vaccine)  
PPSV23 (48) Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
Moderate or severe acute illness with 
or without fever 
RIV  (43) Severe allergic reaction 
(e.g., anaphylaxis) to 
any component of the 
vaccine 
GBS <6 weeks after a previous dose of 
influenza vaccine 
Moderate or severe acute illness with 
or without fever 
Rotavirus (6)  Severe allergic reaction 
(e.g., anaphylaxis) after 






Altered immunocompetence other 
than SCID 
Chronic gastrointestinal disease(h) 
Spina bifida or bladder exstrophy(h) 
Moderate or severe acute illness with 
or without fever 
Tdap (49) Severe allergic reaction 
(e.g., anaphylaxis) after 
a previous dose or to a 
vaccine component 
Encephalopathy (e.g., 
coma, decreased level of 
consciousness,  
prolonged seizures), not 
attributable to another 
identifiable cause, 
within 7 days of 
administration of 
previous dose of DTP, 
DTaP, or Tdap 
GBS <6 weeks after a previous dose of 
tetanus-toxoid–containing vaccine 
Progressive or unstable neurological 
disorder, uncontrolled seizures, or 
progressive encephalopathy until a 
treatment regimen has been 
established and the condition has 
stabilized 
History of Arthus-type 
hypersensitivity reactions after a 
previous dose of diphtheria-toxoid—
containing or tetanus-toxoid–
containing vaccine; defer vaccination 
until at least 10 years have elapsed 
since the last tetanus-toxoid–
containing vaccine 
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Moderate or severe acute illness with 
or without fever 
Varicella(d),(e
) 
(50) Severe allergic reaction 
(e.g., anaphylaxis) after 




from hematologic and 






therapy(f) or patients 




Recent (≤11 months) receipt of 
antibody-containing blood product 
(specific interval depends on product) 
Moderate or severe acute illness with 
or without fever 
Zoster (51)  Severe allergic reaction 
(e.g., anaphylaxis) after 




from hematologic and 






therapy(f) or patients 




Moderate or severe acute illness with 
or without fever 
Abbreviations: DT = diphtheria and tetanus toxoids; DTaP = diphtheria and tetanus toxoids and acellular pertussis; 
DTP = diphtheria toxoid, tetanus toxoid, and pertussis; GBS = Guillain-Barré syndrome; Hib = Haemophilus influenzae 
type b; HIV = human immunodeficiency virus; HPV = human papillomavirus; IIV = inactivated influenza vaccine; IPV = 
inactivated poliovirus; LAIV = live, attenuated influenza vaccine; MenACWY = quadrivalent meningococcal conjugate 
vaccine; MMR = measles, mumps, and rubella; MPSV4 = quadrivalent meningococcal polysaccharide vaccine; PCV13 = 
pneumococcal conjugate vaccine; PPSV23= pneumococcal polysaccharide vaccine; SCID = severe combined 
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immunodeficiency; RIV=recombinant influenza vaccine; Td = tetanus and diphtheria toxoids; Tdap = tetanus toxoid, 
reduced diphtheria toxoid, and acellular pertussis. 
(a) Events or conditions listed as precautions should be reviewed carefully. Benefits of and risks for administering a 
specific vaccine to a person under these circumstances should be considered. If the risk from the vaccine is believed to 
outweigh the benefit, the vaccine should not be administered. If the benefit of vaccination is believed to outweigh the risk, 
the vaccine should be administered. Whether and when to administer DTaP to children with proven or suspected 
underlying neurologic disorders should be decided on a case-by-case basis. 
(b) In addition, ACIP recommends LAIV not be used for pregnant women, immunosuppressed persons, persons with egg 
allergy, and children aged 2-4 years who have asthma or who have had a wheezing episode noted in the medical record 
within the past 12 months, or for whom parents report that a health-care provider stated that they had wheezing or 
asthma within the last 12 months. LAIV should not be administered to persons who have taken influenza antiviral 
medications within the previous 48 hours. Persons who care for severely immunosuppressed persons who require a 
protective environment should not receive LAIV, or should avoid contact with such persons for 7 days after receipt.  
(c) Source: (52). 
(d) HIV-infected children may receive varicella vaccine if CD4+ T-lymphocyte count is ≥15% and should receive MMR 
vaccine if they are aged ≥12 months and do not have evidence of current severe immunosuppression (i.e., individuals aged 
≤5 years must have CD4+T lymphocyte [CD4] percentages ≥15% for ≥6 months; and individuals aged >5 years must have 
CD4+percentages ≥15% and CD4+≥200 lymphocytes/mm3 for ≥6 months) or other current evidence of measles, rubella, 
and mumps immunity. In cases when only CD4+cell counts or only CD4+percentages are available for those older than 
age 5 years, the assessment of severe immunosuppression can be based on the CD4+values (count or percentage) that are 
available. In cases when CD4+percentages are not available for those aged ≤5 years, the assessment of severe 
immunosuppression can be based on age-specific CD4+counts at the time CD4+counts were measured; i.e., absence of 
severe immunosuppression is defined as ≥6 months above age-specific CD4+count criteria: CD4+count >750 
lymphocytes/mm3 while aged ≤12 months and CD4+count ≥500 lymphocytes/mm3 while aged 1 through 5 years. 
Sources: (1,50). 
(e) MMR and varicella-containing vaccines can be administered on the same day. If not administered on the same day, 
these vaccines should be separated by at least 28 days. 
(f) A substantially immunosuppressive steroid dose is considered to be ≥2 weeks of daily receipt of 20 mg or 2 mg/kg body 
weight of prednisone or equivalent. 
(g) If active tuberculosis is suspected, MMR should be delayed. Measles vaccination might suppress tuberculin reactivity 
temporarily. Measles-containing vaccine can be administered on the same day as tuberculin skin or IGRA testing. If 
testing cannot be performed until after the day of MMR vaccination, the test should be postponed for ≥4 weeks after the 
vaccination. If an urgent need exists to skin test or IGRA, do so with the understanding that reactivity might be reduced 
by the vaccine. 
(h) For details, see (53). 
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TABLE 4-2. Conditions incorrectly perceived as contraindications to 
vaccination (i.e., vaccines may be given under these conditions) 
Vaccine Conditions commonly misperceived as 
contraindications  
General for all 
vaccines, including 
DTaP, pediatric DT, 
adult Td, 
adolescent-adult 
Tdap, IPV, MMR, 
Hib, hepatitis A, 
hepatitis B, 
varicella, rotavirus, 
PCV13, IIV, LAIV, 
PPSV23, 
MenACWY, MPSV4, 
HPV, and herpes 
zoster 
Mild acute illness with or without fever 
Mild to moderate local reaction (i.e., swelling, redness, 
soreness); low-grade or moderate fever after previous dose 
Lack of previous physical examination in well-appearing 
person 
Current antimicrobial therapy(a) 
Convalescent phase of illness 
Preterm birth (hepatitis B vaccine is an exception in certain 
circumstances)(b) 
Recent exposure to an infectious disease 
History of penicillin allergy, other nonvaccine allergies, 
relatives with allergies, or receiving allergen extract 
immunotherapy 
History of GBS(c) 
DTaP Fever of <105°F (<40.5°C), fussiness or mild drowsiness after a 
previous dose of DTP/DTaP 
Family history of seizures 
Family history of sudden infant death syndrome 
Family history of an adverse event after DTP or DTaP 
administration 
Stable neurologic conditions (e.g., cerebral palsy, well-
controlled seizures, or developmental delay) 
Hepatitis B Pregnancy 
Autoimmune disease (e.g., systemic lupus erythematosus or 
rheumatoid arthritis) 
HPV Immunosuppression 
Previous equivocal or abnormal Papanicolaou test 
Known HPV infection 
Breastfeeding 
History of genital warts 
IIV Nonsevere (e.g., contact) allergy to latex, thimerosal, or egg  
Concurrent administration of Coumadin (generic: warfarin) or 
aminophylline 
IPV Previous receipt of ≥1 dose of oral polio vaccine 
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LAIV Health-care providers that see patients with chronic diseases 
or altered immunocompetence (an exception is providers for 
severely immunocompromised patients requiring care in a 
protected environment) 
Breastfeeding 
Contacts of persons with chronic disease or altered 
immunocompetence (an exception is contacts of severely 
immunocompromised patients requiring care in a protected 
environment) 
MMR(d),(e) Positive tuberculin skin test 
Simultaneous tuberculin skin or interferon-gamma release 
assay (IGRA) testing(f) 
Breastfeeding 
Pregnancy of recipient’s mother or other close or household 
contact 
Recipient is female of child-bearing age 
Immunodeficient family member or household contact 
Asymptomatic or mildly symptomatic HIV infection 
Allergy to eggs 
PPSV23 History of invasive pneumococcal disease or pneumonia 
Rotavirus Prematurity 
Immunosuppressed household contacts 
Pregnant household contacts 
Tdap History of fever of ≥105°F (≥40.5°C) for <48 hours after 
vaccination with a previous dose of DTP or DTaP 
History of collapse or shock-like state (i.e., hypotonic 
hyporesponsive episode) within 48 hours after receiving a 
previous dose of DTP/DTaP 
History of seizure <3 days after receiving a previous dose of 
DTP/DTaP 
History of persistent, inconsolable crying lasting >3 hours 
within 48 hours after receiving a previous dose of DTP/DTaP 
History of extensive limb swelling after DTP/DTaP/Td that is 
not an Arthus-type reaction 
History of stable neurologic disorder 
History of brachial neuritis 
Latex allergy that is not anaphylactic 
Breastfeeding 
Immunosuppression 
Varicella Pregnancy of recipient’s mother or other close or household 
contact 
Immunodeficient family member or household contact(g) 
Asymptomatic or mildly symptomatic HIV infection 
Humoral immunodeficiency (e.g., agammaglobulinemia) 
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Zoster Therapy with low-dose methotrexate (≤0.4 mg/kg/week), 
azathioprine (≤3.0 mg/kg/day), or 6-mercaptopurine (≤1.5 
mg/kg/day) for treatment of rheumatoid arthritis, psoriasis, 
polymyositis, sarcoidosis, inflammatory bowel disease, or other 
conditions 
Health-care providers of patients with chronic diseases or 
altered immunocompetence 
Contacts of patients with chronic diseases or altered 
immunocompetence 
Unknown or uncertain history of varicella in a U.S.-born 
person 
Abbreviations: DT = diphtheria and tetanus toxoids; DTP = diphtheria toxoid, tetanus toxoid, and pertussis; 
DTaP = diphtheria and tetanus toxoids and acellular pertussis; GBS = Guillain-Barré syndrome; HBsAg = hepatitis 
B surface antigen; Hib = Haemophilus influenzae type b; HIV = human immunodeficiency virus; HPV = human 
papillomavirus; IIV = inactivated influenza vaccine; IPV = inactivated poliovirus; LAIV = live, attenuated influenza 
vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella; 
MPSV4 = quadrivalent meningococcal polysaccharide vaccine; PCV = pneumococcal conjugate vaccine; PPSV23= 
pneumococcal polysaccharide vaccine; Td = tetanus and diphtheria toxoids; Tdap = tetanus toxoid, reduced 
diphtheria toxoid, and acellular pertussis. 
(a) Antibacterial drugs might interfere with Ty21a oral typhoid vaccine, and certain antiviral drugs might interfere 
with varicella-containing vaccines and LAIV4. 
(b) Hepatitis B vaccination should be deferred for infants weighing <2,000 g if the mother is documented to be 
HBsAg negative. Vaccination should commence at chronological age 1 month or at hospital discharge. For infants 
born to HBsAg-positive women, hepatitis B immune globulin and hepatitis B vaccine should be administered 
within 12 hours after birth, regardless of weight.  
(c) An exception is Guillain-Barré syndrome within 6 weeks of a dose of influenza vaccine or tetanus-toxoid–
containing vaccine, which are precautions for influenza vaccines and tetanus-toxoid containing vaccines, 
respectively. 
(d) MMR and varicella vaccines can be administered on the same day. If not administered on the same day, these 
vaccines should be separated by at least 28 days. 
(e) HIV-infected children should receive immune globulin after exposure to measles. HIV-infected children can 
receive varicella and measles vaccine if CD4+ T-lymphocyte count is >15%. (54). 
(f) Measles vaccination might suppress tuberculin reactivity temporarily. Measles-containing vaccine can be 
administered on the same day as tuberculin skin or IGRA testing. If testing cannot be performed until after the day 
of MMR vaccination, the test should be postponed for at least 4 weeks after the vaccination. If an urgent need 
exists to skin test or IGRA, do so with the understanding that reactivity might be reduced by the vaccine. 
(g) If a vaccinee experiences a presumed vaccine-related rash 7-25 days after vaccination, the person should avoid 
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5. Preventing and Managing Adverse 
Reactions 
Updates 
Major changes to the best practice guidance include 1) more descriptive characterization 
of anaphylactic allergy and 2) incorporation of protocols for managing adverse 
reactions. 
Benefit and Risk Communication 
Parents, guardians, legal representatives, and adolescent and adult patients should be 
informed about the benefits of and risks from vaccines in language that is culturally 
sensitive and at an appropriate educational level. Opportunity for questions should be 
provided before each vaccination. Discussion of the benefits of and risks from 
vaccination is sound medical practice and is required by law. 
The National Childhood Vaccine Injury Act of 1986 (1) requires that vaccine information 
materials be developed for each vaccine covered by the Act (uscode.house.gov). These 
materials, known as vaccine information statements (VISs), must be provided by all 
public and private vaccination providers each time a vaccine is administered. Copies of 
VISs are available from state health authorities responsible for vaccination and from 
CDC (http:// www.cdc.gov/vaccines/hcp/vis/index.html ). Translations of VISs into 
languages other than English are available from certain state vaccination programs and 
from the Immunization Action Coalition website (http://www.immunize.org). The act 
does not require that a signature be obtained; however, documentation of consent might 
be recommended or required by certain state or local health authorities or school 
authorities. 
Some parents or patients question the need for or safety of vaccinations and want to 
discuss the risks from and benefits of certain vaccines. Some refuse certain vaccines or 
reject all vaccinations for personal or religious reasons. Having a basic understanding of 
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how patients and parents of patients view vaccine risk and developing effective 
approaches to address vaccine safety concerns are imperative for vaccination providers. 
Each person understands and reacts to vaccine information on the basis of different 
factors, including previous experience, education, personal values, method of data 
presentation, perceptions of the risk for disease and perceived ability to control these 
risks, and risk tolerance. In some circumstances, decisions about vaccination are based 
on inaccurate information about risk provided by the media and certain websites. 
Websites and other sources of vaccine information may be inaccurate or incomplete. 
Health care providers can be a pivotal source of science-based credible information by 
discussing with parents and patients the risks from and benefits of vaccines, which helps 
patients make informed decisions. 
When a parent or patient initiates a discussion about a perceived vaccine adverse 
reaction, the health care provider should discuss the specific concerns and provide 
factual information, using appropriate language. Effective, empathetic vaccine risk 
communication is essential in responding to misinformation and concerns, with health 
care providers recognizing that risk assessment and decision-making can be difficult 
and confusing. Certain vaccines might be acceptable to a parent who is resistant to other 
vaccines. This partial acceptance can be used to facilitate additional communication. 
Their concerns can be addressed using the VIS and offering other resource materials 
(e.g., vaccination information from CDC: 
http://www.cdc.gov/vaccines/hcp/vis/index.html ). 
The American Academy of Pediatrics (AAP) does not recommend that providers exclude 
from their practice patients whose parents or guardians question or refuse vaccination. 
However, an effective public health strategy is to identify common ground and discuss 
measures that need to be followed if the decision is to defer vaccination (2). Health care 
providers should reinforce key points about each vaccine, including safety, and 
emphasize risks for disease among unvaccinated children. Parents should be advised of 
state laws regarding entry to schools or child-care facilities, which might require that 
unvaccinated children be excluded from the facility during outbreaks 
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(www.cdc.gov/vaccines/imz-
managers/coverage/schoolvaxview/requirements/index.html). These discussions 
should be documented in the patient’s medical record, including the refusal to receive 
certain vaccines (i.e., informed refusal). When a vaccine is refused when first offered the 
provider should take the opportunity to offer the vaccine again at the next visit. 
Preventing Adverse Reactions 
Vaccines are intended to produce active immunity to specific antigens. An adverse 
reaction is an undesirable side effect that occurs after a vaccination. Vaccine adverse 
reactions are classified as 1) local, 2) systemic, or 3) allergic (additional information is 
available at http://www.fda.gov). Local reactions (e.g., redness) are usually the least 
severe and most frequent. Systemic reactions (e.g., fever) occur less frequently than 
local reactions, and severe allergic reactions (e.g., anaphylaxis) are the least frequent 
reactions. Severe adverse reactions are rare (3). 
Some of the systemic reactions may be complicated by the onset of syncope. Syncope 
(vasovagal or vasodepressor reaction) can occur after vaccination and is most common 
among adolescents and young adults. In 2005, the Vaccine Adverse Event Reporting 
System (VAERS) began detecting a trend of increasing syncope reports that coincided 
with the licensure of 3 vaccines for adolescents: human papillomavirus (HPV), 
MenACWY, and Tdap (4). Of particular concern among adolescents has been the risk for 
serious secondary injuries, including skull fracture and cerebral hemorrhage. Of 463 
VAERS reports of syncope during January 1, 2005, to July 31, 2007, a total of 41 listed 
syncope with secondary injury with information on the timing after vaccination, and the 
majority of these syncope reports (76%) occurred among adolescents. Among all age 
groups, 80% of reported syncope episodes occur within 15 minutes of vaccine 
administration (additional information is available at 
http://www.cdc.gov/vaccinesafety/concerns/fainting.html ). Providers should take 
appropriate measures to prevent injuries if a patient becomes weak or dizzy or loses 
consciousness. Adolescents and adults should be seated or lying down during 
vaccination. Vaccine providers, particularly when vaccinating adolescents, should 
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consider observing patients (with patients seated or lying down) for 15 minutes after 
vaccination to decrease the risk for injury should they faint (4). If syncope develops, 
patients should be observed until the symptoms resolve. 
Although allergic reactions are a common concern for vaccine providers, these reactions 
are uncommon and anaphylaxis following vaccines is rare, occurring at a rate of 
approximately one per million doses for many vaccines (5). Epinephrine and equipment 
for managing an airway should be available for immediate use (6). The best practice to 
prevent allergic reactions is to identify individuals at increased risk by obtaining a 
history of allergy to previous vaccinations and vaccine components that might indicate 
an underlying hypersensitivity. Acute allergic reactions following vaccinations might be 
caused by the vaccine antigen, residual animal protein, antimicrobial agents, 
preservatives, stabilizers, or other vaccine components (7). Components of each vaccine 
are listed in the respective package insert. An extensive list of vaccine components and 
their use, as well as the vaccines that contain each component, has been published (8) 
and also is available from CDC 
(http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-
table-2.pdf). Additional information and tables of potential allergens in different 
vaccines are available at (http://www.vaccinesafety.edu/components-Allergens.htm). 
The allergens identified in the history can be cross-checked against the allergens 
identified in package inserts.  
Managing Acute Vaccine Reactions 
Vaccine providers should be familiar with identifying immediate-type allergic reactions, 
including anaphylaxis, and be competent in treating these events at the time of vaccine 
administration. Providers should also have a plan in place to contact emergency medical 
services immediately in the event of a severe acute vaccine reaction.  
Allergic reactions can include: local or generalized urticaria (hives) or angioedema; 
respiratory compromise due to wheezing or swelling of the throat; hypotension; and 
shock. Immediate-immunoglobulin E (IgE)–mediated (type 1) immune reactions, such 
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as anaphylaxis, usually occur within minutes of parenteral administration and involve 
specific IgE interactions with discrete antigens (9,10). Rapid recognition and initiation 
of treatment are required to prevent possible progression to respiratory failure or 
cardiovascular collapse. It is important to note that urticaria may not be present in all 
cases of anaphylaxis. For respiratory or cardiovascular symptoms, or other signs or 
symptoms of anaphylaxis, immediate intramuscular epinephrine is the treatment of 
choice (11,12). Additional doses of epinephrine as well as other drugs also might be 
indicated (Tables 5-1 and 5-2) (12). If hypotension is present, the patient should be 
placed in a recumbent position with the legs elevated. Maintenance of the airway, 
oxygen administration, and intravenous normal saline might be necessary. After the 
patient is stabilized, arrangements should be made for immediate transfer to an 
emergency facility for additional evaluation and treatment. Because anaphylaxis may 
recur after patients begin to recover, monitoring in a medical facility for several hours is 
advised, even after complete resolution of symptoms and signs. Additional information 
on management of patients with anaphylaxis has been published (9). 
Persons Who Have Had an Allergic Reaction Following a 
Previous Immunization 
For an individual patient who has experienced an immediate reaction to immunization, 
it is important to identify the type of reaction that occurred, obtain a history of prior 
allergic reactions, and try to identify the particular agent responsible. An algorithm 
approach to these patients has been published (13) and additional advice is available for 
allergists on the evaluation of these adverse events (10). In general, a history of a severe 
allergic reaction to a vaccine should be considered a contraindication to additional doses 
of the same vaccine (13). Referral of the individual to an allergist for evaluation is 
usually indicated to possibly determine the component responsible, before making 
decisions regarding administration of the additional doses of the same vaccine or other 
vaccines that have the same components. Patients who have not had a severe allergic 
reaction following a vaccine, but who have a history of possible allergy to a vaccine 
component can often be vaccinated safely after careful evaluation (6). 
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Influenza Vaccination of Persons with a History of Egg 
Allergy 
Severe allergic and anaphylactic reactions can occur in response to a number of 
influenza vaccine components, but such reactions are rare (6). All but the recombinant 
inactivated influenza vaccine may have come into contact with egg protein. The use of 
influenza vaccines for persons with a history of egg allergy has been reviewed recently by 
ACIP (14). VAERS data mining did not identify a higher than expected proportion of 
serious allergic events after influenza vaccination during the 2011-2012 season, relative 
to all other reported vaccines and adverse events in the database. Persons with a history 
of egg allergy should receive recombinant inactivated vaccine (if 18 years or older), or 
IIV with the following safety measure: vaccine recipients should be observed for at least 
30 minutes for signs of a reaction after administration of each vaccine dose.  
Other measures, such as dividing and administering the vaccine by a 2-step approach 
and skin testing with vaccine, are not recommended (10). 
All vaccines should be administered in settings in which personnel and equipment for 
rapid recognition and treatment of anaphylaxis are available. ACIP recommends that all 
vaccination providers be certified in cardiopulmonary resuscitation (CPR), have an 
office emergency plan, and ensure that all staff are familiar with the plan (6). Some 
persons who report allergy to egg might not be egg-allergic. Those who are able to eat 
lightly cooked egg (e.g., scrambled egg) without reaction are unlikely to be allergic.  
Egg-allergic persons might tolerate egg in baked products (e.g., bread or cake). 
Tolerance to egg-containing foods does not exclude the possibility of egg allergy (15). 
Egg allergy can be confirmed by a consistent medical history of adverse reactions to eggs 
and egg-containing foods, plus skin and/or blood testing for IgE antibodies to egg 
proteins. 
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A previous severe allergic reaction to influenza vaccine, regardless of the component 
suspected to be responsible for the reaction, is a contraindication to future receipt of the 
vaccine (14). 
Yellow Fever Vaccination of Persons with a History of 
Egg Allergy 
Yellow fever vaccine contains egg protein. There have been insufficient studies to 
determine which patients with egg allergy may be able to receive yellow fever vaccine, 
but there are reports of patients with true egg allergy safely receiving yellow fever 
vaccine after evaluation by specialists with expertise in the management of allergic 
reactions (16,17). According to the manufacturer, persons who are able to eat eggs or egg 
products may receive the vaccine (18). However, potential hypersensitivity reactions 
might occur in persons with a history of minor reactions to eggs. For egg-sensitive 
persons, a scratch test or intradermal test can be performed before administering the 
vaccine to check for reactivity. If a person has a severe egg-sensitivity or has a positive 
skin test to the vaccine, but the vaccination is recommended because of their travel 
destination-specific risk, desensitization can be performed under direct supervision of a 
physician experienced in the management of anaphylaxis. The desensitization proce-
dure is detailed in the product insert (see yellow fever recommendations at 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094074.
htm). 
Vaccines with MMR or Varicella Components and 
Persons with a History of Egg Allergy 
Varicella vaccine is grown in human diploid cell cultures and can safely be administered 
to persons with a severe allergy to eggs or egg proteins (19). Measles and mumps vaccine 
viruses are grown in chick embryo fibroblast tissue culture. However, persons with a 
severe egg allergy can receive measles- or mumps-containing vaccines in the usual 
manner because the content of these proteins is extremely low (20). The rare severe 
General Best Practice Guidelines for Immunization: Preventing and Managing Adverse Reactions 75 
allergic reactions after measles- or mumps-containing vaccines or varicella are thought 
to be caused by other components of the vaccine (e.g., gelatin) (21-24). MMR, MMRV, 
varicella and other vaccines contain hydrolyzed gelatin as a stabilizer.  
Vaccines and Persons with a History of Allergy to 
Substances Other than Eggs 
Persons who have had an anaphylactic reaction to gelatin or gelatin-containing products 
should be evaluated by an allergist prior to receiving gelatin-containing vaccines (6). 
Certain vaccines contain trace amounts of antimicrobial agents or other preservatives 
(e.g., neomycin or thimerosal), although allergies to these are rare. No licensed vaccine 
contains penicillin or penicillin derivatives. 
Most often, neomycin hypersensitivity manifests as contact dermatitis, a delayed-type 
(cell-mediated) immune response rather than immediate-hypersensitivity (IgE-
mediated allergy)–type response (25,26). A history of delayed-type reactions to 
neomycin is not a contraindication for administration of neomycin-containing vaccines. 
There has only been 1 reported case of immediate hypersensitivity reaction following a 
neomycin-containing vaccine (27). Persons who have had anaphylactic reactions to 
neomycin should be evaluated by an allergist prior to receiving vaccines containing 
neomycin (6). 
Thimerosal, an organic mercurial compound in use since the 1930s, is added to certain 
immunobiologics as a preservative. Since mid-2001, vaccines routinely recommended 
for infants younger than 6 months of age have been manufactured without thimerosal as 
a preservative (14). Live, attenuated vaccines have never contained thimerosal. 
Thimerosal-free formulations of inactivated influenza vaccine are available. Inactivated 
influenza vaccine also is available in formulations with only trace amounts of 
thimerosal, which remains as a manufacturing residual but is not added at the higher 
concentration that would be necessary for it to function as a preservative. Thimerosal at 
a preservative concentration is present in certain other vaccines that can be 
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administered to children (e.g., Td and DT). Information about the thimerosal content of 
vaccines is available from FDA at http://www.fda.gov/cber/vaccine/thimerosal.htm. 
Reactions to thimerosal have been described as local delayed-type hypersensitivity 
reactions with only rare reports of immediate reactions (28-31). Thimerosal elicits 
positive delayed-type hypersensitivity patch tests in 1%-18% of persons tested; however, 
these tests have no relevance to acute allergic reactions that might occur within minutes 
or hours after immunization (32,33). The majority of persons do not experience 
reactions to thimerosal administered as a component of vaccines even when patch or 
intradermal tests for thimerosal indicate hypersensitivity (31). A local or delayed-type 
hypersensitivity reaction to thimerosal is not a contraindication to receipt of a vaccine 
that contains thimerosal (34). 
Latex is sap from the rubber tree. Latex contains naturally occurring plant proteins that 
can be responsible for immediate-type allergic reactions. Latex is processed to form 
either natural rubber latex products such as gloves or dry, natural rubber products such 
as syringe plunger tips and vial stoppers. Synthetic rubber is also used in gloves, syringe 
plungers, and vial stoppers but does not contain the latex proteins linked to immediate-
type allergic reactions. Natural rubber latex or dry, natural rubber used in vaccine 
packaging generally is noted in the manufacturers’ package inserts. 
Immediate-type allergic reactions due to latex allergy have been described after 
vaccination, but such reactions are rare (35).  
If a person reports a severe anaphylactic allergy to latex, vaccines supplied in vials or 
syringes that contain natural rubber latex should be avoided if possible (6). If not, if the 
decision is made to vaccinate, providers should be prepared to treat immediate allergic 
reactions due to latex, including anaphylaxis. The most common type of latex 
hypersensitivity is a delayed-type (type 4, cell-mediated) allergic contact dermatitis (36). 
For patients with a history of contact allergy to latex, vaccines supplied in vials or 
syringes that contain dry natural rubber or natural rubber latex may be administered.  
Reporting Adverse Events After Vaccination 
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Modern vaccines are safe and effective; however, adverse events have been reported 
after administration of all vaccines (3). More complete information about adverse 
reactions to a specific vaccine is available in the package insert for each vaccine and 
from CDC at http://www.cdc.gov/vaccines/vac-gen/side-effects.htm. An adverse event 
is an untoward event that occurs after a vaccination that might be caused by the vaccine 
product or vaccination process. These events range from common, minor, local 
reactions to rare, severe, allergic reactions (e.g., anaphylaxis). Reporting to VAERS 
helps establish trends, identify clusters of adverse events, or generate hypotheses. 
However, establishing evidence for cause and effect on the basis of case reports and case 
series alone is usually not possible, because health problems that have a temporal 
association with vaccination do not necessarily indicate causality. 
Many adverse events require more detailed epidemiologic studies to compare the 
incidence of the event among vaccinees with the incidence among unvaccinated persons. 
Potential causal associations between reported adverse events after vaccination can be 
assessed through epidemiologic or clinical studies. 
The National Childhood Vaccine Injury Act of 1986 (1) requires health care personnel 
and vaccine manufacturers to report to VAERS specific adverse events that occur after 
vaccination. The reporting requirements are different for manufacturers and health care 
personnel. Manufacturers are required to report all adverse events that occur after 
vaccination to VAERS, whereas health-care providers are required to report events that 
appear in the reportable events table on the VAERS website at 
http://vaers.hhs.gov/reportable.htm. 
In addition to the mandated reporting of events listed on the reportable events table, 
health care personnel should report to VAERS all events listed in product inserts as 
contraindications, as well as all clinically significant adverse events, even if they are 
uncertain that the adverse event is related causally to vaccination (6). Persons other 
than health care personnel also can report adverse events to VAERS. 
There are 3 ways to report to VAERS: 
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1. Submit the report online via a secure website at 
https://vaers.hhs.gov/esub/step1,  
2. Fax a completed VAERS form to 877-721-0366, or  
3. Mail a completed VAERS form to VAERS, P.O. Box 1100, Rockville, MD 
20849-1100.  
A VAERS form can be downloaded from the VAERS website at 
http://vaers.hhs.gov/resources/vaers_form.pdf . VAERS forms also can be requested by 
e-mail (info@vaers.org), telephone (800-822-7967), or fax (877-721-0366). 
National Vaccine Injury Compensation Program 
The National Vaccine Injury Compensation Program, established by the National 
Childhood Vaccine Injury Act of 1986 (1), is a no-fault system in which persons thought 
to have experienced an injury or to have died as a result of administration of a covered 
vaccine can seek compensation. The program became operational on October 1, 1988, 
and is intended as an alternative to civil litigation under the traditional tort system in 
that negligence need not be proven. Claims arising from covered vaccines must first be 
adjudicated through the program before civil litigation can be pursued. 
The program relies on the Vaccine Injury Table, which lists the vaccines covered by the 
program and the injuries (including death), disabilities, illnesses, and conditions for 
which compensation might be awarded. The table defines the time during which the first 
symptom or substantial aggravation of an injury must appear after vaccination to be 
eligible. Successful claimants receive a legal presumption of causation if a condition 
listed in the table is proven, thus avoiding the need to prove actual causation in an 
individual case. Claimants also can prevail for conditions not listed in the reportable 
events table if they prove causation for covered vaccines. Additional information is 
available from the Health Resources and Services Administration (HRSA at 
http://www.hrsa.gov/vaccinecompensation or by telephone at 800-338-2382). Persons 
General Best Practice Guidelines for Immunization: Preventing and Managing Adverse Reactions 79 
who would like to file a claim for vaccine injury should contact the U.S. Court of Federal 
Claims (717 Madison Place, N.W., Washington, DC 20005; telephone: 202-357-6400). 
TABLE 5-1: Rapid overview: Emergent management of anaphylaxis in 




The most common signs and symptoms are cutaneous (eg, sudden onset of generalized 
urticaria, angioedema, flushing, pruritus). However, 10 to 20% of patients have no skin 
findings. 
Danger signs: Rapid progression of symptoms, evidence of respiratory distress (e.g., stridor, 
wheezing, dyspnea, increased work of breathing, retractions, persistent cough, cyanosis), signs 
of poor perfusion, abdominal pain, vomiting, dysrhythmia, hypotension, collapse. 
Acute 
management: 
The first and most important therapy in anaphylaxis is epinephrine. There are NO absolute 
contraindications to epinephrine in the setting of anaphylaxis. 
Airway: Immediate intubation if evidence of impending airway obstruction from angioedema. 
Delay may lead to complete obstruction. Intubation can be difficult and should be performed 
by the most experienced clinician available. Cricothyrotomy may be necessary. 
IM epinephrine (1 mg/mL preparation): Epinephrine 0.01 mg/kg should be injected 
intramuscularly in the midouter thigh. For large children (>50 kg), the maximum is 0.5 mg per 
dose. If there is no response or the response is inadequate, the injection can be repeated in 5 to 
15 minutes (or more frequently). If epinephrine is injected promptly IM, patients respond to 
one, two, or at most, three injections. If signs of poor perfusion are present or symptoms are 
not responding to epinephrine injections, prepare IV epinephrine for infusion (see below). 
Place patient in recumbent position, if tolerated, and elevate lower extremities. 
Oxygen: Give 8 to 10 L/minute via facemask or up to 100% oxygen, as needed. 
Normal saline rapid bolus: Treat poor perfusion with rapid infusion of 20 mL/kg. Reevaluate 
and repeat fluid boluses (20 mL/kg), as needed. Massive fluid shifts with severe loss of 
intravascular volume can occur. Monitor urine output. 
Albuterol: For bronchospasm resistant to IM epinephrine, give albuterol 0.15 mg/kg 
(minimum dose: 2.5 mg) in 3 mL saline inhaled via nebulizer. Repeat, as needed. 
H1 antihistamine: Consider giving diphenhydramine 1 mg/kg (max 40 mg) IV. 
H2 antihistamine: Consider giving ranitidine 1 mg/kg (max 50 mg) IV. 
Glucocorticoid: Consider giving methylprednisolone 1 mg/kg (max 125 mg) IV. 
Monitoring: Continuous noninvasive hemodynamic monitoring and pulse oximetry monitoring 
should be performed. Urine output should be monitored in patients receiving IV fluid 




Epinephrine infusion:(b) In patients with inadequate response to IM epinephrine and IV saline, 
give epinephrine continuous infusion at 0.1 to 1 mcg/kg/minute, titrated to effect. 
Vasopressors:(b) Patients may require large amounts of IV crystalloid to maintain blood 
pressure. Some patients may require a second vasopressor (in addition to epinephrine). All 
vasopressors should be given by infusion pump, with the doses titrated continuously according 
to blood pressure and cardiac rate/function monitored continuously and oxygenation 
monitored by pulse oximetry 
IM: intramuscular; IV: intravenous. 
(a) A child is defined as a prepubertal patient weighing less than 40 kg. 
(b) All patients receiving an infusion of epinephrine and/or another vasopressor require continuous noninvasive 
monitoring of blood pressure, heart rate and function, and oxygen saturation. We suggest that pediatric centers 
provide instructions for preparation of standard concentrations and also provide charts for established infusion 
rate for epinephrine and other vasopressors in infants and children. 
 
Table 5-2: Rapid overview: Emergency management of anaphylaxis in 
adults 
Diagnosis is made clinically: The most common signs and symptoms are cutaneous 
(e.g., sudden onset of generalized urticaria, 
angioedema, flushing, pruritus). However, 10 to 20% of 
patients have no skin findings. 
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 Danger signs: Rapid progression of symptoms, respiratory distress (e.g., stridor, wheezing, dyspnea, 
increased work of breathing, persistent cough, 
cyanosis), vomiting, abdominal pain, hypotension, 
dysrhythmia, chest pain, collapse. 
Acute management: The first and most important treatment in anaphylaxis 
is epinephrine. There are NO absolute contraindications 
to epinephrine in the setting of anaphylaxis. 
Airway: Immediate intubation if evidence of impending 
airway obstruction from angioedema. Delay may lead to 
complete obstruction. Intubation can be difficult and 
should be performed by the most experienced clinician 
available. Cricothyrotomy may be necessary. 
Promptly and simultaneously, give: IM epinephrine (1 mg/mL preparation): Give 
epinephrine 0.3 to 0.5 mg intramuscularly, preferably 
in the midouter thigh. Can repeat every 5 to 15 minutes 
(or more frequently), as needed. If epinephrine is 
injected promptly IM, most patients respond to one, 
two, or at most, three doses. If symptoms are not 
responding to epinephrine injections, prepare IV 
epinephrine for infusion (see below). 
Place patient in recumbent position, if tolerated, and 
elevate lower extremities. 
Oxygen: Give 8 to 10 L/minute via facemask or up to 
100% oxygen, as needed. 
Normal saline rapid bolus: Treat hypotension with 
rapid infusion of 1 to 2 liters IV. Repeat, as needed. 
Massive fluid shifts with severe loss of intravascular 
volume can occur. 
Albuterol (salbutamol): For bronchospasm resistant to 
IM epinephrine, give 2.5 to 5 mg in 3 mL saline via 
nebulizer. Repeat, as needed. 
Adjunctive therapies: H1 antihistamine:(a) Consider giving diphenhydramine 
25 to 50 mg IV (for relief of urticaria and itching only). 
H2 antihistamine:(a) Consider giving ranitidine 50 mg 
IV. 
Glucocorticoid:(a) Consider giving methylprednisolone 
125 mg IV. 
Monitoring: Continuous noninvasive hemodynamic 
monitoring and pulse oximetry monitoring should be 
performed. Urine output should be monitored in 
patients receiving IV fluid resuscitation for severe 
hypotension or shock. 
Treatment of refractory symptoms: Epinephrine infusion : For patients with inadequate 
response to IM epinephrine and IV saline, give 
epinephrine continuous infusion, beginning at 0.1 
mcg/kg/minute by infusion pump . Titrate the dose 
continuously according to blood pressure, cardiac rate 
and function, and oxygenation. 
 Vasopressors: Some patients may require a second vasopressor (in addition to epinephrine). All 
vasopressors should be given by infusion pump, with 
the doses titrated continuously according to blood 
pressure and cardiac rate/function and oxygenation 
monitored by pulse oximetry. 
 Glucagon: Patients on beta blockers may not respond to epinephrine and can be given glucagon 1 to 5 mg IV 
over 5 minutes, followed by infusion of 5 to 15 
mcg/minute. (b),(c) Rapid administration of glucagon can 
cause vomiting. 
Instructions on how to prepare and administer epinephrine for IV continuous infusions are available as 
separate tables in UpToDate. 
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IM: intramuscular; IV: intravenous. 
(a) These medications should not be used as initial or sole treatment. 
(b) All patients receiving an infusion of epinephrine and another vasopressor require continuous noninvasive 
monitoring of blood pressure, heart rate and function, and oxygen saturation. 
(c) For example, the initial infusion rate for a 70 kg patient would be 7 mcg/minute. This is consistent with the 
recommended range for non–weight-based dosing for adults, which is 2 to 10 mcg/minute. Non–weight-based 
dosing can be used if the patient's weight is not known and cannot be estimated. 
 
 Reproduced with permission from: Campbell RL, Kelso JM. Anaphylaxis: Emergency treatment. In: 
UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on 03/08/2017) Copyright © 2017 
UpToDate, Inc. For more information visit www.uptodate.com. 
Source: (37).  
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6. Vaccine Administration 
Updates 
Major changes to the best practice guidance include 1) allowances for alternate 
administration route (subcutaneous instead of intramuscular) for hepatitis A vaccine and 
2) an age cutoff of 12 years through 17 years of age for validating a dose of intradermal 
influenza vaccine if given in error. 
Infection Control and Sterile Technique 
General Precautions 
Persons administering vaccinations should follow appropriate precautions to minimize 
risk for disease exposure and spread. Hands should be cleansed with an alcohol-based 
waterless antiseptic hand rub or washed with soap and water before preparing vaccines 
for administration and between each patient contact (1). Occupational Safety and Health 
Administration (OSHA) regulations do not require gloves to be worn when 
administering vaccinations, unless persons administering vaccinations have open 
lesions on their hands or are likely to come into contact with a patient’s body fluids (2). 
If worn, gloves should be changed between patients. 
Vaccine Administration: Preparation and Timely 
Disposal 
Vaccines should be drawn up in a designated clean medication area that is not adjacent 
to areas where potentially contaminated items are placed. Multi-dose vials to be used for 
more than one patient should not be kept or accessed in the immediate patient 
treatment area. This is to prevent inadvertent contamination of the vial through direct 
or indirect contact with potentially contaminated surfaces or equipment that could then 
lead to infections in subsequent patients (3).  
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Different vaccines should never be mixed in the same syringe unless specifically licensed 
for such use (4). Single-dose vials and manufacturer-filled syringes are designed for 
single-dose administration and should be discarded if vaccine has been withdrawn or 
reconstituted and subsequently not used within the time frame specified by the 
manufacturer. Syringes that are prefilled by the manufacturer and activated (i.e., syringe 
cap removed or needle attached) but unused should be discarded at the end of the clinic 
day. For inactivated vaccines manufacturers, typically recommend use within the same 
day that a vaccine is withdrawn or reconstituted. When in doubt about the appropriate 
handling of a vaccine, vaccination providers should contact that vaccine’s manufacturer.  
 ACIP discourages the routine practice of providers’ prefilling syringes for several 
reasons. Because the majority of vaccines have a similar appearance after being drawn 
into a syringe, prefilling might result in administration errors. Because unused prefilled 
syringes also typically must be discarded if not used within the same day that they are 
filled, vaccine wastage might occur. The FDA does not license administration syringes 
for vaccine storage.  
In certain circumstances in which a single vaccine type is being used (e.g., in 
preparation for a community influenza vaccination campaign), filling a small number 
(10 or fewer) of syringes may be considered (5). The doses should be administered as 
soon as possible after filling, by the same person who filled the syringes. Unused 
syringes that are prefilled by the manufacturer and activated (i.e., syringe cap removed 
or needle attached) should be discarded at the end of the clinic day.  
Safe Use of Needles and Syringes 
Needles and syringes used for vaccine injections must be sterile and disposable. A 
separate needle and syringe should be used for each injection. Changing needles 
between drawing vaccine from a vial and injecting it into a recipient is not necessary 
unless the needle has been damaged or contaminated (6). 
Bloodborne diseases (e.g., hepatitis B, hepatitis C, human immunodeficiency virus 
[HIV]) are occupational hazards for clinicians and other health-care providers. The 
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Needlestick Safety and Prevention Act (2) was enacted in 2000 to reduce the incidence 
of needlestick injury and the consequent risk for bloodborne diseases acquired from 
patients. The act directed OSHA to strengthen its existing bloodborne pathogen 
standards. The revised standards became effective in 2001 (2). These federal regulations 
require the use of engineering and work practice controls to eliminate or minimize 
employee exposure to bloodborne pathogens (see 
https://www.osha.gov/SLTC/bloodbornepathogens/standards.html). Engineering 
controls means controls (e.g., sharps disposal containers, self-sheathing needles, safer 
medical devices, such as sharps with engineered sharps injury protections and 
needleless systems) that isolate or remove the bloodborne pathogens hazard from the 
workplace (see 
https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&
p_id=10051). Needle-shielding or needle-free devices that might satisfy the 
occupational safety regulations for administering injectable vaccines are available in the 
United States (7-8). The regulations also require maintenance of records documenting 
injuries caused by needles and other medical sharp objects and that nonmanagerial 
employees be involved in the evaluation and selection of safety-engineered devices 
before they are procured. Additional information about implementation and 
enforcement of these regulations is available from OSHA. 
To prevent inadvertent needlestick injury or reuse, safety mechanisms should be 
deployed after use and needles and syringes should be discarded immediately in labeled, 
puncture-proof containers located in the same room where the vaccine is administered 
(5). Used needles should never be recapped. 
Route of Administration 
Injectable Route 
Routes of administration are recommended by the manufacturer for each 
immunobiologic (Table 6-1). With the exceptions of bacille Calmette-Guérin (BCG) 
vaccine and smallpox vaccine (administered intraepidermally), injectable vaccines are 
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administered by the intramuscular, subcutaneous, or intradermal route. Deviation from 
the recommended route of administration might reduce vaccine efficacy (9, 10) or 
increase the risk for local adverse reactions (11-13). 
The method of administration of injectable vaccines is determined, in part, by the 
inclusion of adjuvants in some vaccines. An adjuvant is a vaccine component distinct 
from the antigen that enhances the immune response to the antigen, but might also 
increase risk of adverse reactions. To decrease risk of local adverse events, inactivated 
vaccines containing an adjuvant should be injected into a muscle. Administering a 
vaccine containing an adjuvant either subcutaneously or intradermally can cause local 
irritation, induration, skin discoloration, inflammation, and granuloma formation.  
Intramuscular Injections 
Needle Length 
Injectable immunobiologics should be administered where local, neural, vascular, or 
tissue injury is unlikely. Use of longer needles has been associated with less redness or 
swelling than occurs with shorter needles because of injection into deeper muscle mass 
(11). Appropriate needle length depends on age and body mass. Injection technique is 
the most important parameter to ensure efficient intramuscular vaccine delivery. 
For all intramuscular injections, the needle should be long enough to reach the muscle 
mass and prevent vaccine from seeping into subcutaneous tissue, but not so long as to 
involve underlying nerves, blood vessels, or bone (10,14-16). Vaccinators should be 
familiar with the anatomy of the area into which they are injecting vaccine. 
Intramuscular injections are administered at a 90-degree angle to the skin, preferably 
into the anterolateral aspect of the thigh or the deltoid muscle of the upper arm, 
depending on the age of the patient (Table 6-2). 
The needle gauge for intramuscular injection is 22-25 gauge. A decision on needle 
length and site of injection must be made for each person on the basis of the size of the 
muscle, the thickness of adipose tissue at the injection site, the volume of the material to 
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be administered, injection technique, and the depth below the muscle surface into which 
the material is to be injected (Figure 1). Some experts allow intramuscular injection with 
a ⅝-inch needle but ONLY if the skin is stretched flat (16). If the subcutaneous and 
muscle tissue are bunched to minimize the chance of striking bone (14), a 1-inch needle 
or larger is required to ensure intramuscular administration. Aspiration before injection 
of vaccines or toxoids (i.e., pulling back on the syringe plunger after needle insertion but 
before injection) is not necessary because no large blood vessels are present at the 
recommended injection sites, and a process that includes aspiration might be more 
painful for infants (17). 
Infants (Aged <12 Months) 
For the majority of infants, the anterolateral aspect of the thigh is the recommended site 
for injection because it provides comparatively larger muscle mass than the deltoid 
(Figure 2) (18). In certain circumstances (e.g., physical obstruction to other sites and no 
reasonable indication to defer doses), the gluteal muscle can be used. If the gluteal 
muscle must be used, care should be taken to define the anatomic landmarks.(a) For the 
majority of infants, a 1-inch needle is sufficient to penetrate the thigh muscle.  
Toddlers (Aged 12 Months-2 Years) 
For toddlers, the anterolateral thigh muscle is preferred, and when this site is used, the 
needle should be at least 1 inch long. The deltoid muscle can be used if the muscle mass 
is adequate. If 2 vaccines are to be administered in a single limb, they should be spaced 
an inch apart (4,19).  
Children (Aged 3-10 Years) 
The deltoid muscle is preferred for children aged 3-10 years (18); the needle length for 
deltoid site injections can range from ⅝ to 1 inch on the basis of technique. The 
anterolateral thigh can also be used (20). In this case the needle length should be 1 inch 
to 1.25 inches. Knowledge of body mass can be useful for estimating the appropriate 
needle length (21). 
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Young Adolescents (Aged 11-18 years) 
The deltoid muscle is preferred for adolescents 11-18 years of age. The anterolateral 
thigh can also be used. For injection into the anterolateral thigh, most adolescents will 
require a 1-1.5-inch needle to ensure intramuscular administration (21). 
Adults (Aged ≥19 Years) 
For adults, the deltoid muscle is recommended for routine intramuscular vaccinations 
(18) (Figure 3). The anterolateral thigh also can be used. For adults a measurement of 
body mass/weight is allowable prior to vaccination, understanding that resources to 
measure body mass/weight are not available in all clinical settings. For men and women 
who weigh <130 lbs (<60 kg), a ⅝-inch needle is sufficient to ensure intramuscular 
injection in the deltoid muscle if the injection is made at a 90-degree angle and the 
tissue is not bunched. For men and women who weigh 130-152 lbs (60-70 kg), a 1-inch 
needle is sufficient. For women who weigh 152-200 lbs (70-90 kg) and men who weigh 
152-260 lbs (70-118 kg), a 1- to 1.5-inch needle is recommended. For women who weigh 
>200 lbs (>90 kg) or men who weigh >260 lbs (>118 kg), a 1.5-inch needle is 
recommended (Table 6-2) (15). 
Subcutaneous Injections 
Subcutaneous injections are administered at a 45-degree angle, usually into the thigh for 
infants aged <12 months and in the upper-outer triceps area of persons aged ≥12 
months. Subcutaneous injections may be administered into the upper-outer triceps area 
of an infant if necessary. A ⅝-inch, 23- to 25-gauge needle should be inserted into the 
subcutaneous tissue (Figures 4 and 5) (4). 
Intradermal Injections 
One brand of injectable influenza vaccine is licensed to be administered intradermally. 
It is packaged as a pre-filled 3/50-inch microneedle injector system and approved for 
persons 18-64 years of age. The approved site is the skin over the deltoid muscle.  
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Intradermal influenza vaccine injection of someone 12-17 years of age can be counted as 
a valid dose on the presumption that their skin thickness is similar to someone 18-64 
years of age. A dose of intradermal vaccine given to someone younger than 12 years of 
age or older than 64 years of age should not be counted as valid (personal 
communication with manufacturer).  
Oral Route 
Rotavirus and oral typhoid vaccines are the only vaccines administered orally in the 
United States. Oral typhoid capsules should be administered as directed by the 
manufacturer. The capsules should not be opened or mixed with any other substance. 
Rotavirus vaccines are licensed for infants. There are 2 brands of rotavirus vaccine, and 
they have different types of applicators. Providers should consult package inserts for 
details. A dose of rotavirus vaccine need not be repeated if the vaccine is spit up or 
vomited. The infant should receive the remaining recommended doses of rotavirus 
vaccine following the routine schedule (5). 
Intranasal Route 
LAIV is approved for healthy nonpregnant persons aged 2-49 years and is the only 
vaccine administered by the intranasal route. The administration device is a nasal 
sprayer with a dose-divider clip that allows introduction of one 0.1-mL spray into each 
naris. The tip should be inserted slightly into the naris before administration. Even if the 
person coughs or sneezes immediately after administration or the dose is expelled any 
other way, the vaccine dose need not be repeated (5). 
Severely immunosuppressed persons (i.e., those who require care in a protected 
environment, e.g., bone marrow transplant patients, patients with severe combined 
immunodeficiency disease) should not administer LAIV. It would be uncommon for 
persons with these conditions to be in a role administering vaccines. Other persons at 
increased risk for influenza complications can administer LAIV. These include persons 
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with underlying medical conditions placing them at higher risk or who are likely to be at 
risk, including pregnant women, persons with asthma, and persons aged ≥50 years (22). 
Multiple Injections 
If multiple vaccines are administered at a single visit, administer each preparation at a 
different anatomic site (23). The location of all injection sites with the corresponding 
vaccine injected should be documented in each patient’s medical record. Health-care 
practices should consider using a vaccination site map so that all persons administering 
vaccines routinely use a particular anatomic site for each particular vaccine.  
 For infants and younger children, if more than 2 vaccines are injected in a single limb, 
the thigh is the preferred site because of the greater muscle mass; the injections should 
be sufficiently separated (i.e., ≥1 inch if possible) so that any local reactions can be 
differentiated (8,24). For older children and adults, the deltoid muscle can be used for 
more than one intramuscular injection. If a vaccine and an immune globulin 
preparation are administered simultaneously (e.g., Td/Tdap and tetanus immune 
globulin [TIG], hepatitis B and hepatitis B immunoglobulin [HBIG]), separate anatomic 
sites (i.e., different limbs) should be used for each injection (25,26).  
Jet Injections 
Jet injectors are needle-free devices that pressurize liquid medication, forcing it through 
a nozzle orifice into a narrow stream capable of penetrating skin to deliver a drug or 
vaccine into intradermal, subcutaneous, or intramuscular tissues (27,28). Immune 
responses generated by jet injectors against both attenuated and inactivated viral and 
bacterial antigens are usually equivalent to, and occasionally greater than, immune 
responses induced by needle injection. However, local reactions or injuries (e.g., skin 
laceration, transient neuropathy, hematoma) are sometimes more frequent on delivery 
of vaccine by jet injectors compared with needle injection, depending on the inherent 
irritability of the vaccine and operator technique (28).  
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Multiple use jet injectors using the same nozzle for consecutive injections without 
intervening sterilization were used in mass vaccination campaigns from the 1950s 
through the 1990s (28); however, these were found to be unsafe because of the 
possibility of bloodborne pathogen transmission (29-32) and should not be used. A new 
generation of jet injectors with disposable cartridges and syringes has been developed 
since the 1990s. With a new, sterile dose chamber and nozzle for each patient and 
correct use, these devices do not have the same safety concerns as multiple-use nozzle 
jet injectors. Several of the newer devices have been approved by FDA for sale in the 
United States (28) and for use with individual vaccines. Jet injectors prevent needlestick 
injuries to health-care providers (2) and can overcome improper, unsterile reuse and 
other drawbacks of needles and syringes in developing countries (7,33,34). 
Methods for Alleviating Discomfort and Pain Associated 
with Vaccination 
Comfort measures, such as distraction (e.g., playing music or pretending to blow away 
the pain), cooling of the injection site(s), topical analgesia, ingestion of sweet liquids, 
breastfeeding, swaddling, and slow, lateral swaying can help infants or children cope 
with the discomfort associated with vaccination (35-37). Pretreatment (30-60 minutes 
before injection) with a 5% topical lidocaine-prilocaine emulsion might decrease the 
pain of vaccination by causing superficial anesthesia (38,39). Evidence indicates that 
this cream does not interfere with the immune response to MMR (40). Topical 
lidocaine-prilocaine emulsion should not be used on infants aged <12 months who are 
receiving treatment with methemoglobin-inducing agents (e.g., acetaminophen, amyl 
nitrate, nitroprusside, dapsone) because of the possible development of 
methemoglobinemia (41). Use of a topical refrigerant (vapocoolant) spray immediately 
before vaccination can reduce the short-term pain associated with injections and can be 
as effective as lidocaine-prilocaine cream (42). Evidence does not support use of 
antipyretics before or at the time of vaccination; however, they can be used for the 
treatment of fever and local discomfort that might occur following vaccination. Studies 
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of children with previous febrile seizures have not demonstrated antipyretics to be 
effective in the prevention of febrile seizures (43). 
Clinical Implications of Nonstandard Vaccination Practices 
Best practice guidance for route, site, and dosage of immunobiologics is derived from 
data from clinical trials, practical experience, normal periodicity of health-care visits, 
and theoretical considerations. ACIP discourages variations from the recommended 
route, site, volume, or number of doses of any vaccine. 
Variation from the recommended route and site can result in inadequate protection. In 
adults (but not in infants) (44), the immunogenicity of hepatitis B is substantially lower 
when the gluteal rather than the deltoid site is used for administration (6). Hepatitis B 
administered intradermally might result in a lower seroconversion rate and final titer of 
hepatitis B surface antibody than when administered by the deltoid intramuscular route 
(45,46). Hepatitis B administered by any route other than intramuscular, or in adults at 
any site other than the deltoid or anterolateral thigh, should not be counted as valid and 
should be repeated (6). Similarly, doses of rabies vaccine administered in the gluteal site 
should not be counted as valid doses and should be repeated (47). Hepatitis A vaccine 
and meningococcal conjugate vaccine do not need to be repeated if administered by the 
subcutaneous route (48-49). However, for DTaP, Hib, and PCV13, there is no evidence 
related to immunogenicity of these 3 vaccines given subcutaneously. Providers should 
address circumstances in which dose(s) of these vaccines have been administered 
subcutaneously on a case-by-case basis. Inactivated influenza vaccine is immunogenic 
when administered in a lower-than-standard dose by the intradermal route to healthy 
adult volunteers. Intradermal injection produced antibody responses similar to 
intramuscular injection in vaccinees aged 18-60 years (50). However, the 
immunogenicity for persons aged ≥65 years is inadequate, and varying the 
recommended route and dose either with the intradermal product licensed through 64 
years of age or with other influenza vaccines is not recommended (19). 
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Live, attenuated injectable vaccines (e.g., MMR, varicella, yellow fever) and certain 
inactivated vaccines (e.g., meningococcal polysaccharide) are recommended by the 
manufacturers to be administered by subcutaneous injection. PPSV23and IPV are 
recommended by the manufacturer to be administered by the subcutaneous or 
intramuscular route. Response to vaccines recommended by the subcutaneous route is 
unlikely to be affected if the vaccines are administered by the intramuscular rather than 
subcutaneous route. Repeating doses of vaccine administered by the intramuscular 
route when recommended to be by the subcutaneous route is not necessary (6). 
Administering volumes smaller than recommended (e.g., inappropriately divided doses) 
might result in inadequate protection. Using reduced doses administered at multiple 
vaccination visits that equal a full dose or using smaller divided doses is not 
recommended (4). Any vaccination using less than the standard dose should not be 
counted, and the person should be revaccinated according to age unless serologic testing 
indicates that an adequate response has developed. However, if 2 half-volume 
formulations of vaccine have already been administered on the same clinic day to a 
patient recommended for the full volume formulation, these 2 doses can count as one 
full dose. If less than a full recommended dose of a vaccine is administered because of 
syringe, applicator, or needle leakage, the dose should be repeated (5). Using larger-
than-recommended dosages can be hazardous because of excessive local or systemic 
concentrations of antigens or other vaccine constituents. 
(a) If the gluteal muscle is chosen, injection should be administered lateral and superior to a line between the posterior superior iliac 
spine and the greater trochanter or in the ventrogluteal site, the center of a triangle bounded by the anterior superior iliac spine, the 
tubercle of the iliac crest, and the upper border of the greater trochanter. 
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TABLE 6-1. Dose and route of administration for selected vaccines 
Vaccine Dose Route 
DTaP, DT, Td, Tdap 0.5 mL IM 
DTaP-HepB-IPV 0.5 mL IM 
DTaP/Hib 0.5 mL IM 
DTaP-IPV/Hib 0.5 mL IM 
DTaP-IPV 0.5 mL IM 
Hib 0.5 mL IM 
Hib-MenCY 0.5 mL IM 
HepA ≤18 years: 0.5 mL 
≥19 years: 1.0 mL 
IM 
HepB ≤19 years: 0.5 mL(a) 
≥20 years: 1.0 mL 
IM 
HepA-HepB ≥18 years: 1.0 mL IM 
LAIV 0.2 mL divided dose between 
nares 
Intranasal spray 
IIV 6-35 months: 0.25 mL or 0.5 mL 
≥3 years: 0.5 mL 




MMR 0.5 mL Subcut 
MMRV 0.5 mL Subcut 
MenACWY 0.5 mL IM 
MPSV4 0.5 mL Subcut 
PCV13 0.5 mL IM 
PPSV23 0.5 mL IM or Subcut 
HPV  0.5 mL IM 
IPV 0.5 mL IM or Subcut 
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Rotavirus (RV1 or RV5) (1.0 mL or 2.0 mL) Oral 
Varicella 0.5 mL Subcut 
Herpes zoster 0.65 mL Subcut 
Abbreviations: DT = diphtheria and tetanus toxoids; DTaP = diphtheria and tetanus toxoids and acellular 
pertussis; HepA = hepatitis A; HepB = hepatitis B; Hib = Haemophilus influenzae type b; HPV = human 
papillomavirus; IIV = inactivated influenza vaccine; IM = intramuscular; IPV = inactivated poliovirus; LAIV = live, 
attenuated influenza vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; MenCY = bivalent 
meningococcal conjugate vaccine component; MMR = measles, mumps, and rubella; MMRV = measles, mumps, 
rubella, and varicella; MPSV4 = quadrivalent meningococcal polysaccharide vaccine; PCV13 = pneumococcal 
conjugate vaccine; PPSV23= pneumococcal polysaccharide vaccine; RV1 = live, attenuated monovalent rotavirus 
vaccine; RV5 = live, reassortment pentavalent rotavirus vaccine; Subcut = subcutaneous; Td = tetanus and 
diphtheria toxoids; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis. 
Source: Adapted from Immunization Action Coalition: http://www.immunize.org.  
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TABLE 6-2. Needle length and injection site of IM injections for children 
aged ≤18 years (by age) and adults aged ≥19 years (by sex and weight) 
Age group Needle length Injection site 
Children (birth-18 years) 
Neonates(a) 5/8 inch (16 mm)(b) Anterolateral thigh 
Infants, 1-12 months 1 inch (25 mm) Anterolateral thigh 
Toddlers, 1-2 years 1-1.25 inch (25-32 
mm) 
Anterolateral thigh(c) 
5/8(b)-1 inch (16-25 
mm) 
Deltoid muscle of arm 
Children, 3-10 years 5/8(b)-1 inch (16-25 
mm) 
Deltoid muscle of arm(c) 
1-1.25 inches (25-32 
mm) 
Anterolateral thigh 
Children, 11-18 years 
5/8(b)-1 inch (16-25 
mm) 
Deltoid muscle of arm(c) 
1-1.5 inches (25-38 
mm) 
Anterolateral thigh 
Adults (≥19 years) 
Men and women, <60 kg (130 lbs) 1 inch (25 mm)(d) Deltoid muscle of arm 
Men and women, 60-70 kg (130-
152 lbs) 
1 inch (25 mm) 
Men, 70-118 kg (152-260 lbs) 1-1.5 inches (25-38 
mm) 
Women, 70-90 kg (152-200 lbs) 
Men, >118 kg (260 lbs) 1.5 inches (38 mm) 
Women, >90 kg (200 lbs) 
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Abbreviation: IM = intramuscular. 
Source: (14). 
(a) First 28 days of life. 
(b) If skin is stretched tightly and subcutaneous tissues are not bunched. 
(c) Preferred site. 
(d) Some experts recommend a 5/8-inch needle for men and women who weigh <60 kg. 
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Figure 1. Intramuscular needle insertion 
 
Source: Adapted from California Immunization Branch. 
Alternate Text: This drawing shows intramuscular needle insertion into a cross-
section of skin. The needle is inserted at a 90-degree angle and penetrates the dermis, 
fatty tissue (subcutaneous), and muscle tissue. 
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Figure 2. Intramuscular/subcutaneous site of administration: anterolateral 
thigh 
 
Source: Adapted from Minnesota Department of Health. 
Alternate Text: This drawing shows a mother holding an infant. The anterolateral 
aspect of the infant’s thigh is shaded, showing the proper site for 
intramuscular/subcutaneous vaccine administration.  
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Figure 3. Intramuscular site of administration: deltoid 
 
Source: Adapted from Minnesota Department of Health. 
Alternate Text: This line drawing is a side view of an adult. The deltoid muscle of the 
arm is shaded, showing the proper site for intramuscular vaccine administration.  
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Figure 4. Subcutaneous site of administration: triceps 
 
Source: Adapted from the Minnesota Department of Health. 
Alternate Text:  This line drawing is a rear/dorsal view of an adult. The triceps muscle 
of the arm is shaded, showing the proper site for subcutaneous vaccine administration. 
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Figure 5. Subcutaneous needle insertion 
 
Source: Adapted from California Immunization Branch. 
Alternate Text: This drawing shows subcutaneous needle insertion into a cross-
section of skin. The needle is inserted at a 45-degree angle and penetrates the dermis 
and fatty tissue (subcutaneous) but not the muscle tissue.  
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7. Storage and Handling of Immunobiologics 
Updates 
Most of the 2011 language was removed because this content is now codified and 
continually updated in the CDC’s Vaccine Storage and Handling Toolkit, available at 
www.cdc.gov/vaccines/recs/storage/toolkit/default.htm. This content included Storage 
Units, Monitoring Storage Temperature, Vaccine Inventory, and Vaccine Transport. 
General Principles 
Failure to adhere to recommended specifications for storage and handling of 
immunobiologics can reduce or destroy their potency, resulting in inadequate or no 
immune response in the recipient 
(www.cdc.gov/vaccines/recs/storage/toolkit/default.htm.). Recommendations 
in the product package inserts, including methods for reconstitution of the vaccine, 
should be followed carefully. Maintenance of vaccine quality is the shared responsibility 
of all handlers of vaccines from the time a vaccine is manufactured until administration. 
All vaccines should be inspected on delivery and monitored during storage to ensure 
that the recommended storage temperatures are maintained. Vaccines should continue 
to be stored at recommended temperatures immediately upon receipt until use. 
Inadequate vaccine storage also can result in significant costs to replace vaccine 
inventory (www.cdc.gov/vaccines/recs/storage/toolkit/default.htm). 
Storage Temperature 
Vaccines licensed for refrigerator storage should be stored at 36°F-46°F (2°C-8°C). 
Liquid vaccines containing an aluminum adjuvant permanently lose potency when 
exposed to freezing temperatures. Inactivated vaccines that are stored in a liquid state 
(i.e., non-lyophilized [freeze-dried]) but that do not contain aluminum adjuvants should 
also generally be kept at refrigerator temperature, although whether or not they lose 
potency when frozen is not known. Inactivated lyophilized vaccines generally do not 
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need to be frozen, but lyophilized varicella-containing vaccines that are recommended 
to be stored frozen lose potency when exposed to higher temperatures because the 
viruses degrade more quickly at storage temperatures that are warmer than 
recommended (Table 7-1). These varicella-containing vaccines also can be prone to 
losses in sterility if kept too cold, due to increased gas permeability of the rubber vaccine 
vial (observed with use of dry ice at temperatures below -58°F or -50°C [personal 
communication, manufacturer]).  
Response to Out-of-Range Temperature Reading 
An out-of-range temperature reading should prompt immediate action. A plan should 
be developed ahead of time to address various types of emergencies that might require 
removal of vaccine from the original storage unit. Transfer of vaccines to a 
predesignated alternative emergency storage site might be necessary if a temperature 
problem cannot be resolved immediately (e.g., plugging in an unplugged unit or closing 
a door that has been left open). It is critical to avoid freezing vaccine during transport 
(improperly packing vaccine with ice can damage vaccines). Vaccine should be marked 
“do not use” and moved to the alternate site after verifying that the alternate unit is at 
the proper temperature. Determinations of vaccine viability in practice include 
consideration of both time and magnitude of temperature excursions and should be 
made in consultation with state/local public health departments or the vaccine 
manufacturer, as one or both of these groups may have additional information based on 
a broad international perspective. Damage to the immunogenicity of a vaccine exposed 
to temperatures outside of the recommended range might not be apparent visually. As a 
general rule, vaccines that have been stored at inappropriate temperatures should not 
be administered unless public health authorities or the manufacturer determine it is safe 
and effective to do so. If such vaccines already have been administered, vaccine exposed 
to inappropriate temperatures that is inadvertently administered should generally be 
repeated. Clinicians should consult promptly with state or local health departments in 
these situations. Consultation with CDC is available when necessary. 
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TABLE 7-1. Vaccine storage temperature recommendations 
Nonlyophilized, aluminum-adjuvanted vaccines  
Vaccines Vaccine storage 
temperature 
Diluent storage temperature 
Diphtheria-tetanus-
containing vaccines 




Do not freeze 
No diluent(a) 
HepA and HepB  36°F-46°F (2°C-8°C) 
Do not freeze 
No diluent 
PCV 36°F-46°F (2°C-8°C) 
Do not freeze 
No diluent 
HPV(b) 36°F-46°F (2°C-8°C) 
Do not freeze 
No diluent 
Nonlyophilized, nonaluminum-adjuvanted vaccines 
Vaccines Vaccine storage 
temperature 
Diluent storage temperature 
PRP-OMP Hib 36°F-46°F (2°C-8°C) No diluent 
IPV 36°F-46°F (2°C-8°C)  No diluent 
MenACWY(b),(c) 36°F-46°F (2°C-8°C)  No diluent 
PPSV 36°F-46°F (2°C-8°C)  No diluent 
IIV(b) 36°F-46°F (2°C-8°C)  No diluent 
Lyophilized (non-varicella) vaccines 
Vaccines Vaccine storage 
temperature 
Diluent storage temperature 
PRP-T Hib(b) 
 
36°F-46°F (2°C-8°C)(d) 35°F-46°F (2°C-8°C) 
Do not freeze 
PRP-T Hib-MenCY 36°F-46°F (2°C-8°C) 35°F-77°F (2°C-25°C) 
Do not freeze 
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MMR(b) 36°F-46°F (2°C-8°C)(d) 35°F-77°F (2°C-25°C) 
Can be refrigerated or stored at 
room temperature 
MPSV4 36°F-46°F (2°C-8°C)(d) Data are lacking on ideal pre-
reconstitution storage requirements. 
After reconstitution, vaccine should 
be stored at 35°F-46°F (2°C-8°C) 
Do not freeze 
Varicella-containing vaccines 
Vaccines Vaccine storage 
temperature 
Diluent storage temperature 
MMRV(b) -58°F-5°F (-50°C to -
15°C) 
35°F-77°F (2°C-25°C) 
Can be refrigerated or stored at 
room temperature 
Varicella(b) -58°F-5°F (-50°C to -
15°C) 
35°F-77°F (2°C-25°C) 
Can be refrigerated or stored at 
room temperature 
Herpes zoster(b) -58°F-5°F (-50°C to -
15°C) 
35°F-77°F (2°C-25°C) 
Can be refrigerated or stored at 
room temperature 
Noninjectable vaccines 
Vaccines Vaccine storage 
temperature 
Diluent storage temperature 
RV5 vaccine(b) 36°F-46°F (2°C-8°C) 
Do not freeze 
No diluent 
RV1 vaccine(b) 36°F-46°F (2°C-8°C) 
Do not freeze 
The diluent may be stored at a 
controlled room temperature 20°C-
25°C (68°F-77°F). 
Do not freeze 
LAIV 36°F-46°F (2°C-8°C) No diluent 
Abbreviations: DT = diphtheria and tetanus toxoids; DTaP = diphtheria and tetanus toxoids and acellular 
pertussis; HepA = hepatitis A; HepB = hepatitis B; Hib = Haemophilus influenzae type b; HPV = human 
papillomavirus; IIV = inactivated influenza vaccine; IPV = inactivated poliovirus; LAIV = live, attenuated influenza 
vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella; 
MMRV = measles, mumps, rubella, and varicella; MPSV4 = quadrivalent meningococcal polysaccharide vaccine; 
PCV13 = pneumococcal conjugate vaccine; PPSV23= pneumococcal polysaccharide vaccine; PRP-OMP = 
polyribosylribitol phosphate-meningococcal outer membrane protein conjugate; PRP-T = polyribosylribitol 
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phosphate polysaccharide conjugated to a tetanus toxoid; PRP-T Hib = polyribosylphosphate tetanus-toxoid 
conjugate Hib vaccine; PRP-T Hib-MenCY = polyribosylphosphate-tetanus-toxoid Hib vaccine with a bivalent 
Meningococcal vaccine; RV = rotavirus; RV1 = live, attenuated monovalent rotavirus vaccine; RV5 = live, 
reassortment pentavalent rotavirus vaccine; Td = tetanus and diphtheria toxoids; Tdap = tetanus toxoid, reduced 
diphtheria toxoid, and acellular pertussis. 
Sources: (1,2).  
(a) DTaP-Tripedia is sometimes used as a diluent for ActHib. 
(b) Protect from light. 
(c) There are 2 meningococcal conjugate vaccines; Menactra is nonlyophilized, and Menveo is lyophilized. Both 
powder and diluent should be stored at 35°F-46°F. 
(d) The lyophilized pellet may be stored at freezer temperature; the reconstituted vaccine should be stored at 
refrigerator temperature. 
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8. Altered Immunocompetence 
Updates 
This section incorporates general content from the Infectious Diseases Society of 
America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the 
Immunocompromised Host (1), to which CDC provided input in November 2011. The 
evidence supporting this guidance is based on expert opinion and arrived at by 
consensus.  
General Principles 
Altered immunocompetence, a term often used synonymously with 
immunosuppression, immunodeficiency, and immunocompromise, can be classified as 
primary or secondary. Primary immunodeficiencies generally are inherited and include 
conditions defined by an inherent absence or quantitative deficiency of cellular, 
humoral, or both components that provide immunity. Examples include congenital 
immunodeficiency diseases such as X-linked agammaglobulinemia, SCID, and chronic 
granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss 
or qualitative deficiency in cellular or humoral immune components that occurs as a 
result of a disease process or its therapy. Examples of secondary immunodeficiency 
include HIV infection, hematopoietic malignancies, treatment with radiation, and 
treatment with immunosuppressive drugs. The degree to which immunosuppressive 
drugs cause clinically significant immunodeficiency generally is dose related and varies 
by drug. Primary and secondary immunodeficiencies might include a combination of 
deficits in both cellular and humoral immunity. Certain conditions like asplenia and 
chronic renal disease also can cause altered immunocompetence.  
Determination of altered immunocompetence is important to the vaccine provider 
because incidence or severity of some vaccine-preventable diseases is higher in persons 
with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza 
vaccine, pneumococcal vaccines) are recommended specifically for persons with these 
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diseases (2,3). Administration of live vaccines might need to be deferred until immune 
function has improved. This is primarily a safety concern, because persons who have 
altered immunocompetence and receive live vaccines might be at increased risk for an 
adverse reaction because of uninhibited growth of the attenuated live virus or bacteria. 
Vaccines might be less effective during the period of altered immunocompetence. 
Inactivated vaccines might best be deferred during a period of altered 
immunocompetence; in this circumstance, the concern is with effectiveness and not 
safety. Additionally, if an inactivated vaccine is administered during the period of 
altered immunocompetence, it might need to be repeated after immune function has 
improved.  
The degree of altered immunocompetence in a patient should be determined by a 
physician. The challenge for clinicians and other health-care providers is assessing the 
safety and effectiveness of vaccines for conditions associated with primary or secondary 
immunodeficiency, especially when new therapeutic modalities are being used and 
information about the safety and effectiveness of vaccines has not been characterized 
fully in persons receiving these drugs (Table 8-1). Laboratory studies can be useful for 
assessing the effects of a disease or drug on the immune system. Tests useful to assess 
humoral immunity include immunoglobulin (and immunoglobulin subset) levels and 
specific antibody levels (e.g., tetanus and diphtheria). Tests that demonstrate the status 
of cellular immunity include lymphocyte numbers (i.e., a complete blood count with 
differential), a test that delineates concentrations and proportions of lymphocyte 
subsets (i.e., B and T lymphocytes, CD4+ B lymphocytes versus CD8+ T lymphocytes), 
and tests that measure T-cell proliferation or function in response to specific or 
nonspecific stimuli (e.g., lymphocyte proliferation assays) (4,5). The ability to 
characterize a drug or disease condition as affecting cellular or humoral immunity is 
only the first step; using this information to draw inferences about whether particular 
vaccines are indicated or whether caution is advised with use of live or inactivated 
vaccines is more complicated and might require consultation with an infectious diseases 
or immunology specialist. 
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Altered Immunocompetence as an Indication to Receive a 
Vaccine Outside of Routinely Recommended Age Groups 
This section describes situations in which vaccines are recommended outside of the 
routine-age-based recommendation because the risk for vaccine-preventable disease is 
increased due to altered immunocompetence. Persons with altered immunocompetence 
generally are recommended to receive polysaccharide-based vaccines (PCV13, PPSV23, 
and Hib), on the basis of increased risk for disease if the vaccine is withheld. For certain 
specific categories of altered immunocompetence, patients are also recommended to 
receive polysaccharide based vaccines (MenACWY, Hib-MenCY, and MPSV4).  
Pneumococcal Vaccines 
Two types of vaccine against invasive pneumococcal disease are available in the United 
States: PCV13 and PPSV23. PCV13 is recommended routinely for all children beginning 
at age 2 months through age 59 months and for adults aged 65 years or older. PCV13 is 
also recommended for children, adolescents, and adults with conditions that place them 
at high risk for invasive disease from Streptococcus pneumoniae. PCV13 is 
recommended for persons aged 6-64 years who have not previously received PCV13 and 
have congenital immunodeficiency disorders (including B- or T-lymphocyte deficiency, 
complement deficiencies, and phagocytic disorders), anatomic or functional asplenia 
(including sickle cell disease and other hemoglobinopathies), HIV infection, cochlear 
implant, cerebrospinal fluid leak, chronic renal failure, nephrotic syndrome, iatrogenic 
immunosuppression, or other immunocompromising conditions.  
PPSV23 is licensed for use in persons aged ≥2 years and recommended routinely for 
adults aged 65 years and older. PPSV23 is also recommended for persons age 2 through 
64 years with congenital immunodeficiency disorders, anatomical and functional 
asplenia, HIV infection, cochlear implant, cerebrospinal fluid leak, and iatrogenic 
immunosuppression. Complete recommendations on use of PCV13 and PPSV23 are 
available in the Recommended Immunization Schedules for Persons Aged 0 Through 18 
Years and the Recommended Adult Immunization Schedule (2,6). 
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Meningococcal Vaccines 
Three types of meningococcal vaccines are licensed in the United States: meningococcal 
conjugate (MenACWY and Hib-MenCY), meningococcal polysaccharide (MPSV4), and 
serogroup B meningococcal (MenB) vaccines. Persons with functional or anatomic 
asplenia (including sickle cell disease) and persistent complement component deficiency 
(including persons taking eculizumab [Soliris]) (7) are at increased risk for 
meningococcal disease and should receive both MenACWY and MenB vaccines. For 
children 2 months through 23 months of age, an age-appropriate series of 
meningococcal conjugate vaccine should be administered. If MenACWY-D (Menactra) is 
administered to a child with asplenia, it should be after 2 years of age and at least 4 
weeks after the completion of all PCV13 doses. A 2-dose primary series of either 
MenACWY-CRM (Menveo) or MenACWY-D (Menactra) should be administered to 
persons 2 years of age or older with asplenia or complement deficiency. Following the 
primary series of vaccine, a 3-year interval to the next dose is recommended for persons 
who received their previous dose at younger than 7 years. A 5-year interval is 
recommended for persons who received their previous dose at age 7 years or older. 
Although MPSV4 is the only meningococcal vaccine licensed for persons older than 55 
years of age, adults 56 years and older with asplenia or complement deficiency should be 
vaccinated with MenACWY-CRM or MenACWY-D rather than MPSV4 (8). 
Meningococcal serogroup B vaccines are licensed for persons 10-25 years of age and are 
recommended for persons 10 years of age or older for persons with high-risk conditions 
like functional or anatomic asplenia or persistent complement component deficiency. 
There are presently no recommendations for booster doses of either MenB vaccine 
(9,10). Complete recommendations for use of meningococcal vaccines are available in 
the Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and 
the Recommended Adult Schedule (2,6). 
Hib Vaccines 
Hib conjugate vaccines are available in single or combined antigen preparations. Hib 
vaccine is recommended routinely for all children through age 59 months. Children 12 
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through 59 months who are at high risk for invasive Hib disease (i.e., recipients of 
chemotherapy or radiation for malignant neoplasms, recipients of hematopoietic cell 
transplant, or those with functional or anatomic asplenia, HIV infection, 
immunoglobulin deficiency, or early complement component deficiency) and who are 
unvaccinated or received only one dose of Hib disease before 12 months of age should 
receive 2 additional doses of Hib vaccine; those who received 2 or more doses of Hib 
before 12 months of age should receive one additional dose. A child younger than 5 years 
of age receiving chemotherapy or radiation therapy should have Hib doses repeated if 
the doses were received during therapy or within 14 days of starting therapy; repeat 
doses should be started at least 3 months after completion of therapy. Recipients of 
hematopoietic cell transplants should be revaccinated with 3 doses of Hib vaccine, 
starting 6-12 months after successful transplant, regardless of vaccination history or 
age. Children 5-18 years of age with HIV who are unimmunized(a) should receive a dose 
of Hib vaccine; Hib vaccination is not recommended in HIV-infected adults. 
Unimmunized(a) asplenic patients older than 59 months of age or adults should receive a 
dose of Hib vaccine. Anyone 15 months of age or older who is undergoing a splenectomy 
and is unimmunized(a) should receive a dose of Hib vaccine (11). Complete 
recommendations for use of Hib vaccine are available in the Recommended 
Immunization Schedules for Persons Aged 0 Through 18 Years and the Recommended 
Adult Immunization Schedule (2,6).  
Vaccination of Contacts of Persons with Altered 
Immunocompetence 
Household contacts and other close contacts of persons with altered 
immunocompetence should receive all age- and exposure-appropriate vaccines, with the 
exception of smallpox vaccine (12,13). Receipt of vaccines will prevent the vaccine-
preventable disease, so there can be no potential transmission to the contact with 
altered immunocompetence. The live MMR, varicella, and rotavirus vaccines should be 
administered to susceptible household contacts and other close contacts of 
immunocompromised patients when indicated. Zoster vaccine can be administered 
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when indicated. MMR vaccine viruses are not transmitted to contacts, and transmission 
of varicella-zoster virus vaccine strain is rare (14,15). No specific precautions are needed 
unless the varicella vaccine recipient has a rash after vaccination, in which case direct 
contact with susceptible household contacts with altered immunocompetence should be 
avoided until the rash resolves (14,15). All members of the household should wash their 
hands after changing the diaper of an infant who received rotavirus vaccine. This 
minimizes rotavirus transmission, as shedding may occur up to one month after the last 
dose (16,17). Household and other close contacts of persons with altered 
immunocompetence should receive annual influenza vaccination. Introduction of low 
levels of vaccine viruses into the environment likely is unavoidable when administering 
LAIV. LAIV vaccine viruses are cold-adapted, so they can replicate in the nose and 
generate an immune response without entering the lungs (i.e., they are temperature 
sensitive and replicate poorly at core body temperatures). No instances have been 
reported of illness caused by attenuated vaccine virus infections among health-care 
providers or immunocompromised patients. LAIV may be administered to healthy 
household and other close contacts of persons with altered immunocompetence unless 
the person with altered immunocompetence is in a protective environment, typically 
defined as a specialized patient-care area with a positive airflow relative to the corridor, 
high-efficiency particulate air filtration, and frequent air changes (3). No preference 
exists for inactivated influenza vaccine use by health-care workers or other persons who 
have close contact with persons with lesser degrees of immunosuppression (e.g., 
persons with diabetes, persons with asthma taking high-dose corticosteroids, or persons 
infected with HIV), and no preference exists for inactivated influenza vaccine use by 
health-care workers or other healthy persons aged 5-49 years in close contact with all 
other groups at high risk. 
Inactivated Vaccines: Safety  
All inactivated vaccines can be administered safely to persons with altered 
immunocompetence, whether the vaccine is a killed whole-organism or a recombinant, 
subunit, split-virus, toxoid, polysaccharide, or polysaccharide protein-conjugate vaccine.  
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Inactivated Vaccines: Effectiveness 
Except for inactivated influenza vaccine, vaccination during chemotherapy or radiation 
therapy should be avoided if possible because antibody response might be suboptimal. 
Patients vaccinated within a 14-day period before starting immunosuppressive therapy 
or while receiving immunosuppressive therapy should be considered unimmunized and 
should be revaccinated at least 3 months after therapy is discontinued if immune 
competence has been restored. Patients who have quantitative B-cell deficiencies and 
are receiving immunoglobulin therapy should not receive either inactivated or live 
vaccines while receiving the immunoglobulin therapy because of concerns about 
effectiveness of the vaccines. Patients on chemotherapy with anti-B cell antibodies (e.g., 
rituximab) should wait at least 6 months after therapy before being vaccinated with 
inactivated vaccines. Some experts recommended longer than 6 months for some anti-B 
cell antibodies. For other forms of altered immunocompetence, if inactivated vaccines 
are indicated, the usual schedules are recommended. However, the effectiveness of such 
vaccinations might be suboptimal (1). 
Live, Attenuated Viral and Bacterial Vaccines: Effectiveness 
The same rationale regarding effectiveness that exists with inactivated vaccines also 
exists with live vaccines.  
Live, Attenuated Viral and Bacterial Vaccines: Safety 
Severe complications have followed vaccination with certain live, attenuated viral and 
live, attenuated bacterial vaccines among persons with altered immunocompetence (18-
26). Persons with most forms of altered immunocompetence should not receive live 
vaccines (MMR, varicella, MMRV, LAIV, zoster, yellow fever, Ty21a oral typhoid, BCG, 
smallpox, and rotavirus). However, exceptions exist, and are discussed in this section. 
Patients with any defect in phagocytic function (e.g., chronic granulomatous disease, 
leukocyte adhesion deficiency, myeloperoxidase deficiency, Chediak-Higashi syndrome) 
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should NOT receive live bacterial vaccines. Patients with a specific type of defect in 
phagocytic function—chronic granulomatous disease—should receive otherwise 
indicated live attenuated viral vaccines in addition to inactivated vaccines but should 
NOT receive live bacterial vaccines. Patients with defects in phagocytic function that are 
undefined or known to be accompanied by defects in T-cell and natural killer cell 
function (e.g., leukocyte adhesion deficiency, myeloperoxidase deficiency, Chediak-
Higashi syndrome) should NOT receive live attenuated viral or bacterial vaccines. These 
conditions include specific deficits in T-cell and natural killer cell function, reducing the 
response to live viral vaccine antigens to an extent not seen in chronic granulomatous 
disease (1). Children with deficiencies in complement should receive otherwise indicated 
live, attenuated viral and live, attenuated bacterial vaccines. Children with asplenia 
should not receive LAIV, but can receive other indicated live, attenuated viral and live, 
attenuated bacterial vaccines.  
Persons with severe cell-mediated immunodeficiency should not receive live, attenuated 
viral or bacterial vaccines. Patients with defects of the interferon-gamma/interleukin-12 
axis should not receive live bacterial vaccines. Patients with deficiencies of interferon-
gamma or interferon-alpha should not receive live viral or live bacterial vaccine. These 
defects involve a deficiency in cytokine production which affects the immune response 
to a wide scope of antigens, both bacterial and viral (1). Two factors support vaccination 
of HIV-exposed or HIV-infected infants with rotavirus vaccines: 1) the HIV diagnosis 
might not be established in infants born to HIV-infected mothers before the age of the 
first rotavirus vaccine dose (only 1.5%-3% of HIV-exposed infants in the United States 
will be determined to be HIV-infected), and 2) the vaccine strains of rotavirus are 
considerably attenuated. Patients taking exogenous interferon as therapy should not 
receive live bacterial or live viral vaccines.  
Children with HIV infection are at increased risk for complications from varicella and 
herpes zoster infection compared with immunocompetent children (27,28). Limited 
data among HIV-infected children younger than 8 years (specifically, those individuals 
with CDC class N, A, or B with age-specific CD4+ T-lymphocyte percentages of ≥15%) 
indicate that single-component varicella vaccine is immunogenic, effective, and safe 
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(14,28). Data on use of varicella vaccine in HIV-infected adolescents and adults are 
lacking. However, on the basis of expert opinion, the safety of varicella vaccine in HIV-
infected persons older than 8 years with comparable levels of immune function 
(CD4+T-lymphocyte count greater than 200 cells/mm3) is likely to be similar to that of 
children aged younger than 8 years (14). Varicella vaccine should be considered for 
persons who meet these criteria. Eligible HIV-infected persons 12 months of age or 
older should receive 2 doses of single-component varicella vaccine with a 3-month 
interval between doses (14,28). Doses separated by <3 months are invalid for persons 
with HIV infection. MMRV vaccine should not be administered to any HIV-infected 
person. 
Persons with HIV infection are at increased risk for severe complications if infected with 
measles. No severe or unusual adverse events have been reported after measles 
vaccination among HIV-infected persons who did not have evidence of severe 
immunosuppression (29-32). Two doses of MMR vaccine are recommended for all HIV-
infected individuals aged ≥12 months who do not have evidence of current severe 
immunosuppression (i.e., individuals aged ≤5 years must have CD4+T lymphocyte 
[CD4+] percentages ≥15% for ≥6 months, and individuals aged >5 years must have 
CD4+percentages ≥15% and CD4+≥200 lymphocytes/mm3 for ≥6 months) and do not 
have current evidence of measles, rubella, and mumps immunity. In cases when only 
CD4+cell counts or only CD4+percentages are available for those >5 years, the 
assessment of severe immunosuppression can be based on the CD4+values (count or 
percentage) that are available. In cases when CD4+percentages are not available for 
those aged ≤5 years, the assessment of severe immunosuppression can be based on age-
specific CD4+counts at the time CD4+counts were measured; i.e., absence of severe 
immunosuppression is defined as ≥6 months above age-specific CD4+count criteria: 
CD4+count >750 lymphocytes/mm3 while aged ≤12 months and CD4+count ≥500 
lymphocytes/mm3 while aged 1 through 5 years (33). Similarly, repeat doses of MMR 
vaccination are recommended for individuals with perinatal HIV infection who were 
vaccinated prior to establishment of effective combination antiretroviral therapy 
(cART). They should receive 2 appropriately spaced doses of MMR vaccine once 
effective cART has been established (individuals aged ≤5 years must have 
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CD4+percentages ≥15% for ≥6 months; individuals aged >5 years must have 
CD4+percentages ≥15% and CD4+≥200 lymphocytes/mm3 for ≥6 months) unless they 
have other acceptable current evidence of measles, rubella, and mumps immunity. 
HIV-infected persons who are receiving regular doses of IGIV are unlikely to respond to 
varicella vaccine or MMR vaccine because of the continued presence of passively 
acquired antibody. However, because of the potential benefit, MMR and varicella 
vaccines should be considered approximately 14 days before the next scheduled dose of 
IGIV (if not otherwise contraindicated), although an optimal immune response might 
not occur depending on the presence of neutralizing antibodies against the vaccine 
virus. Vaccination should be repeated (if not otherwise contraindicated) after the 
recommended interval (see Table 3-5 in the Timing and Spacing of Immunobiologics of 
this document). In most cases, this is after the therapy has been discontinued.  
Patients with leukemia, lymphoma, or other malignancies whose disease is in remission, 
who have restored immunocompetence, and whose chemotherapy has been 
discontinued for at least 3 months can receive live-virus vaccines. Persons with impaired 
humoral immunity (e.g., hypogammaglobulinemia or dysgammaglobulinemia) may be 
vaccinated with varicella vaccine (14). However, most persons with these disorders also 
receive periodic doses of IGIV. Appropriate spacing should be maintained between 
administration of IGIV and varicella vaccine in an attempt to prevent an inadequate 
response to vaccination caused by the presence of neutralizing antibodies from the IGIV.  
Zoster incidence is higher in persons with altered immunocompetence (34). Adults with 
most types of altered immunocompetence are expected to maintain residual immunity 
to varicella-zoster virus because of chronic latent infection that protects against primary 
varicella but provides incomplete protection against zoster. Zoster vaccine is 
contraindicated in persons with primary or acquired immunodeficiency (e.g., 
lymphoma, leukemia, tumors involving bone marrow, and patients receiving 
chemotherapy) and some HIV infected patients (34). Zoster vaccine may be 
administered to certain persons age 60 or older with altered immunocompetence, such 
as persons receiving low dosages of immunosuppressive medications, those with 
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isolated B-cell deficiencies (i.e., impaired humoral immunity), or those with HIV 
infection who have CD4+ T-lymphocyte counts >200 cells/mm3. 
Recipients of Hematopoietic Cell Transplants 
A hematopoietic cell transplant (HCT) results in immunosuppression because of the 
hematopoietic ablative therapy administered before the transplant, drugs used to 
prevent or treat graft-versus-host disease, and, in some cases, from the underlying 
disease process necessitating transplantation (35-37). HCT involves ablation of the bone 
marrow followed by reimplantation of the person’s own stem cells or stem cells from a 
donor. Antibody titers to vaccine-preventable diseases (e.g., tetanus, poliovirus, 
measles, mumps, rubella, and encapsulated bacteria) decrease 1-4 years after autologous 
or allogeneic HCT if the recipient is not revaccinated. HCT recipients of all ages are at 
increased risk for certain vaccine-preventable diseases, including diseases caused by 
encapsulated bacteria (i.e., pneumococcal, meningococcal, and Hib infections). As a 
result, HCT recipients who received vaccines prior to their HCT should be revaccinated 
routinely after HCT, regardless of the source of the transplanted stem cells (35-37). 
Vaccination or revaccination doses of pneumococcal vaccines, DTaP vaccine, Hib 
vaccine, hepatitis A vaccine, hepatitis B vaccine, meningococcal vaccines, IPV, 
inactivated influenza vaccines, and human papillomavirus (HPV) vaccines (for 
individuals aged 9-26 years) are recommended after HCT (1,35). Varicella, zoster, and 
MMR vaccines may be administered after HCT if 24 months have passed since HCT, the 
patient does NOT have graft-vs-host disease, and is considered immunocompetent. 
Yellow fever vaccine, rabies vaccine, tick-borne encephalitis vaccine, and Japanese 
encephalitis vaccine are not routinely administered vaccines, so their use post-HCT will 
be driven by a disease-specific risk such as exposure or travel. If someone has received 
yellow fever vaccine prior to an HCT, another dose should be administered post-HCT 
(38). BCG, LAIV, typhoid vaccine, and rotavirus vaccine are not recommended after 
HCT. Most inactivated vaccines should be initiated 6 months after the HCT (37). 
Inactivated influenza vaccine should be administered beginning at least 6 months after 
HCT and annually thereafter for the life of the patient. A dose of inactivated influenza 
vaccine can be given as early as 4 months after HCT, but a second dose should be 
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considered in this situation (37). A second dose is recommended routinely for all 
children younger than 9 years receiving influenza vaccine for the first time. Sequential 
administration of 3 doses of pneumococcal conjugate vaccine is recommended, 
beginning 3-6 months after the transplant, followed by a dose of PPSV23 (35). Some 
sources state a 4-week interval between these doses as reasonable with the dose of 
PPSV23 being replaced by a dose of PCV13 in the context of graft-versus-host disease 
(35). Others sources support 3 doses of PCV13 at 8-week intervals, with a dose of 
PPSV23 recommended 8 weeks after the last dose of PCV13 and 12 months after the 
HCT (1). A 3-dose regimen of Hib vaccine should be administered beginning 6 months 
after transplant; at least 1 month should separate the doses (37). This series should be 
given regardless of whether or not vaccine doses were administered prior to the HCT. 
The revaccination schedule for pertussis-containing vaccines includes 3 doses of DTaP 
for patients <7 years (14). For patients ≥7 years, providers have 3 options for 
revaccination: 1) 3 doses of DTaP; 2) one dose of Tdap and 2 doses of DT; or 3) one dose 
of Tdap and 2 doses of Td (16). 
Providers need to make a clinical judgment whether they will follow the revaccination 
schedule described above, even if doses were not administered prior to the HCT. There 
are specific recommendations for Hib and pertussis-containing vaccines. Use of the 3-
dose Hib schedule following HCT is supported for both patients that received Hib prior 
to HCT and those who did not receive Hib prior to HCT (6,11). For children >6 years 
who did not receive previous doses of pertussis-containing vaccine prior to the HCT, the 
preferred schedule following a dose of HCT is a dose of Tdap followed by 2 doses of Td 
(personal communication, subject matter experts). This is identical to one of the 
alternative regimens for revaccination doses, described above. 
Conditions or Drugs that Might Cause Immunodeficiencies 
Asplenia and use of corticosteroids or certain drugs have the potential to be 
immunosuppressive and are presumed to cause some degree of altered 
immunocompetence. 
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Anatomic or Functional Asplenia 
Persons with anatomic asplenia (e.g., surgical removal or congenital absence of the 
spleen) or functional asplenia (as occurs in persons with sickle cell disease) are at 
increased risk for infection by encapsulated bacteria, especially S. pneumoniae 
(pneumococcus), N. meningitidis (meningococcus), and Hib (7,8,39). Children should 
receive an age-appropriate series of PCV13. Unvaccinated children 2-5 years should 
receive 2 doses of PCV13. Children ≥6 years should receive a dose of PCV13 if they have 
not previously received a dose of PCV13. Persons aged ≥2 years should receive 2 doses of 
PPSV23 separated by 5 years, beginning 8 or more weeks after completing all 
recommended doses of PCV13 (6,7,40,41). In circumstances where both PCV13 and 
PPSV23 are indicated, doses of PCV13 should be administered first followed by PPSV23 
8 weeks after the last dose of PCV13.  
Meningococcal conjugate (MenACWY) and serogroup B (MenB) vaccines are 
recommended for persons with anatomic or functional asplenia (including sickle cell 
disease). For children 2-23 months of age, a series of MenACWY-CRM (Menveo) or Hib-
MenCY (MenHibrix) should be administered. For persons ≥2 years of age, a 2-dose 
primary series of either MenACWY-CRM or MenACWY-D (Menactra) should be 
administered. If a person with functional or anatomic asplenia is catching up on 
pneumococcal conjugate vaccine (PCV13), and the provider only carries MenACWY-D, 
indicated doses of PCV13 should be completed first and MenACWY-D should be given 4 
weeks after the PCV13 series is completed. Following the primary series of vaccine, a 3-
year interval to the next dose is recommended for asplenic children who received their 
last previous dose at age younger than 7 years. A 5-year interval for asplenic persons is 
recommended for persons who received their last previous dose at age 7 years or older. 
Meningococcal B (MenB) vaccine should be administered as either a 2-dose series of 
MenB-4C (Bexsero) or a 3-dose series of MenB-FHbp (Trumenba). The same vaccine 
product must be used for all doses. Based on available data and expert opinion, MenB-
4C or MenB-FHbp may be administered concomitantly with MenACWY vaccines, but at 
a different anatomic site, if feasible. There are presently no recommendations for 
booster doses of either MenB vaccine. 
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Hib vaccine is recommended routinely for all children through age 59 months. Children 
12-59 months with functional or anatomic asplenia and who are unvaccinated or who 
received only one dose of Hib disease before 12 months of age should receive 2 doses of 
Hib vaccine; those who received 2 or more doses of Hib before 12 months of age should 
receive one additional dose. Unimmunized(a) asplenic patients older than 59 months of 
age should receive one dose of Hib vaccine. Anyone ≥15 months of age who is 
undergoing a splenectomy and is unimmunized(a) should receive one dose of Hib 
vaccine.  
Pneumococcal, meningococcal, and Hib vaccinations should be administered at least 14 
days before elective splenectomy, if possible. If the vaccinations are not administered 
before surgery, they should be administered after the procedure as soon as the patient’s 
condition is stable. 
Corticosteroids 
The amount of systemically absorbed corticosteroids and the duration of administration 
needed to suppress the immune system of an otherwise immunocompetent person are 
not well defined. Although the immunosuppressive effects of steroid treatment vary, the 
majority of clinicians consider a dose equivalent to either ≥2 mg/kg of body weight or 
≥20 mg/day of prednisone or equivalent for persons who weigh >10 kg when 
administered for ≥14 consecutive days as sufficiently immunosuppressive to raise 
concern about the safety of vaccination with live-virus vaccines (37). This dosage is 
referred to as “high-dose corticosteroids”. Corticosteroids used in greater than 
physiologic doses also can reduce the immune response to vaccines. Vaccination 
providers should defer live-virus vaccination for at least 1 month after discontinuation 
of high-dose systemically absorbed corticosteroid therapy administered for ≥14 days. 
Following vaccination, the decision needs to be made when to restart 
immunosuppressive therapy. There are no specific recommendations about when to 
restart immunosuppressive medicines. However, when initiating immunosuppressive 
therapy, providers should wait 4 weeks after a live vaccine and 2 weeks after an 
inactivated vaccine. However, if patients require therapy for chronic inflammatory 
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conditions, this therapy should not be delayed because of past administration of 
vaccines (1). 
Corticosteroid therapy usually is not a contraindication to administering live-virus 
vaccine when administration is 1) short term (i.e., <14 days); 2) a low to moderate dose 
(i.e., <20 mg of prednisone or equivalent per day or <2mg/kg body weight per day for a 
young child); 3) long-term, alternate-day treatment with short-acting preparations; 4) 
maintenance physiologic doses (replacement therapy); or 5) topical (skin or eyes), 
inhaled, or by intra-articular, bursal, or tendon injection (37). No evidence of an 
increased risk for more severe reactions to live, attenuated viral vaccines has been 
reported among persons receiving corticosteroid therapy by aerosol, and such therapy is 
not a reason to delay vaccination.  
Other Immunosuppressive Drugs 
When feasible, clinicians should administer all indicated vaccines before initiation of 
chemotherapy, before treatment with other immunosuppressive drugs, and before 
radiation or splenectomy. Persons receiving chemotherapy or radiation for leukemia 
and other hematopoietic malignancies, or for solid tumors, should be assumed to have 
altered immunocompetence. Live, attenuated vaccines should not be administered for at 
least 3 months after such immunosuppressive therapy. Inactivated vaccines 
administered during chemotherapy should be readministered after immune competence 
is regained. Children vaccinated before receiving chemotherapy for leukemia, 
lymphoma, other malignancies, or radiation generally are thought to retain immune 
memory after treatment, although revaccination with the common childhood vaccines 
after chemotherapy for acute lymphoblastic leukemia might be indicated (42). In 
general, revaccination of a person after chemotherapy or radiation therapy is considered 
unnecessary if the previous vaccination occurred before therapy and not during therapy, 
with the exception of recipients of HCT, who should be revaccinated as recommended 
previously. Determination of the level of immune memory and the need for 
revaccination should be made by the treating physician. 
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Certain immunosuppressive medications are administered to prevent solid organ 
transplant rejection. Live vaccines should be withheld for 2 months following 
discontinuation of anti-rejection therapies in patients with a solid organ transplant. 
Zoster vaccine should be withheld one month following discontinuation of anti-rejection 
therapies (34).  
Other immunosuppressive medications include human immune mediators like 
interleukins and colony-stimulating factors, immune modulators, and medicines like 
tumor necrosis factor-alpha inhibitors and anti-B cell antibodies. Inactivated and live 
vaccines should be administered 2 or more weeks before initiating such therapies. Live 
vaccines should be withheld 3 months following such therapies, and both inactivated 
and live vaccines should be withheld at least 6 months following therapy with anti-B cell 
antibodies. Some experts recommend longer than 6 months following anti-B cell 
antibodies. Anti-B cell antibodies suppress antibody-producing cells for a prolonged 
duration, hence the longer interval recommended before administering vaccines (17). 
Zoster vaccine is an exception and should be withheld 1 month following anti-B cell 
antibodies. 
(a) Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 months of age are 
considered unimmunized. 
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Abbreviations: AIDS = acquired immunodeficiency syndrome; BCG = bacille Calmette-Guérin; HepB = hepatitis 
B; Hib = Haemophilus influenzae type b; HIV = human immunodeficiency virus; IG = immunoglobulin; IGIV = 
immune globulin intravenous; IgA = immune globulin A; IgG = immune globulin G; LAIV = live, attenuated 
influenza vaccine; MMR = measles, mumps, and rubella; MMRV = measles, mumps, rubella, and varicella; MPSV4 
= quadrivalent meningococcal polysaccharide vaccine; OPV = oral poliovirus vaccine (live); PPSV23= 
pneumococcal polysaccharide vaccine; SCID = severe combined immunodeficiency; Ty21a = live oral typhoid 
vaccine. 
Source: (43).  
(a) Other vaccines that are universally or routinely recommended should be given if not contraindicated. An 
exception is patients with B-cell deficiencies receiving immunoglobulins, who should not receive either live or 
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inactivated vaccines, due to safety (live vaccines) and efficacy (live and inactivated vaccines) concerns. 
(b) OPV is no longer available in the United States. 
(c) This table refers to contraindications for nonemergency vaccination (i.e., the ACIP recommendations); 
emergency response recommendations are addressed in the clinical guidance for smallpox vaccine use in an 
emergency. 
(d) Children 12-59 months: if unimmunized or received zero or only 1 dose, and that dose was administered before 
12 months of age, should receive 2 Hib doses, 8 weeks apart; if received 2 or more doses before age 12 months, and 
none after 12 months, should receive 1 Hib dose 8 weeks after the last dose; if completed a primary series and 
received a booster dose at age 12 months or older, no additional Hib doses are recommended. 
(e) There are no data to support IgA deficiency as a contraindication for yellow fever vaccine. 
(f) Live bacterial vaccines: BCG and oral Ty21a Salmonella Typhi vaccine. 
(g) Live viral vaccines: MMR, MMRV, OPV, LAIV, yellow fever, zoster, rotavirus, varicella, and vaccinia (smallpox). 
Nonemergency smallpox vaccination is not recommended for children younger than 18 years or the general public. 
(h) Regarding T-lymphocyte immunodeficiency as a contraindication for rotavirus vaccine, data exist only for SCID. 
(i) Symptomatic HIV infection or CD4+ T-lymphocyte count of <200/mm3 or <15% of total lymphocytes for 
children aged <6 years is a contraindication to yellow fever vaccine administration. Asymptomatic HIV infection 
with CD4+ T-lymphocyte count of 200-499/mm3 for persons aged ≥6 years or 15%-24% of total lymphocytes for 
children aged <6 years is a precaution for yellow fever vaccine administration. Details of yellow fever vaccine 
recommendations are available from CDC (44) 
(j) Patients 5-18 years of age who have not received a Hib primary series and a booster dose or at least one Hib dose 
after 14 months of age. 
(k) HIV-infected children should be considered for varicella vaccine if CD4+ T-lymphocyte count is ≥15% and 
should receive MMR vaccine if they are aged ≥12 months and do not have 1) evidence of current severe 
immunosuppression (i.e., individuals aged ≤5 years must have CD4+T lymphocyte [CD4] percentages ≥15% for ≥6 
months; and individuals aged >5 years must have CD4+percentages ≥15% and CD4+≥200 lymphocytes/mm3 for 
≥6 months) and 2) other current evidence of measles, rubella, and mumps immunity. In cases when only CD4+cell 
counts or only CD4+percentages are available for those older than age 5 years, the assessment of severe 
immunosuppression can be based on the CD4+values (count or percentage) that are available. In cases when 
CD4+percentages are not available for those aged ≤5 years, the assessment of severe immunosuppression can be 
based on age-specific CD4+counts at the time CD4+counts were measured; i.e., absence of severe 
immunosuppression is defined as ≥6 months above age-specific CD4+count criteria: CD4+count >750 
lymphocytes/mm3 while aged ≤12 months and CD4+count ≥500 lymphocytes/mm3 while aged 1 through 5 years 
(33). 
(l) Withholding inactivated vaccines also is recommended with some forms of immunosuppressive therapy, like 
anti-CD20 antibodies, induction or consolidation chemotherapy, or patients with major antibody deficiencies 
receiving immunoglobulins. Inactivated influenza vaccine is an exception, but consideration should be given to 
repeating doses of any inactivated vaccine administered during these therapies. 
(m) Persons younger than 60 months undergoing chemotherapy or radiation therapy who have not received a Hib 
primary series and a booster dose or at least one Hib dose after 14 months of age; HCT patients of any ages, 
regardless of Hib vaccine history. 
(n) Persons older than 59 months who are asplenic and persons 15 months or older who are undergoing elective 
splenectomy who have not received a Hib primary series and a booster dose or at least one Hib dose after 14 
months of age.  
 (o) Indicated based on the risk from dialysis-based bloodborne transmission. 
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9. Special Situations 
Updates 
Major revisions to this section of the best practices guidance include the timing of 
intramuscular administration and the timing of clotting factor deficiency replacement. 
Concurrent Administration of Antimicrobial Agents and Vaccines 
With a few exceptions, use of an antimicrobial agent does not interfere with the 
effectiveness of vaccination. Antibacterial agents have no effect on inactivated, 
recombinant subunit, or polysaccharide vaccines or toxoids. They also have no effect on 
response to live, attenuated vaccines, except live oral Ty21a typhoid and BCG vaccines. 
Ty21a typhoid vaccine should not be administered to persons receiving antimicrobial 
agents until 72 hours after the last dose of antimicrobial (1). If feasible, to avoid a 
possible reduction in vaccine effectiveness, antibacterial drugs should not be started or 
resumed until 1 week after the last dose of Ty21a. Antimicrobial or immunosuppressive 
agents may interfere with the immune response to BCG and should only be used under 
medical supervision (for additional information, see 
http://www.merck.com/product/usa/pi_circulars/b/bcg/bcg_pi.pdf). 
Antiviral drugs used for treatment or prophylaxis of influenza virus infections have no 
effect on the response to inactivated influenza vaccine (2). However, live, attenuated 
influenza vaccine should not be administered until 48 hours after cessation of therapy 
with antiviral influenza drugs. If feasible, to avoid possible reduction in vaccine 
effectiveness, antiviral medication should not be administered for 14 days after LAIV 
administration (2). If influenza antiviral medications are administered within 2 weeks 
after receipt of LAIV, the LAIV dose should be repeated 48 or more hours after the last 
dose of antiviral medication. Alternatively, persons receiving antiviral drugs within the 
period 2 days before to 14 days after vaccination with LAIV may be revaccinated with 
another approved vaccine formulation (e.g., IIV or recombinant influenza vaccine). 
Antiviral drugs active against herpesviruses (e.g., acyclovir or valacyclovir) might reduce 
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the efficacy of vaccines containing live, attenuated varicella zoster virus (i.e., Varivax, 
ProQuad, and Zostavax) (3,4). These drugs should be discontinued at least 24 hours 
before administration, if possible. If clinically appropriate, delay use or resumption of 
antiviral therapy for 14 days after vaccination. No data exist to suggest that commonly 
used antiviral drugs have an effect on rotavirus vaccine or MMR. 
Administration of Live Vaccines and Tuberculin Skin Tests 
(TSTs) and Interferon-gamma Release Assays (IGRAs) 
Measles illness, severe acute or chronic infections, HIV infection, and malnutrition can 
create a relatively anergic state during which the TST might have a false-negative 
reaction (5-7). Although live, attenuated measles vaccine theoretically can suppress TST 
reactivity, the degree of suppression is likely less than that occurring from acute 
infection from wild-type measles virus. Screening children for tuberculosis exposure is 
accomplished by medical history rather than TST testing; universal TST screening of all 
children is no longer recommended, though TST screening is sometimes indicated (e.g., 
for persons at increased risk for tuberculosis exposure based on medical history, or for 
employees for occupational health reasons). 
In a general screening situation, a TST may be administered simultaneously with live 
vaccines, or should be deferred for 28 days after vaccination. The TST and measles-
containing vaccine can be administered at the same visit (this is the preferred option). 
Simultaneously administering the TST and measles-containing vaccine does not 
interfere with reading the TST result at 48-72 hours and ensures that the person has 
received measles vaccine. If the measles-containing vaccine has been administered 
recently, TST screening should be delayed for at least 4 weeks after vaccination. A delay 
in performing the TST removes the concern of any theoretical transient suppression of 
TST reactivity. Some providers choose to perform TST screening and then delay the 
vaccine until the patient returns to have the TST read. This option is the least favored 
because it delays receipt of the measles-containing vaccine.  
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Because of similar concerns about smallpox vaccine and TST suppression, a TST should 
not be performed until 4 weeks after smallpox vaccination (8).No data exist regarding 
the potential degree of TST suppression that might be associated with other live, 
attenuated virus vaccines (e.g., varicella or yellow fever). However, in the absence of 
data, following guidelines for measles-containing vaccine when scheduling TST 
screening and administering other live, attenuated virus vaccines is prudent. If the 
opportunity to vaccinate might be missed, vaccination should not be delayed only 
because of these theoretical considerations.  
A test that is more specific for infection with Mycobacterium tuberculosis than TST, the 
interferon-gamma release assay (IGRA), was licensed in 2005. The IGRA requires only a 
single visit to complete and is less sensitive to the effects of previous BCG vaccination 
(9). The same timing guidelines that apply to the interval between a live vaccine and 
TST apply to IGRA (i.e., 28 days between live vaccine and IGRA if they do not occur on 
the same day), because IGRA (like TST) might be suppressed through immunologic 
mechanisms. The potential for a previous TST to cause boosting of future TST results 
should be considered in adults who might have latent tuberculosis and have a negative 
initial TST (9). The 2-step test, in which the test is given twice in a short time frame, 
reduces the chance of these false negatives, which are important to identify among 
adults who may have had or plan to have repeat testing anyway—for example, health-
care personnel who are tested yearly (9). Because this test consists of 2 TSTs (or a TST 
followed by IGRA) separated by an interval of 1-3 weeks, there is a greater window of 
time during which live vaccine replication could suppress reactivity. If a live vaccine is 
administered, the first dose of a 2-step TST should be delayed for 4 weeks, and if 
additional doses of live vaccines are indicated thereafter, they should be delayed until 
the second TST (or the IGRA after an initial TST). 
TST or IGRA reactivity in the absence of active tuberculosis is not a contraindication to 
administration of any vaccine, including live, attenuated virus vaccines. 
Note that TST screening of an asymptomatic individual is clinically different than 
testing a person suspected to have active tuberculosis. If a person is suspected to have 
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active tuberculosis, MMR vaccine is typically not administered. Active tuberculosis 
should be considered severe acute illness, and moderate or severe acute illness is a 
precaution for vaccination. 
Although no studies have reported on the effects of MMR vaccine on persons with active 
untreated tuberculosis, a theoretical basis exists for concern that measles vaccine might 
exacerbate active tuberculosis (10). As a result, before administering MMR to persons 
with untreated active tuberculosis, initiating antituberculosis therapy is advisable (10). 
Considering whether concurrent immunosuppression (e.g., immunosuppression caused 
by HIV infection) is present before administering live, attenuated vaccines also is 
necessary, because immunosuppression is a contraindication to MMR vaccine. 
Vaccination of Preterm Infants 
In the majority of cases, preterm infants (infants born before 37 weeks’ gestation), 
regardless of birth weight, should be vaccinated at the same chronological age and 
according to the same schedule and using the same precautions as for full-term infants 
and children. Birth weight and size are not factors in deciding whether to vaccinate a 
clinically stable preterm infant (11-15), except for hepatitis B vaccination. The full 
recommended dose of each vaccine should be used. Divided or reduced doses are not 
recommended. 
Decreased seroconversion rates might occur among certain preterm infants (i.e., those 
with low birth weights [<2,000 g]) after administration of hepatitis B vaccine at birth 
(16). However, by the chronological age of 1 month, all preterm infants, regardless of 
initial birth weight, are likely to respond as adequately as larger infants (17-19). Infants 
weighing <2,000 g born to HBsAg-negative mothers should receive the first dose of the 
hepatitis B vaccine series at chronological age 1 month or hospital discharge, if hospital 
discharge occurs when the infant is younger than one month of age. Preterm low-birth-
weight–infants born to HBsAg-positive mothers should receive immunoprophylaxis 
with hepatitis B vaccine within 12 hours after birth. The initial vaccine dose should not 
be counted toward completion of the hepatitis B series, and 3 additional doses of 
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hepatitis B vaccine should be administered, beginning when the infant is aged 1 month. 
For mothers with unknown HBsAg status, hepatitis B vaccine is recommended within 12 
hours of birth regardless of low-birth-weight status.  
In addition to hepatitis B vaccines, hepatitis B Immunoglobulin (HBIG) is 
recommended for infants whose mothers are HBsAg positive or unknown. If the mother 
is HBsAg positive, HBIG must be given within 12 hours of birth. If the mother’s HBsAg 
status is unknown, providers should first attempt to determine the mother’s status. 
Regardless, if the infant is preterm or low birth weight, HBIG must be given within 12 
hours of birth. If the infant is neither preterm nor low birth weight, providers have up to 
7 days from birth to determine if the mother is HBsAg negative; because the protective 
efficacy of HBIG declines the longer that administration is delayed, if results are 
unlikely to be known by day 7 of life, HBIG should be given no later than day 7 if not 
earlier. If the mother is determined to be HBsAg positive, HBIG should be administered 
as soon as possible (20).  
If a child aged at least 6 weeks has been in the hospital since birth, deferral of rotavirus 
vaccine is recommended until the time of discharge. If an infant were to be vaccinated 
with rotavirus vaccine while still needing care in the NICU or nursery, at least a 
theoretic risk exists for vaccine virus being transmitted to infants in the same unit who 
are acutely ill and to preterm infants who are not age-eligible for vaccine (21). The 
rotavirus vaccine series should not be initiated for infants aged ≥15 weeks, 0 days. 
Breastfeeding and Vaccination 
With 2 exceptions, neither inactivated nor live-virus vaccines administered to a lactating 
woman affect the safety of breastfeeding for women or their infants. Although live 
viruses in vaccines can replicate in the mother, the majority of live viruses in vaccines 
have been demonstrated not to be excreted in human milk. Varicella vaccine virus has 
not been found in human milk (22). Although rubella vaccine virus has been excreted in 
human milk, the virus usually does not infect the infant. If infection does occur, it is well 
tolerated because the virus is attenuated (23). Inactivated, recombinant, subunit, 
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polysaccharide, and conjugate vaccines, as well as toxoids, pose no risk for mothers who 
are breastfeeding or for their infants. Breastfeeding is a contraindication for smallpox 
vaccination of the mother because of the theoretical risk for contact transmission from 
mother to infant. Yellow fever vaccine should be avoided in breastfeeding women, 
because 2 cases (one confirmed, one probable) of yellow-fever vaccine associated acute 
neurotropic disease (YEL-AND) have been detected in infants whose mothers were 
vaccinated but were not vaccinated themselves. In both infants, vaccine virus was 
recovered from the cerebrospinal fluid of the infant, but the exact mode of transmission 
was not precisely determined because vaccine virus was not recovered from breast milk 
(24). However, when nursing mothers cannot avoid or postpone travel to areas endemic 
for yellow fever in which risk for acquisition is high, these women should be vaccinated. 
Limited data indicate that breastfeeding can enhance the response to certain vaccine 
antigens (25). There are no data to suggest that passive transfer of antibodies in human 
milk can affect the efficacy of live-virus vaccines. Breastfed infants should be vaccinated 
according to the recommended schedule (26-28). 
Vaccination During Pregnancy 
No evidence exists of risk to the fetus from vaccinating pregnant women with 
inactivated virus or bacterial vaccines or toxoids (29,30). In spite of the lack of evidence 
of risk, HPV vaccine, an inactivated vaccine, is not recommended during pregnancy. 
Live vaccines administered to a pregnant woman pose a theoretical risk to the fetus; 
therefore, live, attenuated virus and live bacterial vaccines generally are contraindicated 
during pregnancy. Women should avoid conception for 4 weeks after vaccination with 
live vaccines. However, benefits of vaccinating pregnant women usually outweigh 
potential risks when the likelihood of disease exposure is high, when infection would 
pose a risk to the mother or fetus, and when the vaccine is unlikely to cause harm. 
Recommendations for vaccination during pregnancy are developed using ACIP’s 
Guiding Principles for Development of ACIP Recommendations for Vaccination During 
Pregnancy and Breastfeeding (31). 
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Women who are pregnant should receive a dose of Tdap for the prevention of infant 
pertussis whether or not they have previously received Tdap. Vaccination of the mother 
generates antibodies that pass transplacentally to the fetus (32). Vaccination in the third 
trimester optimizes the duration of this antibody protection until after birth. 
Additionally, preventing pertussis in the mother reduces the risk that the infant is 
exposed to pertussis after birth (33). Health care personnel should administer Tdap 
during pregnancy, preferably during the third trimester. If Tdap is not administered 
during pregnancy to women who have never received it, it should be administered 
immediately postpartum. Pregnant women who are not vaccinated or are only partially 
vaccinated against tetanus should complete the primary series (34). Women for whom 
Td is indicated but who did not complete the recommended 3-dose series during 
pregnancy should receive follow-up after delivery to ensure the series is completed. One 
dose of the tetanus vaccine series should be Tdap, if Tdap has not already been received.  
Pregnant and postpartum women are at higher risk for severe illness and complications 
from influenza than women who are not pregnant (2,35). Pregnant women have 
protective levels of anti-influenza antibodies after vaccination (36,37). Passive transfer of 
anti-influenza antibodies that might provide protection from vaccinated women to 
neonates has been reported (36,38-41). Routine vaccination with inactivated influenza 
vaccine is recommended for all women who are or will be pregnant (in any trimester) 
during influenza season. 
IPV can be administered to pregnant women who are at risk for exposure to wild-type 
poliovirus. This includes travelers to areas or countries where polio is epidemic or 
endemic; members of communities or specific population groups with disease caused by 
wild polioviruses; laboratory workers who handle specimens that might contain 
polioviruses; health-care personnel who have close contact with patients who might be 
excreting wild polioviruses; and unvaccinated persons whose children will be receiving 
oral poliovirus vaccine (42). Hepatitis A, pneumococcal polysaccharide, meningococcal 
conjugate, and meningococcal polysaccharide vaccines should be considered for women 
at increased risk for those infections (43-45). Pregnant women who must travel to areas 
where there is a risk for acquiring yellow fever should receive yellow fever vaccine, 
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because the limited theoretical risk from vaccination is outweighed substantially by the 
risk for yellow fever infection (24,46). Hepatitis B vaccine is not contraindicated in 
pregnancy and should be given to a pregnant woman for whom it is indicated (20,47). 
Pregnancy is a contraindication for smallpox (vaccinia) vaccine and measles-, mumps-, 
rubella-, and varicella-containing vaccines. Smallpox vaccine is the only vaccine known 
to harm a fetus when administered to a pregnant woman. In addition, smallpox vaccine 
should not be administered to a household contact of a pregnant woman (8). Women 
who are pregnant should not have close contact with anyone who has recently (within 
the last 28 days) received the smallpox vaccine. Data from studies of children born to 
mothers inadvertently vaccinated with rubella vaccine during pregnancy demonstrate 
rubella antibody in unvaccinated infants. This could represent passive transfer of 
maternal antibody or a fetal antibody response to vaccine virus infection in the fetus. No 
cases of congenital rubella or varicella syndrome or abnormalities attributable to fetal 
infection have been observed among infants born to susceptible women who 
inadvertently received rubella or varicella vaccines during pregnancy (48-50). Because 
of the importance of protecting women of childbearing age against rubella and varicella, 
reasonable practices in any vaccination program include asking women if they are 
pregnant or might become pregnant in the next 4 weeks; not vaccinating women who 
state that they are or plan to become pregnant within that interval; explaining the 
theoretical risk for the fetus if MMR, varicella, or MMRV vaccine were administered to a 
woman who is pregnant; and counseling women who are vaccinated not to become 
pregnant during the 4 weeks after MMR, varicella, or MMRV vaccination (10,48-51). 
MMRV is an unlikely option for a pregnant woman because the vaccine is only licensed 
through 12 years of age. Routine pregnancy testing of women of childbearing age before 
administering a live-virus vaccine is not recommended (3,10). If a pregnant woman is 
inadvertently vaccinated or becomes pregnant within 4 weeks after MMR or varicella 
vaccination, she should be counseled about the theoretical basis of concern for the fetus; 
however, MMR or varicella vaccination during pregnancy should not be considered a 
reason to terminate pregnancy (3,10,50). 
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Persons who receive MMR vaccine do not transmit the vaccine viruses to contacts (10). 
Transmission of varicella vaccine virus to contacts is exceedingly rare (3). MMR and 
varicella vaccines should be administered when indicated to children and other 
household contacts of pregnant women (10). Infants living in households with pregnant 
women should be vaccinated with rotavirus vaccine according to the same schedule as 
infants in households without pregnant women. 
Pregnant women should be evaluated for evidence of immunity to rubella and varicella 
and be tested for the presence of HBsAg during every pregnancy (10,20,52). Women 
without evidence of immunity to rubella and varicella should be vaccinated immediately 
after delivery. A second dose of varicella vaccine should be administered 4-8 weeks 
later. A woman found to be HBsAg positive should be followed-up carefully to ensure 
that the infant receives HBIG and begins the hepatitis B vaccine series no later than 12 
hours after birth and that the infant completes the recommended hepatitis B vaccine 
series on schedule (20). No known risk exists for the fetus from passive immunization of 
pregnant women with immune globulin preparations. 
Persons Vaccinated Outside the United States 
Clinicians have a limited ability to determine whether persons are protected on the basis 
of their country of origin and their vaccination records alone. Vaccines administered 
outside the United States generally can be accepted as valid if the schedule (i.e., 
minimum ages and intervals) is similar to that recommended in the United States. With 
the exception of influenza vaccine, only written documentation should be accepted as 
evidence of previous vaccination. Written records are more likely to predict protection if 
the vaccines, dates of administration, intervals between doses, and age at the time of 
vaccination are comparable to U.S. recommendations. Although vaccines with 
inadequate potency have been produced in other countries (53,54), the majority of 
vaccines used worldwide are produced with adequate quality control standards and are 
potent. 
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Persons vaccinated outside of the United States can enter the country through a number 
of different mechanisms. Those seeking to immigrate to the United States may be 
vaccinated under the authority of a civil surgeon or a panel physician. Some enter the 
United States as refugees and are vaccinated under the authority of the Office of Refugee 
Resettlement, part of the Administration for Children and Families, in the Department 
of Health and Human Services.  
Adopted children’s birth countries often have vaccination schedules that differ from the 
recommended childhood vaccination schedule in the United States. Differences in the 
U.S. schedule and those used in other countries include the vaccines administered, the 
recommended ages of administration, and the number and timing of doses. 
Data are inconclusive regarding the extent to which an internationally adopted child’s 
vaccination record reflects the child’s protection. A child’s record might indicate 
administration of MMR vaccine when only single-antigen measles vaccine was 
administered. A study of children adopted from orphanages in the People’s Republic of 
China, Russia, and countries in Eastern Europe determined that 67% of children with 
documentation of >3 doses of DTP before adoption had nonprotective titers to these 
antigens (54). In contrast, children adopted from these countries who received 
vaccination in the community (not only from orphanages) and had documentation of ≥1 
doses of DTP exhibited protective titers 67% of the time (54). However, antibody testing 
was performed by using a hemagglutination assay, which tends to underestimate 
protection and cannot directly be compared with antibody concentration (55). Data are 
likely to remain limited for areas other than the People’s Republic of China, Russia, and 
Eastern Europe. Health-care providers should ensure that household contacts of 
international adoptees are vaccinated adequately, particularly for measles, hepatitis A, 
and hepatitis B (56). 
Health-care providers may use one of multiple approaches if the immunogenicity of 
vaccines or the completeness of series administered to persons outside the United States 
is in question. Repeating the vaccinations is an acceptable option that usually is safe and 
prevents the need to obtain and interpret serologic tests. If avoiding unnecessary 
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injections is desired, judicious use of serologic testing might help determine which 
vaccinations are needed. For some vaccines, the most readily available serologic tests 
cannot document protection against infection. This best practices document provides 
guidance on possible approaches to evaluation and revaccination for each vaccine 
recommended in the United States (Table 9-1). 
DTaP Vaccine 
Vaccination providers can revaccinate children younger than 7 years of age with DTaP 
vaccine without regard to recorded doses; however, data indicate increased rates of local 
adverse reactions after the fourth and fifth doses of DTaP (57). If a revaccination 
approach is adopted and a severe local reaction occurs, serologic testing for specific IgG 
antibody to tetanus and diphtheria toxins can be measured before administering 
additional doses. Protective concentration(a) indicates that additional doses are 
unnecessary and subsequent vaccination should occur as age appropriate. No 
established serologic correlates exist for protection against pertussis. 
For a child whose record indicates receipt of ≥3 doses of DTP or DTaP, serologic testing 
for specific IgG antibody to both diphtheria and tetanus toxin before additional doses is 
a reasonable approach. If a protective concentration is present, recorded doses are 
considered valid, and the vaccination series should be completed as age appropriate. An 
indeterminate antibody concentration might indicate immunologic memory but waning 
antibody; serologic testing can be repeated after a booster dose if vaccination providers 
or parents want to avoid revaccination with a complete series. 
Alternately, for a child whose records indicate receipt of ≥3 doses, a single booster dose 
can be administered followed by serologic testing after 1 month for specific IgG antibody 
to both diphtheria and tetanus toxins. If the child has a protective concentration, the 
recorded doses are considered valid, and the vaccination series should be completed as 
age appropriate. Children with an indeterminate concentration after a booster dose 
should be revaccinated with a complete series. 
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Hepatitis A Vaccine 
Children aged 12-23 months without documentation of hepatitis A vaccination or 
serologic evidence of immunity should be vaccinated on arrival in the United States 
(45). Persons who have received 1 dose should receive the second dose if 6-18 months 
have passed since the first dose was administered. 
Hepatitis B Vaccine 
Persons not known to be vaccinated for hepatitis B should receive an age-appropriate 
series of hepatitis B vaccine. A person whose records indicate receipt of ≥3 doses of 
vaccine is considered protected, and additional doses are not needed if ≥1 dose was 
administered at age ≥24 weeks. Persons who received their last hepatitis B vaccine dose 
at an age <24 weeks should receive an additional dose at age ≥24 weeks. People who 
have received <3 doses of vaccine should complete the series at the recommended 
intervals and ages. 
All foreign-born persons and immigrants, refugees, and internationally adopted 
children born in Asia, the Pacific Islands, Africa, and other regions of high or 
intermediate hepatitis B endemicity should be tested for HBsAg, regardless of 
vaccination status (58). Those determined to be HBsAg positive should be monitored for 
development of liver disease. Household members of HBsAg-positive children or adults 
should be vaccinated if they are not already immune. 
Hib Vaccine 
Interpretation of a serologic test to verify whether children who were vaccinated >2 
months previously are protected against Hib bacteria can be difficult. Because the 
number of vaccinations needed for protection decreases with age and because adverse 
events are rare (59), age-appropriate vaccination should be provided. Hib vaccination is 
not recommended routinely for persons aged ≥5 years (59). 
General Best Practice Guidelines for Immunization: Special Situations  155 
Meningococcal Vaccine 
Quadrivalent meningococcal conjugate vaccines are not routinely used in other 
countries in adolescents (the United Kingdom is the exception). Unless patients have 
documented receipt they should be considered unvaccinated and receive the age-
appropriate doses. 
MMR Vaccine 
The simplest approach to resolving concerns about MMR vaccination is to revaccinate 
with 1 or 2 doses of MMR vaccine, depending on age. Serious adverse events after MMR 
vaccinations are rare (10). No evidence indicates that administering MMR vaccine 
increases the risk for adverse reactions among persons who are already immune to 
measles, mumps, or rubella as a result of previous vaccination or natural disease. Doses 
of measles-containing vaccine administered before the first birthday should not be 
counted as part of the series (10). Alternatively, serologic testing for IgG antibody to 
vaccine viruses indicated on the vaccination record can be considered. Serologic testing 
is widely available for measles and rubella IgG antibody. A person whose record 
indicates receipt of monovalent measles or measles-rubella vaccine on or after the first 
birthday and who has protective antibody against measles and rubella should receive 1 
or 2 doses of MMR or MMRV as age appropriate to ensure protection against mumps 
and varicella (and rubella if measles vaccine alone had been administered). If a person 
whose record indicates receipt of MMR at age ≥12 months has a protective 
concentration of antibody to measles, no additional vaccination is needed unless a 
second dose is required for school entry. 
Pneumococcal Vaccines 
Many industrialized countries now routinely use pneumococcal vaccines. Although 
recommendations for pneumococcal polysaccharide vaccine also exist in many 
countries, the pneumococcal conjugate vaccine might not be routinely administered. 
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PCV13 and PPSV23 should be administered according to age-appropriate vaccination 
schedules or as indicated by the presence of underlying medical conditions (43,60). 
Poliovirus Vaccine 
The simplest approach to vaccinating with poliovirus vaccine is to revaccinate persons 
aged <18 years with IPV according to the U.S. schedule. Adverse events after IPV are 
rare (42). Children appropriately vaccinated with 3 doses of OPV in economically 
developing countries might have suboptimal seroconversion, including to type 3 
poliovirus (42). 
Rotavirus Vaccine 
Rotavirus vaccination should not be initiated for infants aged ≥15 weeks, 0 days. Infants 
who began the rotavirus vaccine series outside the United States but who did not 
complete the series and who are still aged ≤8 months, 0 days, should follow the routine 
schedule and receive doses to complete the series. If the brand of a previously 
administered dose is live, reassortment pentavalent rotavirus vaccine or is unknown, a 
total of 3 doses of rotavirus vaccine should be documented for series completion. All 
doses should be administered by age 8 months, 0 days.  
Td and Tdap Vaccines 
Children aged ≥7 years who are not considered fully vaccinated for pertussis should 
receive Tdap vaccine. “Fully vaccinated” means at least 5 doses of DTaP before the 
seventh birthday or at least 4 doses of DTaP before the seventh birthday if the fourth 
dose is given after the fourth birthday. One dose of Tdap is recommended after the 
seventh birthday. If additional doses of vaccine are needed, Td should be administered 
as age appropriate.  
Varicella Vaccine 
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Varicella vaccine is not available in most countries. A person who lacks evidence of 
varicella immunity should be vaccinated as age appropriate (3,59). 
Zoster Vaccine 
In the United States, zoster vaccination is recommended for all persons aged ≥60 years 
who have no contraindications, including persons who report a previous episode of 
zoster or who have chronic medical conditions. For persons who do not have 
documentation of receipt of zoster vaccine, the vaccine should be offered at the patient’s 
first clinical encounter with the health-care provider. The vaccine is administered as a 
single 0.65-mL subcutaneous dose. Zoster vaccination is not indicated to treat acute 
zoster, to prevent persons with acute zoster from developing postherpetic neuralgia, or 
to treat ongoing postherpetic neuralgia. Patients do not need to be asked about their 
history of varicella or to have serologic testing conducted to determine zoster immunity 
prior to administration of zoster vaccine. 
Vaccinating Persons with Increased Bleeding Risk 
Providers often avoid giving intramuscular injections or choose alternative routes for 
persons with bleeding disorders because of the risk for hematoma formation after 
injections. In one study, hepatitis B vaccine was administered intramuscularly to 153 
persons with hemophilia. The vaccination was administered with a 23-gauge or smaller 
caliber needle, followed by application of steady pressure to the site for 1-2 minutes. The 
vaccinations resulted in a low (4%) bruising rate, and no patients required factor 
supplementation (61). Whether antigens that produce more local reactions (e.g., 
pertussis) would produce an equally low rate of bruising is unknown. 
When hepatitis B or any other intramuscularly administered vaccine is indicated for a 
patient with a bleeding disorder, the vaccine should be administered intramuscularly if a 
physician familiar with the patient’s bleeding risk determines that the vaccine can be 
administered by this route with reasonable safety. If the patient receives antihemophilia 
or similar therapy, intramuscularly administered vaccinations can be scheduled shortly 
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after such therapy is administered. A fine-gauge needle (23-gauge or smaller caliber) 
should be used for the vaccination, followed by firm pressure on the site, without 
rubbing, for at least 2 minutes. The patient or family should be given information on the 
risk for hematoma from the injection. Patients receiving anticoagulation therapy 
presumably have the same bleeding risk as patients with clotting factor disorders and 
should follow the same guidelines for intramuscular administration. If possible, 
vaccination could be scheduled prior to the use of these medications, so that the 
patients’ risk of bleeding is not increased by their therapeutic action. 
(a) Enzyme immunoassay tests are available. Physicians should contact the laboratory performing the test for interpretive standards 
and limitations. Protective concentrations for antibody to diphtheria and tetanus toxins are defined as >0.1 IU/mL. 
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TABLE 9-1. Approaches to evaluation and vaccination of persons 
vaccinated outside the United States who have no (or questionable) 




DTaP Revaccination with DTaP, 
with serologic testing for 
specific IgG antibody to 
tetanus and diphtheria 
toxins in the event of a 
severe local reaction 
Persons whose records indicate 
receipt of ≥3 doses: serologic testing 
for specific IgG antibody to 
diphtheria and tetanus toxins before 
administering additional doses (see 
text), or administer a single booster 
dose of DTaP, followed by 
serological testing after 1 month for 
specific IgG antibody to diphtheria 
and tetanus toxins with 




Serologic testing for IgG antibodies 
to hepatitis A 
HepB Age-appropriate 
revaccination and serologic 














MMR Revaccination with MMR Serologic testing for IgG antibodies 
to measles, mumps, and rubella 
Pneumococcal 
conjugate (or in 
some cases, both 
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revaccination of persons 




revaccination of persons 
who lack evidence of 
varicella immunity  
— 
Zoster  Age-appropriate 
revaccination 
— 
Abbreviations: DTaP = diphtheria and tetanus toxoids and acellular pertussis; HBsAg = hepatitis B surface 
antigen; HepA = hepatitis A; HepB = hepatitis B; Hib = Haemophilus influenzae type b; HPV = human 
papillomavirus; IgG = immune globulin G; MMR = measles, mumps, and rubella; PCV13 = pneumococcal conjugate 
vaccine; PPSV23= pneumococcal polysaccharide vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis. 
(a) There is a recommended approach for all vaccines and an alternative approach for some vaccines. 
(b) In rare instances, hepatitis B vaccine can give a false-positive HBsAg result up to 18 days after vaccination; 
therefore, blood should be drawn to test for HBsAg before vaccinating (20). 
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10. Vaccination Records 
Records of Health-Care Providers 
Appropriate and timely vaccination documentation helps ensure not only that persons 
in need of recommended vaccine doses receive them but also that adequately vaccinated 
patients do not receive excess doses. Curtailing the number of excess doses 
administered to patients controls costs incurred by patients, providers, insurers, 
vaccination programs, and other stakeholders. In addition, avoidance of excess doses of 
vaccines should decrease the number of adverse reactions to vaccines. Health care 
providers who administer vaccines covered by the National Vaccine Injury 
Compensation Program (VICP) are required under the National Childhood Vaccine 
Injury Act (1) to ensure that the permanent medical record of the recipient (or a 
permanent office log or file) indicates the date the vaccine was administered, the vaccine 
manufacturer, the vaccine lot number, and the name, address, and title of the person 
administering the vaccine. This Act applies to any vaccine for which there is a routine 
recommendation for childhood vaccination, even if many or most doses of the vaccine 
are administered to adults (e.g., influenza vaccine). In addition, the provider is required 
to record the edition date of the VIS distributed and the date those materials were 
provided. The Act considers a health-care provider to be any licensed health care 
professional, organization, or institution, whether private or public (including federal, 
state, and local departments and agencies), under whose authority a specified vaccine is 
administered. This information should be kept for all vaccines, not just for those 
required by the Act. Providers and staff members also should systematically update 
patients’ permanent medical records to reflect any documented episodes of adverse 
events after vaccination and any serologic test results related to vaccine-preventable 
diseases (e.g., those for rubella screening and anti-HBs). 
Personal Records of Patients 
Official childhood vaccination records have been adopted by every state and territory 
and the District of Columbia to encourage uniformity of records and to facilitate 
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assessment of vaccination status by schools and child-care centers. The records also are 
key tools in vaccination education programs aimed at increasing parental and patient 
awareness of the need for vaccines. This record can exist in electronic file format or in 
hardcopy format. A permanent vaccination record should be established for each 
newborn infant and maintained by the parent or guardian. The parent or guardian 
should be educated about the importance of keeping the record up-to-date and 
instructed to keep the record indefinitely. These records should be distributed to new 
parents and/or guardians before discharge from the hospital or birthing center. Using 
vaccination records for adolescents and adults also is encouraged. Standardized adult 
vaccination records are available at http://www.immunize.org. 
Immunization Information Systems (IISs) 
IISs (formerly referred to as immunization registries) are confidential, population-
based, computerized information systems that collect and consolidate vaccination data 
from multiple health care providers within a geographic area. IISs are a critical tool that 
can increase and sustain vaccination coverage by consolidating vaccination records from 
multiple providers, generating reminder and recall vaccination notices for each person, 
and providing official vaccination forms and vaccination coverage assessments (2). 
Providers should be aware of state and/or regional IISs and requirements for reporting. 
Changing vaccination providers during the course of an individual’s vaccination series is 
common in the United States. In addition to changes in providers, the vaccination 
records of persons who have changed vaccination providers often are unavailable or 
incomplete or might not have been entered into an IIS (2). Missing or inaccurate 
information regarding vaccines received previously might preclude accurate 
determination of which vaccines are indicated at the time of a visit, resulting in 
administration of extra doses. 
A fully operational IIS also can prevent duplicate vaccinations, forecast when the next 
dose is due, limit missed appointments, allow recall for those who missed appointments, 
determine when vaccines need to be repeated (the technical IIS term for this is 
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“evaluation”), reduce vaccine waste, and reduce staff time required to produce or locate 
vaccination records or certificates. Most IISs have additional capabilities, such as 
measurement of vaccination update and coverage, aid in tracking vaccine inventory and 
placing vaccine orders, recall of vaccine by lot number, maintenance of lifetime 
vaccination histories, and interoperability with other health information systems. The 
National Vaccine Advisory Committee recommends that vaccination providers 
participate in these systems when possible. Electronic health records should maintain 
interoperability with IISs as part of an effort to improve the quality of care, reduce 
health disparities, engage patients and families in their health, improve the coordination 
of care, improve population health, and ensure adequate privacy and security protection 
for personal health information (see 
www.cdc.gov/ehrmeaningfuluse/introduction.html) 
One of the national Healthy People objectives for 2020 is 95% participation of children 
aged <6 years in a fully operational population-based IIS (objective 20.1) (3,4). 
Participating in an IIS means having two or more vaccinations recorded in the IIS. 2012 
IIS data indicate that approximately 86% of children aged <6 years with two or more 
vaccinations were participating in IISs (4,5).  
The National Vaccine Advisory Committee recommends that public health departments 
work toward including adults in all state IISs, reduce barriers to including adult 
vaccination records in IISs, and ensure that IISs meet new standards of EHR 
interoperability to track and maintain adult vaccination records (6). 
 Nationally, 57.8 million U.S. adults aged 19 years or older participated in an IIS in 2012 
(4). This number reflects adults who may have had childhood vaccines entered during 
childhood and now have aged to adults. In 2013, 32% of U.S. adults had a record in the 
IIS and at least one vaccination administered during adulthood.   
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11. Vaccination Programs 
Updates 
The major revision to this section is the addition of language related to Affordable Care 
Act (1) coverage of adult vaccination.  
General Principles 
Universal vaccination is a critical part of quality health-care and should be accomplished 
through routine and catch-up vaccination provided in physicians’ offices, public health 
clinics, and other appropriate settings. In the United States, vaccination is considered 
primarily the responsibility of individual health care providers and health care systems 
serving patients.  
Certain programs and other efforts attempt to ensure all patients receive the full 
schedule of appropriate vaccinations by removing barriers posed by access to 
immunizations, cost, or other factors. Such efforts may include school-located clinics, 
school-based health centers, back-to-school immunization clinics, public health clinics 
for schoolchildren, periodic influenza vaccination clinics, public health nurse tracking of 
childhood immunizations, and government-sponsored financing of vaccines through the 
Vaccines for Children and Section 317 program http:// 
www.cdc.gov/vaccines/hcp/admin/vfc.html ).  
In the United States, vaccination programs have eliminated many vaccine-preventable 
diseases and markedly reduced the incidence of others (2). Because infants and young 
children were the principal recipients of most vaccines developed during the twentieth 
century (e.g., poliovirus vaccine), many persons in the United States might believe that 
vaccinations are solely for the young; however, vaccinations are recommended for 
persons of all ages (3,4). Improved vaccination coverage can result in additional 
reductions in the incidence of vaccine-preventable diseases that affect persons 
throughout the life span, and decrease associated morbidity and mortality.  
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Vaccination of Children and Adolescents 
Physicians and other pediatric vaccination providers should adhere to the standards for 
child and adolescent vaccination practices (5). These standards are published by the 
National Vaccine Advisory Committee and define appropriate vaccination practices for 
both public and private sectors. The standards provide guidance on practices that 
eliminate barriers to vaccination, including eliminating unnecessary prerequisites for 
receiving vaccinations, eliminating missed opportunities to vaccinate, improving 
procedures to assess vaccination needs, enhancing knowledge about vaccinations among 
parents and providers, and improving management and reporting of adverse events. In 
addition, the standards address the importance of recall and reminder systems and 
using assessments to monitor clinic or office vaccination coverage levels. Health-care 
providers should simultaneously administer as many vaccine doses as possible as 
indicated on the Recommended Immunization Schedules for Persons Aged 0 Through 
18 Years (3). 
While rates of childhood vaccination are generally higher than rates of adult 
vaccination, for some doses coverage rates are still low, like the birth dose of hepatitis B 
vaccine. Community health-care providers, as well as state and local public health 
vaccination programs, should coordinate with partners to identify and maximize 
outreach to populations at risk for undervaccination and vaccine-preventable diseases. 
For example, the Special Supplemental Nutrition Program for Women, Infants, and 
Children (WIC) is a categorical federal grant program administered by the U.S. 
Department of Agriculture through state health departments. The program provides 
supplemental foods, health-care referrals, and nutrition education to low-income 
pregnant, breastfeeding, or postpartum women, as well as to infants and children aged 
<5 years. Between 8.5 and 8.9 million people participated in this program in 2013 
(http://www.fns.usda.gov/pd/wicmain.htm). In collaboration, WIC and state 
vaccination programs assess regularly the vaccination coverage levels of WIC 
participants and develop new strategies and aggressive outreach procedures in sites with 
coverage levels <90%. Vaccination programs and private providers are encouraged to 
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refer eligible children to obtain WIC nutritional services, at 
www.fns.usda.gov/wic/immunization-screening-and-referral-wic (6). 
Adolescent-Specific Issues 
Vaccinations are recommended throughout life, including during adolescence. The age 
range for adolescence is defined as 11-21 years by many professional associations, 
including the American Academy of Pediatrics and the American Medical Association 
(7,8). Definitions of these age cutoffs differ depending on the source of the definition 
and the source’s purpose for creating a definition. Vaccination of adolescents is critical 
for preventing diseases for which adolescents are at particularly high or increasing risk, 
such as meningococcal disease and human papillomavirus infection. Three vaccines 
recommended for adolescents have been licensed since 2005: MenACWY and Tdap 
were licensed in 2005, and HPV was licensed in 2006. A second dose of varicella vaccine 
is recommended for persons who received 1 dose of varicella vaccine after age 12 
months. In addition, annual seasonal influenza vaccination is recommended for persons 
aged >6 months who have no contraindications. To ensure vaccine coverage, clinicians 
and other health-care providers who treat adolescents must review vaccination history 
on every occasion that an adolescent has an office visit. 
National goals for vaccination coverage for adolescents aged 13-15 years were included 
in Healthy People 2020, at http:// www.healthypeople.gov/2020/topics-
objectives/topic/immunization-and-infectious-diseases. Targets of 80% coverage were 
specified for one dose of Tdap, one dose of meningococcal conjugate vaccine, and 3 
doses of HPV vaccine. Results of the published 2014 National Immunization Survey—
Teen indicate that coverage rates for 13-17 years olds is 87.6% for one dose of Tdap and 
79.3% for one dose of meningococcal vaccine. Coverage rates for 13-17 years olds for 
HPV vaccine are considerably lower—39.7% for females and 21.6% for males (9,10).  
Ensuring adolescents receive routine and catch-up vaccination and achieving high levels 
of vaccination coverage present challenges. In general, adolescents do not visit health 
care providers frequently. Health care providers should promote annual preventive 
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visits (11), including one specifically for adolescents aged 11 and 12 years. The annual 
visits should be used as opportunities to provide routinely recommended vaccine doses, 
additional catch-up doses needed for lapsed vaccine series, vaccines recommended for 
high-risk groups, additional doses that might have been recently recommended, and 
other recommended health-care services. Additional strategies include adolescent 
immunizations at community-based venues such as pharmacies and schools.  
All vaccine doses should be administered according to ACIP vaccine-specific statements 
and with the most recent schedules for both routine and catch-up vaccination. Before 
leaving any visit for medical care, adolescents should be encouraged to schedule return 
visits for any additional vaccine doses needed. During visits that occur outside of 
influenza season, providers should discuss and recommend seasonal influenza 
vaccination and make explicit plans for vaccination, including timing and anticipated 
setting (e.g., health care provider’s office, school, or pharmacy). Catch-up vaccination 
with multidose adolescent vaccines generally can occur according to the routine dosing 
schedule for these vaccines, although in some circumstances the clinician or health care 
provider might use minimum intervals for vaccine doses. These circumstances include 
an outbreak that increases risk for disease or the likelihood that doses will be missed in 
the future (e.g., because of transportation challenges). Because of lack of efficacy data 
for HPV vaccine administration using minimum intervals, providers are encouraged, 
when possible, to use routine dosing intervals for females aged 11-26 years and males 
aged 11-21 years who have not yet received 3 HPV vaccine doses as recommended (3,4). 
One of the challenges of adolescent vaccination is ensuring that current, complete 
vaccination histories are available. Insurers, covered services, or reimbursement levels 
can change, and these changes might affect reimbursement for vaccine doses and 
vaccination services directly while also causing disruptions in an adolescent’s access to 
vaccination providers or venues. In circumstances in which a vaccination record is 
unavailable, vaccination providers should attempt to obtain this information from 
various sources (e.g., parent, previous providers, or school records). More detail about 
how to obtain these records is available from CDC at 
http://www.cdc.gov/vaccines/recs/immuniz-records.htm. With the exception of 
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influenza and pneumococcal polysaccharide vaccines, if documentation of a vaccine 
dose is not available, the adolescent should be considered unvaccinated for that dose. 
Regardless of the venue in which an adolescent receives a dose of vaccine, that vaccine 
dose should be documented in the patient’s chart or in an office log, and the information 
should be entered into an IIS. The adolescent also should be provided with a record that 
documents the vaccination history. 
Adult Vaccination 
In 2013, the National Vaccine Advisory Committee published updated standards for 
adult vaccination (12). These standards are targeted to distinct groups involved in adult 
vaccination, including immunizing providers, non-immunizing providers, professional 
health-care organizations, and public health departments. All health-care providers, 
whether they provide immunizations or not, should incorporate immunization needs 
assessment into every clinical encounter, strongly recommend needed vaccine(s) and 
either administer vaccine(s) or refer patients to a provider who can immunize, stay up-
to-date on, and educate patients about vaccine recommendations, implement systems to 
incorporate vaccine assessment into routine clinical care, and understand how to access 
immunization information systems (i.e., immunization registries) (12).  
Vaccination rates in adults are considered suboptimal (13,14). New Healthy People 
2020 goals include specific subsets of adults, including institutionalized adults aged ≥18 
years (for pneumococcal vaccines) and noninstitutionalized adults at high risk aged >18 
years (for pneumococcal vaccines) (9). 
The most substantial barrier to vaccination coverage is lack of knowledge about these 
vaccines among adult patients and adult providers. Other barriers are cost (incomplete 
Medicare coverage for recommended vaccines) (15) and the lack of financing 
mechanisms for newly licensed and recommended vaccines. Effective for private health 
insurance plans drafted or updated after September 2010, coverage for all 
immunizations that are included on the immunization schedule(s) must be covered 
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without deductibles or co-pays, when delivered by an in-network provider. For this 
reason, cost may present less of a barrier to adult vaccination as time passes. 
A common challenge for health-care providers is vaccinating adults with unknown 
vaccination records. In general (except for influenza and pneumococcal polysaccharide 
vaccines), adults should receive a vaccine dose if the dose is recommended and no 
record of previous administration exists. If an adult has a record of military service and 
does not have records available, providers can assume that the person has received all 
vaccines recommended by the military at the time of service entry. Serologic testing 
might be helpful in clarifying immune status if questions remain, because at different 
times and depending on military assignments, there might be inter-service and 
individual differences. 
Evidence-based Interventions to Increase Vaccination 
Coverage 
The independent, nonfederal Task Force on Community Preventive Services, whose 
membership is appointed by CDC, provides public health decision-makers with 
recommendations on population-based interventions to promote health and prevent 
disease, injury, disability, and premature death. The recommendations are based on 
systematic reviews of the scientific literature about effectiveness and cost-effectiveness 
of these interventions. In addition, the task force identifies critical information about 
the other effects of these interventions, the applicability to specific populations and 
settings, and the potential barriers to implementation. Additional information, 
including updates of published reviews, is available from The Community Guide at 
http://www.thecommunityguide.org. 
Beginning in 1996, the task force systematically reviewed published evidence on the 
effectiveness and cost-effectiveness of population-based interventions to increase 
coverage of vaccines recommended for routine use among children, adolescents, and 
adults. A total of 197 articles were identified that evaluated a relevant intervention, met 
inclusion criteria, and were published during 1980-1997. Reviews of 17 specific 
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interventions were published in 1999 (13,14,16,17). Using the results of their review, the 
task force made recommendations about the use of these interventions (15). Several 
interventions were identified and recommended on the basis of published evidence. 
Follow-up reviews were published in 2000, and a review of interventions to improve the 
coverage of adults at high risk was conducted in 2005 (15,17). The interventions and the 
recommendations are summarized in this section of this report (Table 11-1). 
Interventions designated for adults younger than 65 years at high risk for influenza, 
invasive pneumococcal disease, and hepatitis B, include provider reminder systems or a 
menu of items (combinations of strategies ) (Table 11-2). In 1997, the task force 
categorized vaccination requirements for child care, school, and college as a 
recommended strategy (14).  
A 2008 update of the original task force systematic review of the evidence on the 
effectiveness of provider assessment and feedback for increasing coverage rates found 
that this strategy remains an effective intervention (18). This later update reviewed 19 
new studies published during 1997-2007. The updated review supports the original task 
force recommendation for use of assessment and feedback based on strong evidence of 
effectiveness. The task force reviewed studies of assessment and feedback as a strategy 
that were conducted in a range of settings, including private practice, managed care, 
public health, community health settings, and academic centers. Studies have assessed 
the effectiveness of this intervention to improve coverage with MMR, DTP, DTaP, Hib, 
influenza, pneumococcal, and Td vaccines (16). The most updated information on this 
review is available at 
http://www.thecommunityguide.org/vaccines/universally/providerassessment.html. As 
recognized by the task force, routine assessment and feedback of vaccination rates 
obtained at the provider site is one of the most effective strategies for achieving high, 
sustainable vaccine coverage. Since 1995, all states receiving federal funds for 
vaccination programs have been required to conduct annual assessments of vaccination 
rates both in public health clinics and in private provider offices. Primarily to aid local 
and state health departments in their efforts to conduct assessments and assist 
providers, CDC has developed numerous software applications to measure vaccination 
rates in provider practices. 
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Other General Programmatic Issues 
Programmatic challenges, evolving issues, and effective interventions related to adult 
and adolescent vaccination programs have been described by other advisory groups and 
expert groups. Additional evidence-based approaches are being developed for certain 
issues (e.g., settings for adolescent vaccination delivery) through ongoing research and 
evaluation. Among current programmatic challenges, vaccine financing is especially 
difficult because certain problems and solutions differ markedly from one state to 
another. Practitioners interested in beginning or continuing to provide vaccinations to 
patients are encouraged to consult with local and state public health vaccination 
programs to learn about publicly funded programs that might be available in their areas 
for patients who need vaccination but have insufficient health insurance coverage and 
no financial resources. If not already participating, providers who care for adolescents 
and children aged <19 years should enroll in the Vaccines for Children Program (http:// 
www.cdc.gov/vaccines/hcp/admin/vfc.html ). Through this program’s provision of 
ACIP-recommended, federally purchased vaccines, participating providers are able to 
fully vaccinate eligible children whose parents might not otherwise be able to afford the 
vaccinations. Interested providers are encouraged to work with insurers, state and 
specialty-specific medical organizations, vaccine manufacturers, and other stakeholders 
to address financial barriers to achieving high vaccination coverage. With availability of 
safe and effective vaccines for 18 vaccine-preventable diseases, the capacity for realizing 
the potential benefits of these products in the United States depends on reaching 
children, adolescents, and adults through dedicated, knowledgeable vaccination 
providers and efficient, strong vaccination programs at local, state, and federal levels.  
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TABLE 11-1. Recommendations regarding interventions to improve 
coverage of vaccines recommended for routine use among children, 
adolescents, and adults 
Intervention Recommendation 
Increase community demand for vaccination 
Client reminder or recall systems Recommended  
Requirements for entry to schools, child- care 
facilities, and colleges  
Recommended 
Community education alone Insufficient evidence 
Community-based interventions implemented in 
combination 
Recommended 
Clinic-based education  Insufficient evidence 
Patient or family incentives  Recommended 
Patient or family monetary sanctions Insufficient evidence 
Client-held medical records Insufficient evidence 
Enhance access to vaccination services 
Reducing out-of-pocket costs Recommended  
Enhancing access through the U.S. Department of 
Agriculture’s Women, Infants, and Children (WIC) 
program 
Recommended  
Home visits, outreach, and case management 
targeted to particularly hard-to-reach populations 
to increase vaccination rates 
Recommended  
Enhancing access at schools Recommended 
Expanding access in health-care settings  Recommended as part of 
multicomponent interventions 
only 
Enhancing access at organized child care centers  Recommended 
Focus on providers 
Provider reminder or recall systems  Recommended  
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Provider assessment and feedback  Recommended  
Standing orders Recommended  
Provider education alone Insufficient evidence 
Health-care systems-based interventions 
integrated in combination 
Recommended 
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TABLE 11-2. Strategies to improve influenza, pneumococcal 
polysaccharide, and hepatitis B vaccine coverage among high-risk adults 
younger than 65 years 
One or both of these interventions to 
improve access to vaccination services 
1. Expanded access in health-care settings 
2. Reducing client out-of-pocket costs 
PLUS: 
One or more of these provider or system 
based interventions 
1. Standing orders 
2. Provider reminder systems 
3. Provider assessment or feedback 
AND/OR: 
One or both of these interventions to 
increase client demand for vaccination 
services 
1. Client reminder systems 
2. Client education 
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12. Vaccine Information Sources 
In addition to these general recommendations, the following sources contain specific 
and updated vaccine information. 
CDC-INFO Contact Center 
The CDC-INFO contact center is supported by CDC and provides public health-related 
information, including vaccination information, for health-care providers and the 
public, 24 hours a day, 7 days a week. To contact CDC-INFO online at any time, visit 
wwwn.cdc.gov/dcs/RequestForm.aspx. To contact CDC-INFO by telephone, call 
between 8 am to 8 pm Eastern Time Monday through Friday at [English and Spanish]: 
800-232-4636; telephone [TTY]: 800-232-6348. 
CDC’s National Center for Immunization and Respiratory 
Diseases 
CDC’s National Center for Immunization and Respiratory Diseases website provides 
direct access to ACIP’s best practices for vaccination guidance, vaccination schedules, 
automated child schedulers, an adult immunization scheduler, vaccine safety 
information, publications, provider education and training, and links to other 
vaccination-related websites (http://www.cdc.gov/vaccines). 
Morbidity and Mortality Weekly Report (MMWR) 
Some ACIP guidance regarding vaccine use, statements of vaccine policy as they are 
developed, and reports of specific disease activity are published by CDC in the MMWR 
series and can be found at http://www.cdc.gov/vaccines/pubs/ACIP-list.htm. Electronic 
subscriptions are free (http://www.cdc.gov/mmwr/mmwrsubscribe.html). 
Subscriptions to print versions also are available from the Superintendent of 
Documents, U.S. Government Printing Office, Washington, D.C. 20402-9235 
(telephone: 202-512-1800). 
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American Academy of Family Physicians (AAFP) 
Information from the professional organization of family physicians is available at 
http://www.aafp.org. 
American Academy of Pediatrics (AAP) 
Every 3 years, AAP issues the Red Book: Report of the Committee on Infectious 
Diseases, which contains a composite summary of AAP and ACIP recommendations 
concerning infectious diseases and vaccinations for infants, children, and adolescents 
(telephone: 888-227-1770; website: http://www.aap.org). 
American College of Physicians (ACP) 
Produced by faculty of ACP’s Quality Improvement Programs and members of the ACP 
Adult Immunization Advisory Board, the ACP Guide to Adult Immunization helps 
internists develop systematic processes for incorporating immunization in their day-to-
day practice (see http:// www.acponline.org/). 
American Congress of Obstetricians and Gynecologists (ACOG) 
The American Congress of Obstetricians and Gynecologists (ACOG), formerly the 
American College of Obstetricians and Gynecologists, is a professional association of 
physicians specializing in obstetrics and gynecology in the United States. Information 
about ACOG can be found at www.acog.org. 
American Pharmacists Association (APhA) 
Founded in 1852, APhA is the largest association of pharmacists in the United States, 
with more than 62,000 practicing pharmacists, pharmaceutical scientists, student 
pharmacists, pharmacy technicians as members. Information about APhA educational 
activities can be found at www.pharmacist.com/immunization-center. 
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Group on Immunization Education of the Society of Teachers of 
Family Medicine 
The Group on Immunization Education of the Society of Teachers of Family Medicine 
provides information for clinicians, including the free program Shots. Shots includes the 
childhood, adolescent, and adult schedules for iPhone, Palm, and Windows devices, as 
well as online versions (http://www.immunizationed.org/ ). 
Immunization Action Coalition (IAC) 
IAC provides child, teen, and adult immunization information for health care 
professionals and their patients at http://www.immunize.org. Free materials include 
CDC-reviewed technical pieces, patient handouts, VISs in multiple languages, and the 
weekly immunization news and information service “IAC Express,” available at 
http://www.immunize.org/express. Information for the general public about vaccines 
and vaccine-preventable diseases is available at http://www.vaccineinformation.org.  
Institute for Vaccine Safety 
Located at the Johns Hopkins University School of Public Health, the Institute for 
Vaccine Safety provides information about vaccine safety concerns and objective and 
timely information to physicians and health-care providers and parents. The Institute 
for Vaccine Safety also includes links to tables that include all vaccine components 
(http://www.vaccinesafety.edu). 
State and Local Health Departments 
State and local health departments provide technical advice through hotlines, e-mail, 
and websites, including printed information regarding vaccines and immunization 
schedules, posters, and other educational materials (see 
http://www.cdc.gov/vaccines/imz-managers/awardee-imz-websites.html and 
www.cdc.gov/mmwr/international/relres.html). 
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Vaccine Education Center 
Located at the Children’s Hospital of Philadelphia, the Vaccine Education Center 
provides patient and provider vaccine information (http://www.chop.edu/centers-
programs/vaccine-education-center). 
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Adverse event. An untoward event that occurs after a vaccination that might be 
caused by the vaccine product or vaccination process. Adverse events include those that 
have the following characteristics: 1) vaccine induced (caused by the intrinsic 
characteristic of the vaccine preparation and the individual response of the vaccinee): 
these events would not have occurred without vaccination (e.g., vaccine-associated 
paralytic poliomyelitis); 2) vaccine potentiated: the events would have occurred anyway 
but were precipitated by the vaccination (e.g., first febrile seizure in a predisposed 
child); 3) programmatic error: the event was caused by technical errors in vaccine 
preparation, handling, or administration; and 4) coincidental: the event was associated 
temporally with vaccination by chance or caused by underlying illness. Special studies 
are needed to determine whether an adverse event is a reaction to the vaccine or the 
result of another cause. Sources: Chen RT. Special methodological issues in 
pharmacoepidemiology studies of vaccine safety. In: Strom BL, ed. 
Pharmacoepidemiology. 3rd ed. Sussex, England: John Wiley & Sons; 2000:707-732; 
and Fenichel GM, Lane DA, Livengood JR, Horwitz SJ, Menkes JH, Schwartz JF. 
Adverse events following immunization: assessing probability of causation. Pediatr 
Neurol. 1989;5:287--90. 
Adverse reaction. An undesirable medical condition that has been demonstrated to 
be caused by a vaccine. Evidence for the causal relation is usually obtained through 
randomized clinical trials, controlled epidemiologic studies, isolation of the vaccine 
strain from the pathogenic site, or recurrence of the condition with repeated vaccination 
(i.e., rechallenge); synonyms include side effect and adverse effect. 
Adjuvant. A vaccine component distinct from the antigen that enhances the immune 
response to the antigen.  
Antitoxin. A solution of antibodies against a toxin. Antitoxin can be derived from 
either human (e.g., tetanus immune globulin) or animal (usually equine) sources (e.g., 
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diphtheria and botulism antitoxin). Antitoxins are used to confer passive immunity and 
for treatment. 
Hyperimmune globulin (specific). Special preparations obtained from blood 
plasma from donor pools preselected for a high antibody content against a specific 
antigen (e.g., hepatitis B immune globulin, varicella-zoster immune globulin, rabies 
immune globulin, tetanus immune globulin, vaccinia immune globulin, cytomegalovirus 
immune globulin, botulism immune globulin). 
Immune globulin. A sterile solution containing antibodies, which are usually 
obtained from human blood. It is obtained by cold ethanol fractionation of large pools of 
blood plasma and contains 15%-18% protein. Intended for intramuscular 
administration, immune globulin is primarily indicated for routine maintenance of 
immunity among certain immunodeficient persons and for passive protection against 
measles and hepatitis A. 
Immunobiologic. Antigenic substances (e.g., vaccines and toxoids) or antibody-
containing preparations (e.g., globulins and antitoxins) from human or animal donors. 
These products are used for active or passive immunization or therapy. Examples of 
immunobiologics include antitoxin, immune globulin and hyperimmune globulin, 
monoclonal antibodies, toxoids, and vaccines. 
Intravenous immune globulin. A product derived from blood plasma from a donor 
pool similar to the immune globulin pool, but prepared so that it is suitable for 
intravenous use. Intravenous immune globulin is used primarily for replacement 
therapy in primary antibody-deficiency disorders, for treatment of Kawasaki disease, 
immune thrombocytopenic purpura, hypogammaglobulinemia in chronic lymphocytic 
leukemia, and certain cases of human immunodeficiency virus infection (Table 3-5). 
Monoclonal antibody. An antibody product prepared from a single lymphocyte 
clone, which contains only antibody against a single antigen. 
Simultaneous. In the context of vaccine timing and spacing, occurring on the same 
clinic day, at different anatomic sites, and not combined in the same syringe. 
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Toxoid. A modified bacterial toxin that has been made nontoxic, but retains the ability 
to stimulate the formation of antibodies to the toxin. 
Vaccination and immunization. The terms vaccine and vaccination are derived 
from vacca, the Latin term for cow. Vaccine was the term used by Edward Jenner to 
describe material used (i.e., cowpox virus) to produce immunity to smallpox. The term 
vaccination was used by Louis Pasteur in the 19th century to include the physical act of 
administering any vaccine or toxoid. Immunization is a more inclusive term, denoting 
the process of inducing or providing immunity by administering an immunobiologic. 
Immunization can be active or passive. Active immunization is the production of 
antibody or other immune responses through administration of a vaccine or toxoid. 
Passive immunization means the provision of temporary immunity by the 
administration of preformed antibodies. Although persons often use the terms 
vaccination and immunization interchangeably in reference to active immunization, the 
terms are not synonymous because the administration of an immunobiologic cannot be 
equated automatically with development of adequate immunity. 
Vaccine. A suspension of live (usually attenuated) or inactivated microorganisms (e.g., 
bacteria or viruses) or fractions thereof administered to induce immunity and prevent 
infectious disease or its sequelae. Some vaccines contain highly defined antigens (e.g., 
the polysaccharide of Haemophilus influenzae type b or the surface antigen of hepatitis 
B); others have antigens that are complex or incompletely defined (e.g., Bordetella 
pertussis antigens or live, attenuated viruses). 
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